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1. Introduction 
1.1 Staphylococcus aureus  
Staphylococcus aureus was first discovered in 1871. It was identified as bacteria 
responsible for purulent infection in 1880. S. aureus is Gram positive, ubiquitous pathogen 
and commensal to human being. About 20%-25% of the population permanently carry S. 
aureus and at least 60% carry transiently S. aureus1. It colonizes in wet areas, such as 
mucosa from the anterior nostrils to nasopharynx, axilla, wrist and perineum. S. aureus 
together with Escherichia coli and Pseudomonas aeruginosa are the most common 
isolated bacteria from hospital environment. It is also the second bacteria responsible for 
nosocomial infections, after E. coli. The diseases caused by S. aureus vary greatly, from 
dermal or mucosal infection (folliculitis, boil, impetigo and sinusitis) to visceral organ 
infections (endophthalmitis, pneumonia, endocarditis and osteomyelitis), and some life-
threatening syndromes, such as septicemia and toxic shock syndrome2. 
S. aureus is a great burden for health care system, because of its significant morbidity and 
mortality worldwide. It is hazardous for people that have chronic diseases such as diabetes, 
eczema, or immune system deficiency (old people, AIDS) and those who are foreign 
material implant carrier. S. aureus infection can rapidly jeopardize the general health 
condition and threaten the life, mostly due to its multiple antibiotic resistances and various 
virulence factors. 
S. aureus is frequently found in ocular infections, in which retina can be severely damaged 
despite prompt and appropriate treatments. 
1.1.1 Methicillin-resistant S. aureus 
Antibiotic resistance makes S. aureus survive from the antibiotic treatment and spread in 
hospital and community acquired strains. S. aureus can pass genes of antibiotic resistance 
and virulence through horizontal transfer among the strains and can adapt rapidly to the 
new treatment.  
β-lactams is the first antibiotic to treat S. aureus infection. The methicillin, one derivative of 
penicillin of β-lactam antibiotic family, was introduced to clinical usage in 1960. The first 
methicillin-resistant S. aureus (MRSA) isolate was discovered one year later. Then MRSA 
prevailed throughout the world as a multi-resistant hospital pathogen. MRSA strains 
encode a novel speciﬁc penicillin-binding protein (PBP2a), which has a low affinity with all 
β-lactams and makes MRSA resistant to β-lactam antibiotics. This novel PBP2a is encoded 
by methicillin resistance gene (mecA), which is carried by a variable mobile element, called 
staphylococcal cassette chromosome mec (SCCmec). SCCmec can be inserted into the 
chromosome. It is constituted by two complexes, a cassette chromosome recombinase 
(ccr) gene complex and mec complex. The ccr complex controls the insertion site and 
integration of SCCmec into the staphylococcal chromosome. The mec complex contains 
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mecA gene and is classified into six different classes, i.e. A, B, C1, C2, D and E. SCCmec 
could also encode β-lactamases to cleave β-lactams. SCCmec is classified into 9 types 
according to the classes of ccr and mec complexes3. The type I SCCmec was identified in 
1961, type II and III in 1980s, type IV and V in 2000s. The other types of SCCmec were 
less frequent and identified later. SCCmec varies in size. The type I, II and III are larger 
than those of type IV and V. The larger SCCmec, such as SCCmec II and III, contains other 
antibiotic resistances genes.  
1.1.2 HA-MRSA and CA-MRSA 
Table 1. The differences between HA-MRSA and CA-MRSA 
HA-MRSA CA-MRSA 
health care systems general population 
carry a large staphylococcal chromosomal 
cassette mec (SCCmec) belonging to type 
I, II, or III. 
carry small SSCmec type IV or V 
resistant to many classes of non-β-lactam 
antimicrobials 
susceptible to non-β-lactam classes of 
antimicrobials 
seldom carry PVL gene frequently carry PVL gene; the percentage 
continues rising, due to horizontal transfer 
of genes 
 
MRSA spreads rapidly and is continuously developing its capacity of resistance to 
antimicrobial drugs. Considering its ubiquity, virulence and multi-antibiotic resistance, 
MRSA is a great burden to health care systems. At beginning, MRSA strains were confined 
to hospitals and other health care systems. However, MRSA infections were reported in 
healthy populations without exposure to health care system since 1990s. This new 
emergent MRSA is called as community associated (CA)-MRSA, the previous MRSA as 
hospital acquired (HA)-MRSA. CA-MRSA is defined as any MRSA infection diagnosed for 
outpatients or within 48 h of hospitalization without HA-MRSA risk factors.  
CA-MRSA strains are different from HA-MRSA strains in terms of genotypic, 
epidemiological and clinical features4 (Table 1). HA-MRSA strains harbor SCCmec type I, 
II, or III and are resistant to many classes of β-lactam and non-β-lactam antibiotics. CA-
MRSA strains carry small SCCmec type IV or type V and are susceptible to non-β-lactam 
antibiotics. The difference in types of SCCmec could well explain the multi-resistance 
antibiotics of HA-MRSA and the susceptibility of CA-MRSA to non-β-lactam antibiotics5. 
The gene encoding PVL can spread from strain to strain by some bacteriophages. About 
60 to 100% of CA-MRSA strains carry gene encoding PVL6, 7, while HA-MRSA or 
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methicillin-susceptible staphylococcus aureus (MSSA) are rarely discovered carrying gene 
encoding PVL. The percentage of CA-MRSA has significantly increased in MRSA infection 
isolates and may continue to rise in the future. One hypothesis for this increase is due to 
the horizontal transfer of SCCmec elements and PVL gene to the genomes of MSSA5.  
PVL is highly expressed in CA-MRSA strains. The combination of antibiotic resistance and 
virulent toxin expression might be a great burden in treating S. aureus infection. 
1.1.3 Vancomycin-resistant S. aureus 
The percentage of MRSA increases and accounts for more than half of S. aureus infections. 
For severe MRSA infections, such as bacteremia, endocarditis and osteomyelitis, the 
effective antibiotic treatment is prompt intravenous vancomycin. The adjunctive therapies 
can also improve the treatment, such as drainage of abscesses or infected lesions, 
removal of catheters and infected valves8. 
Vancomycin is a glycopeptide antibiotic and works by blocking the construction of bacterial 
cell wall. Vancomycin binds to the precursors of peptidoglycan on the outer surface of 
bacterial cytoplasmic membrane, preventing the synthesis of peptidoglycan in bacterial cell 
wall. The mechanism of vancomycin-resistant enterococci is to produce low-affinity 
precursors of peptidoglycan to eliminate high-affinity precursors. The first vancomycin-
resistant clinical isolates were found in Enterococcus in 1988. Since then, vancomycin-
resistant enterococci spread rapidly worldwide. In 1997, clinical S. aureus isolates 
susceptibly resistant to vancomycin was found, called vancomycin-resistant 
Staphylococcus aureus (VRSA). Then, more evident VRSA strains were found later. 
Vancomycin resistance genes, such as VanA, VanR, VanH and VanB, are located in 
plasmid and transferred to MRSA by conjugation to Enterococcus sp9.  
Vancomycin is the last therapy for infection caused by multi-resistant strains of 
staphylococci, streptococci and enterococci. The emergence of resistance to vancomycin 
means that the bacterial strains can develop resistance to all the antibiotics.  
In recent years, alternatives to vancomycin for the treatment of MRSA infection are 
identified and used. The most effective and wildly used are daptomycin and linezolid. The 
other alternatives to vancomycin include quinupristin-dalfopristin, tigecycline, trimethoprim-
sulfamethoxazole, clindamycin, and tetracyclines. Linezolid is a synthetic oxazolidinone 
antibiotic, which inhibits the synthesis of bacterial proteins. Linezolid is recommended to 
treat skin and soft-tissue infections. There was outbreak of linezolid resistance in MRSA 
strains, which was associated with nosocomial transmission and the extensive usage of 
linezolid. MRSA strains in patients receiving daptomycin are more likely to develop 
resistance to daptomycin. Thereby, vancomycin is still the first choice of antibiotic to MSRA 
infection10.  
Other strategies, such as surveillance cultures, more strict usage of antibiotic, and 
decolonization of S. aureus in bodies, are proposed to control MRSA development in 
hospital environment. 
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1.1.4 Horizontal transfer 
S. aureus could acquire adaptation and evolution very rapidly due to horizontal transfer of 
mobile genetic elements (MGEs). They could gain new antibiotic resistance and new 
virulence factors, which facilitate them to escape from immune system and improve their 
pathogenesis.  
MGEs are segments of DNA, which can move around within a genome and be transferred 
from one stain to another. MGEs encode proteins for antibiotic resistance, virulence and 
host-adaptation. MGEs include plasmids, bacteriophages and transposons. Plasmids and 
bacteriophages are the classic MGEs. They are transferred by 3 genetic transfer 
mechanisms: conjugation (transmission of plasmid), transduction (by the intermediate of 
viral vector), and/or transformation (that can integrate a DNA fragment into the bacterial 
genome)11. 
SCCmec elements are transferred by bacteriophage, for this reason the prevalence of 
MRSA increases continuously. VRSA has emerged through the transposons of vancomycin 
resistance genes; S. aureus pathogenicity islands (SaPIs) carry genes encoding the toxic 
shock toxin 1 and superantigens. Horizontal transfer of SaPIs relies on the specific “helper” 
bacteriophages. PVL and staphylococcal enterotoxin A (sea) are found on inserted 
bacteriophage. PVL gene is frequently found in CA-MRSA, which might be due to selective 
transfer of PVL-carrying prophages to CA-MRSA12. 
1.2 Virulence of S. aureus  
S. aureus expresses various virulence factors, including adhesive factors, exoenzymes 
and toxins (Figure 1). Adhesive factors help S. aureus to adhere to cells and the 
extracellular matrix, and exoenzymes control colonization and dissemination of S. aureus. 
The colonization to host tissue is the first stage of microbial infection, which is associated 
with its structural components and ability to bypass the host defense mechanisms. The 
dissemination of bacteria can promote the spread of bacteria and enlarge the infection.  
Whereas, the toxins have a more offensive function, attacking directly the immune system 
and other cells of the host. For instance, staphylococcal complement inhibitor (SCIN) and 
chemotaxis inhibitory protein of staphylococci (CHIPS) can modulate neutrophil 
chemotaxis and phagocytosis. Superantigenes, another type of toxin, can induce activation 
of lymphocytes, which is responsible for various symptoms, such as toxic shock. 
Enterotoxins target the intestine cells and are responsible for staphylococcal food 
poisoning. Hemolysins are able to lyse erythrocytes and lymphocytes. Leukotoxins also 
lyse other leukocytes. At last, PVL is one of better characterized leukotoxins and is an 
important virulence factor of S. aureus. This study of its effects on organic tissue and 
especially retina could help to find new therapeutic solutions to fight S. aureus infection. 
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Figure 1: The virulence of S. aureus 
The virulence of S. aureus includes MSCRAMMs, exoenzyme and toxins. MSCRAMMs 
and exoenzyme have passive functions on S. aureus colonization and dissemination, while 
toxins target actively immune system or cells of host. CHIPS, chemotaxis inhibitory protein 
of staphylococci; SCIN, staphylococcal complement inhibitor; Clf A, B, clumping factor A, 
B; MSCRAMMs, microbial surface components recognizing adhesive matrix molecules; 
FnBPA, fibronectin-binding protein A. 
1.2.1 Adhesive factors 
S. aureus adheres to extracellular matrix to form colonization, which is the primary step 
before opportunistic infection. This adherent ability is relied on microbial surface 
components recognizing adhesive matrix molecules (MSCRAMMs) on S. aureus surface, 
including fibronectin-binding protein A and B (FnBPA and FnBPB), a collagen binding 
protein Cna, a fibrinogen-binding protein and protein A.  
FnBPA and FnBPB, expressed by two close genes in most S. aureus strains, attach to 
immobilized fibronectin. They are responsible for mediating S. aureus adhering to plasma 
clots and foreign body surface. The collagen-binding protein Cna adheres to collagen 
substrates and collagenous tissues. It is expressed by 38%-56% of S. aureus strains and 
mediates S. aureus binding to cartilage. It is associated with bone and joint infections13. 
Clumping factor A (ClfA) and B (Clf B) are the major fibrinogen (Fg) binding proteins of S. 
aureus. They recognize different parts of fibrinogen. ClfA binds to the carboxyl terminus of 
the γ chain of fibrinogen, while ClfB binds α and β chains of fibrinogen. They mediate S. 
aureus clumping in blood plasma during arthritis and endocarditis. Protein A is expressed 
by 90% of S. aureus stains. Unlikely to other molecules which binds to collagen, fibrinogen 
or fibronectin, protein A binds to the Fc region of immunoglobulin, which inhibits the 
opsonization, thus impairing phagocytosis of PMNs13. 
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1.2.2 Exoenzymes 
S. aureus secretes many exoenzymes to control its colonization and dissemination. The 
dissemination of bacteria can promote the spread of the infections. Those enzymes include 
nuclease, protease, lipase, hyaluronidase and collagenase. The proteases from S. aureus 
include serine, cysteine and metalloenzymes, and are not sensitive to most human 
inhibitors of plasma protease14.  
Aureolysin is a metalloproteinase of S. aureus. It can transform precursor of V8 protease 
into an active form. It inactivates ClfB by cleaving the N-terminal domain of ClfB. ClfB is 
membrane protein. The activation of ClfB can modify bacterial cell surface proteins, leading 
to tear off bacteria from colonization and promote the spread of infection. Hyaluronate 
lyase cleaves acid residues in hyaluronan, a component of extracellular matrix. This 
cleavage can dissociate extracellular matrix and promote bacterial dissemination and 
migration. Staphylocoagulase binds and activates prothrombin, leading to the cleavage 
of fibrinogen to fibrin. It promotes the abscess formation and lethal bacteremia of S. aureus. 
V8 protease is a serine protease, which cleaves specifically peptide bonds formed by 
aspartate and glutamate residues. It degrades the bacterial cell surface fibronectin-binding 
protein, facilitating bacterial dissemination. It can also promote the maturation of other 
virulence factors, such as staphostatins. Lipase can release a large quantity of fatty acids, 
which can help S. aureus to survive in the fatty human or mammalian skin. Staphopains 
A and B are the major secreted cysteine proteases of S. aureus, which may promote the 
invasion and metastatic infections of S. aureus. Staphostatin A and B may inhibit 
Staphopains A and B, respectively, through binding the active sites of these protease14.  
1.2.3 Toxins 
Bacteria can secret toxic substances, which can directly damage host tissue or disable 
host immune system to protect bacteria against host defenses. S. aureus could produce a 
large repertoire of toxins, including CHIPS and SCIN, superantigens, enterotoxins, 
exfoliative toxin, hemolysins and leukotoxins. S. aureus strains express partially those 
toxins, presenting various degree of virulence.  
1.2.3.1 CHIPS and SCIN 
CHIPS and SCIN are toxins simultaneously expressed during the early (exponential) 
growth stage of S. aureus and can both modulate neutrophil chemotaxis, phagocytosis and 
cell killing15.  
CHIPS is a 121-residue protein excreted by about 60% of S. aureus strains. It is potent 
inhibitor of chemotaxis of neutrophils and monocytes toward C5a and the N-
formylmethionyl-leucyl-phenylalanine (fMLP). Indeed, CHIPS binds directly to the 
receptors of C5a and fMLP with high affinity and selectivity. Thereby, it prevents C5a and 
fMLP from binding to their receptors and activating transduction pathways16.  
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SCIN, an 85-residue protein secreted by S. aureus, has an anti-inflammatory action during 
S. aureus infection. It can inhibit the formation of lytic membrane attack complex (C5b-9 
deposition) through disrupting alternative pathway-mediated and classical/lectin 
opsonization (C3b deposition). Thereby, it reduces phagocytosis following the opsonization 
and blocks efficiently the functions of the downstream effectors.  
1.2.3.2 Superantigens and enterotoxins  
Superantigens are proteins that cause non-specific activation of T-cells resulting in 
polyclonal T cell activation and massive cytokine release. S. aureus produces various 
superantigens, including the staphylococcal enterotoxins (SEs), the staphylococcal 
enterotoxin-like (SEls) proteins, and toxic shock syndrome toxin-1 (TSST-1).  
Genes encoding superantigens are located on mobile genetic elements, which are carried 
by about 80% of S. aureus strains. In adaptive immune system, antigen presenting cells 
present antigens to CD4+ T cells by histocompatibility complex (MHC)-II. TSST-1 can bind 
to the invariant regions of MHC-II and interact with the β-chains of T cell receptors (Vβ-
TCR), which can abnormally make cross-bridge between MHC-II and Vβ2-TCRs of 
subtype T-cells without specific antigens. This subpopulation of T cells is non-specifically 
activated and multiplies, resulting in massive release of inflammatory cytokines and toxic 
shock syndrome. By the same mechanism, superantigens cause other less severe 
syndromes, neonatal toxic shock syndrome-like exanthematous disease (NTED) and 
recalcitrant erythematous desquamating disorder (REDD). NTED is found in newborns and 
REDD is found in patients with AIDS17.  
An enterotoxin is an exotoxin released by a microorganism that targets the intestine. 
Staphylococcal enterotoxins have 20 distinct members, such as SEA, SEB, SED, SEE and 
SEF. They are responsible for the Staphylococcal food poisoning. Staphylococcal food 
poisoning, characterized by nausea and vomiting, is usually self-limited and resolves 
typically within 24-48 h after onset, albeit a few cases may result in a lethal toxin shock-
like symptom. Enterotoxins can cause this disease even without the presence of S. 
aureus18. 
1.2.3.3 Exfoliative toxins 
S. aureus produces exfoliative toxins (ETs) A, B, D, which cause a blistering of the skin. 
ETs target desmoglein-1 and act as serine proteases, resulting in mid-epidermal cleavage. 
ETs can cause dermal diseases ranging from blisters to severe exfoliation, such as bullous 
impetigo and staphylococcal scalded skin syndrome. About 5% of S. aureus strains carry 
ETs genes, but only a small proportion cause severe exfoliation. Some authors argued that 
ETs can act also as superantigens to cause autoimmune dermal disease19.  
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1.2.3.4 Hemolysins 
Hemolysins are lipids and proteins that lyse red blood cells by destroying their cell 
membrane. S. aureus expresses β-hemolysin, δ-hemolysin. 
β-Hemolysin, also called beta-toxin, is a sphingomyelinase of S. aureus. It is encoded by 
a bacteriophage in a small percentage of S. aureus. It lyses erythrocytes and human 
lymphocytes by cleaving sphingomyelin in cell membranes to scavenge nutrients and 
escape from immune system. Its structure shows the characteristics of DNase I. However, 
instead of functioning as DNase, it precipitates extracellular DNA. The precipitated DNA 
forms non-specifically cross-linking with hemolysin β and other proteins, an insoluble 
nucleoprotein matrix, which contributes to biofilm formation20.   
δ-hemolysin is an alpha-helical and amphipathic 26-amino acid peptide, expressed in 97% 
of the S. aureus isolates. It is soluble in water and organic solvents. It can perturb the 
membrane after binding to it, resulting in cell lysis. It can lyse erythrocytes of many 
species20. 
1.2.3.5 Leukotoxins 
Leukotoxins kills leukocytes, permitting bacteria to escape from host immune surveillance. 
Some of them are also hemolytic. Some of them are associated with severe infectious 
diseases. PVL is one well characterized leukotoxin, which is associated with necrotizing 
infections. We will review the members of leukotoxins from human isolated S. aureus, to 
better understand pathogenesis of S. aureus. 
1.2.3.5.1 The prevalence of leukotoxins 
Leukotoxins are composed of two distinct proteins, a class S (31–32 kDa) and a class F 
component (33–34 kDa). S component binds initially to the cytoplasmic membrane of 
target cells, then triggering the subsequent F component binding, which organize as 
alternate octamers, called prepores, then form the pore (Figure 2).  
Human S. aureus isolates can produce five leukotoxins: γ-hemolysin consisting of two 
leukotoxins (HlgA/HlgB and HlgC/HlgB), LukAB, PVL and LukED21. The genes of 
HlgA/HlgB, HlgC/HlgB, and LukAB are located in the core genome on chromosome and 
are presented in almost all human S. aureus isolates. In contrast, PVL and LukED genes 
are located on mobile gene elements and could be horizontally transferred in a selective 
way. S. aureus expressing of PVL and LukED is related to some specific infections22. PVL 
gene is located in the temperate bacteriophage and is found in 2%-10% of all clinical S. 
aureus isolates in Europe, about 60% in African or Asian developing countries; PVL gene 
is positive in 60-100% of CA-MRSA isolates, while it is rare in HA-MRSA strains. LukED 
gene is located in a stable S. aureus pathogenicity island (a mobile gene element) and is 
found in 50% -75% clinical S. aureus isolates. S. aureus expressing LukED is associated 
with bullous impetigo and post-antibiotic diarrhea31.  
1.2.3.5.2 The genomic characteristic of leukotoxins 
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The gene encoding γ-hemolysin (HlgA/ HlgB, HlgA /HlgC) is divided into two parts. The 
first part is the locus for HlgA, which is about 400 bases upstream of second part which 
encodes the HlgC and HlgB. In that second party, hlgC and hlgB are separated by a base 
“T” and are simultaneously co-transcribed. For PVL and LukED, the genes of two 
components also are separated by one base “T” and are simultaneously co-transcribed. 
The genes of the two components of LukAB are also co-transcribed together and 
separated by 21 bases23, 24.  
 
 
Figure 2: Crystal structure and pore formation of leukotoxins 
(a) Crystal structures of leukotoxins: the soluble leukotoxin, leukotoxin in pre-pore 
formation, the hetero-octameric pore of leukotoxin. (b) The simple illustration of the 
processes of leukotoxin binding and pore formation. For PVL, LukED, HlgAB and HlgCB, 
the S component binds first to the receptor, then F component binds consecutively to the 
complex. Four S and four F components form a hetero-octameric pre-pore and then a pore. 
For LukA/B, S and F components form a dimer before binding to the receptor and forming 
the hetero-octameric pre-pore and pore. (Images in part a is from University Medical 
Center Utrecht, The Netherlands; images in part b is from András N. Spaan et al, 2017) 
 
1.2.3.5.3 The spectra and receptors of leukotoxins 
The leukotoxins of S. aureus have different cell-type and species-type targets. HlgA/HlgB 
could lyse lymphocytes and all the granule cells, while the other leukotoxins target granule 
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cells with different spectra. Also, PVL and HlgC/ HlgB could incite neurons to undergo 
calcium mobilization and glutamate release25. For a long time, cellular receptor was 
hypothesized to play a great role in the effect of leukotoxin. In recent years, the receptors 
of those leukotoxins are well identified, which can help to explain the spectra of target cells 
and species specificity of these toxins, and their cytotoxicity22 (Table 2). 
 
γ-Hemolysin 
γ-Hemolysin consists of HlgA/HlgB and HlgC/HlgB. 99.5% of human S. aureus isolates 
express genes encoding γ-Hemolysin, which can aggravate septic arthritis and systemic 
infection. HlgA/HlgB has a large spectrum of target cells. It can lyse human and rabbit 
erythrocytes and target most leukocytes: T lymphocytes, granulocytes (neutrophil, basophil, 
eosinophil) and monocytes and their derivative cells (macrophages and dendritic cells). In 
contrast to HlgA/HlgB, HlgC/HlgB has a low capacity to lyse lymphocytes and does not 
lyse erythrocytes. HlgC/HlgB can target human granulocytes, monocytes macrophages 
and dendritic cells and cell line (HL-69) of the precursor of the neutrophils. To identify the 
specific receptors for HlgA/HlgB and HlgC/HlgB, human embryonic kidney cells were 
transfected with a collection of human chemokine receptors and were evaluated for the 
cytotoxic susceptibility to the two leukotoxins. It was shown that HlgA/HlgB bound to 
CXCR1, CXCR2 and CCR2, and HlgC/HlgB bound to C5aR and C5L222.  
 
LukE/D 
CCR5 is a receptor for LukE/D. Different cell lines (human T cell line, PMN-HL-69 
osteosarcoma) are engineered to express CCR5 expression. LukE/D is cytotoxic toward 
cell lines in presence of CCR5, while the presence of other receptors (CCR1, CCR2, CCR3, 
CXCR4, CCR8, and CXCR6) does not make cell lines susceptible to LukE/D. The 
antagonist of CCR5 could effectively suppress LukE/D cytotoxicity. LukE/D can target 
human, rabbit and murine CCR5-bearing cells, and lyse neutrophils, monocytes and 
macrophages26. 
 
LukA/B 
LukA/B is cytotoxic toward human and rabbit neutrophils, monocytes, macrophages and 
dendric cells, but not cytotoxic toward murine leukocytes. CD11b, α subunit of the αM/β2 
integrin (CD11b/CD18), is known as macrophage-1 antigen or complement receptor 3. 
CD11b is identified as a host molecule required for LukA/B-mediated cell killing. LukA/B is 
the most divergent leukotoxin of staphylococcal leukotoxins. The amino acids sequences 
of LukA and LukB share about 30% and 40% with S component and F component of other 
leukotoxins, respectively. In contrast, other leukotoxins have 60%-80% similarity of amino 
acid sequence for S and F components. LukA/B needs to form a stable bicomponent before 
binding to its receptor, while S and F components of other leukotoxins bind separately and 
consecutively to the receptors27 (Figure 2).   
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Table 2. The myeloid receptors, species activity and targeted leukocyte of 
leukotoxins of S. aureus 
Leukotoxin 
names 
Myeloid 
receptors 
Species activity Targeted 
leukocyte 
PVL LukS-PV:C5aR, 
C5L2 
LukF-PV: CD45 
Human (high) 
Rabbit (high) 
Mouse (none) 
Monocytes 
Macrophages 
PMNs 
HlgCB HlgC:C5aR, 
C5L2 
Human (high) 
Rabbit (medium) 
Mouse (low) 
Monocytes 
Macrophages 
PMNs 
HlgAB HlgA: CCR2, 
CXCR1, CXCR2 
Human (high) 
Mouse(medium) 
Monocytes 
Macrophages 
Dendritic cells 
PMNs 
Lymphocyte T 
LukED LukE: CCR5 Human (high) 
Mouse (high) 
Monocytes 
Macrophages 
PMNs 
LukAB LukAB: CD11b Human (high) 
Rabbit (medium) 
Mouse (low) 
Monocytes 
Macrophages 
Dendritic cells 
PMNs 
LukMFʹ LukM: CCR1 Bovine (high) 
 Mouse (medium) 
Human (low) 
PMNs 
Macrophages 
LukPQ LukP: CXCRA, 
CXCR2 
Equine (high) PMNs 
Abbreviated symbols: PVL, Panton-Valentine leukocidin; C5aR, C5a receptor; C5L2, 
C5a receptor-like 2; PMNs, Polymorphonuclear leukocytes; CCR1, 2, 5, CC-chemokine 
receptor1, 2, 5; CXCR1, 2, A, CXC chemokine receptor 1, 2, A. 
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LukMFʹ and LukPQ 
Leukotoxin MFʹ (LukMFʹ) and leukotoxin PQ (LukPQ) are associated with zoonotic 
infections and are rarely found in human S. aureus isolates. LukMFʹ is associated to bovine 
mastitis, not in human infection28. The receptor for LukM is CCR1. LukMFʹ targets actively 
bovine and murine neutrophils and macrophages, and human neutrophils to a lesser extent. 
LukPQ, a newly identified leukotoxin, targets mainly equine neutrophils through equine 
CXCRA and CXCR229.   
 
PVL 
Comparing to other leukotoxins, PVL has the smallest spectrum of target cells. PVL targets 
macrophages and neutrophils, not lymphocytes. In 2013, it was reported that human C5a 
receptors, C5aR and C5L2, were receptors for LukS-PV and mediators of PVL-induced 
cytotoxicity. The antibody against C5aR could effectively block PVL binding to neutrophils 
and macrophages. PVL has preference for animal species and does not recognize murine 
C5aR, which is determined by the second extracellular loop of C5aR21. Many previous 
studies used mice model to study PVL and might bring out some confusing results30. 
Recently, CD45 is identified as one receptor for LukF-PV, which influences the cytotoxicity 
of PVL towards neutrophils31. 
 
 
1.3 Leucocytes  
 
 
Figure 3: Hematopoietic differentiation tree 
In the bone marrow, hematopoietic stem cells differentiate into two types of stem cells: one 
is myeloid stem cell, leading to the formation of red blood cells, platelets and myeloid cells; 
another is a lymphoid stem cell, leading to the formation of lymphocytes. (from website 
national cancer institute https://visualsonline.cancer.gov ) 
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All the leukotoxins target and lyse leukocytes, which is the origin of their name. Leukocytes, 
the body's army of soldiers, are the cells of the immune system. They circulate in the body 
in blood vessels and lymphatic vessels. They fight the invading germs and prevent the 
infections. The leukotoxins kill leukocytes and help S. aureus to escape from immune 
defense and proliferate in human body. It’s necessary to have an overview of leukocytes 
to understand well the cell targets of leukotoxins.  
In the bone marrow, hematopoietic stem cell can differentiate into two types of stem cells: 
one is myeloid progenitor cell, leading to the formation of monocytes, red blood cells and 
neutrophils; another is lymphoid stem cell, leading to the formation of lymphocytes (Figure 
3). Leukocytes circulate in the blood in a quiescent state with low adhesiveness, they have 
short life time about 7 to 12 h. They monitor the environment and can migrate into the 
tissues to defend against the invading microbes. Their main defensive functions are 
phagocytosis, degranulation and oxidative explosion32.  
1.3.1 Polynuclear neutrophils 
Polynuclear neutrophils are the major cell type of granulocytes, occupying more than 40-
75% of circulating leukocytes. Polynuclear neutrophils are the innate immune cells which 
react and migrate immediately to the lesion. 
Migration 
Neutrophils migrate from blood vessels to the tissues, through a process divided into four 
steps: rolling, activation, adhesion, and transendothelial migration. First, P-selectin ligand 
(PSGL-1) on neutrophils interacts with P-selectin expressed at the surface of endothelial 
cells. This interaction is of low-affinity, neutrophils poorly bind to the endothelial cells. 
Continuously being carried away by the blood flow, they roll on the vessel wall. During this 
rolling, neutrophils can be activated by the invading pathogens or proinflammatory 
products. Once being activated, neutrophils could express immediately more adhesive 
molecules on their surface, such as lymphocyte function-associated antigen 1 (LFA-1) 
which interacts with ligand intercellular adhesion molecule (ICAM-1) on endothelial cells. 
This high affinity adhesion allows neutrophils to attach firmly to blood vessels. Then, they 
transform, sneak through the endothelial cell layer and migrate to lesion33.  
Phagocytosis and degranulation 
Neutrophils are effective phagocytes. They imprison pathogens inside an endosome, 
which is internalized into cytoplasm, called phagosome. The granules containing 
degradation enzymes come to merge with phagosome to degrade the contents.  
Neutrophils are granulocytes and have four types of granules with different content. During 
the maturation of neutrophils, the primary granules are fused with phagosome. They 
contain myeloperoxidase, elastases, defensins, lysozymes and azurocidine, which digest 
phagocyted microorganisms. The other granules are formed later than primary granules. 
The second granules are rich in antimicrobial agents, which are released into extracellular 
medium. The third granules contain gelatinases, enzymes, and receptors, which are useful 
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for the neutrophils transendothelial migration. The fourth granules are secretory vesicles, 
which contain many receptors. They are rapidly secreted outside to modify the composition 
of the cytoplasmic membrane, promoting neutrophil activation and adhesion to the 
endothelium34.  
1.3.2 Eosinophils, basophils and mast cells 
Eosinophils are circulating in blood, occupying normally less than 5% of circulating 
leukocytes. They produce and store biologically active molecules, including cytotoxic 
proteins, lipid mediators, chemotactic peptides and cytokines. They are associated with a 
series of disorders, such as asthma, tropical pulmonary eosinophilia. Basophils occupy 
normally less than 1% of circulating leukocytes and are associated with fatal asthma, acute 
and chronic allergy. They abundantly secrete cytokines after being activated to amplify the 
allergy. Mast cells are not flowing leukocytes, they reside in vascularized tissues. They 
have many granules, which contain histamine, proteases and cytokines. They can rapidly 
degranulate after interacting with IgE and release prostaglandins and leukotrienes during 
allergy35.  
1.3.3 Monocytes, macrophages and dendric cells 
Monocytes constitute 3-10% of flowing leukocytes. Monocytes express many receptors, 
such as Toll-like receptors (TLRs), to monitor the environmental changes. In general, they 
flow in blood for 1-3 days, and then migrate into tissue and become resident macrophages 
or dendritic cells. In abnormal conditions, monocytes are activated and transform into 
inflammatory macrophages, which secrete cytokines, myeloperoxidase and superoxide, 
and help in phagocytosis to eliminate harmful materials. Monocytes and macrophages can 
eliminate pathogens, cancer cells and cellular debris by phagocytosis. 
Dendritic cells are antigen-presenting cells in immune system. They reside in tissue which 
is in contact with external environment, such as skin and mucosa. Dendritic cells capture 
and present antigens to T-lymphocytes, which can activate them to undergo immune 
response. They also can promote B cell activation and differentiation by producing 
cytokines and other factors36. 
1.3.4 Lymphocytes T, B and NK 
The flowing lymphocytes constitute 20-40% of the flowing leukocytes in adults and are 
divided into three types of lymphocytes in the peripheral blood: T, B and NK cells, 
representing about 80%, 10% and 10% of total lymphocytes, respectively. T lymphocyte is 
a major cell of the adaptive immune system and can be divided into CD8+ and CD4+ T cells. 
CD8+ T cells are cytotoxic T lymphocytes. They bind to target cells and secrete molecules 
to destroy these cells. CD4+ T cells bind to antigen fragment presented by CMH II from 
dendritic cell, macrophages and B lymphocyte. The CD4+ T cells release cytokines or 
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chemokines and help to develop the clones of B cells which secrete antibodies against the 
presented antigens. B lymphocytes bind and engulf antigens, which are then presented to 
T-cells. Helper T cells can aid B cells to produce specific immunoglobulins to antigenic 
epitopes, called antibodies. Lymphocyte NK is component of innate host defense system. 
They can lyse virally infected cells and malignant cells37.  
1.4 PVL 
In the early 1930s, PVL was first discovered by Panton and Valentine. It is a powerful 
leukotoxin secreted by S. aureus.  
1.4.1 PVL-related clinical diseases 
PVL is often found in necrotizing S. aureus infections, such as furuncles, acute necrotizing 
pneumonia and osteomyelitis. Here are a few examples of S. aureus infections potentially 
aggravated by PVL. 
1.4.1.1 PVL pathophysiology in skin infection 
The skin abscesses are often related to S. aureus infection. The rate of PVL expression in 
S. aureus strains isolated from skin infection is much higher than that from systemic 
infection38. A study included 43 S. aureus isolates from cutaneous infections, among which 
12 (28%) strains expressed PVL gene. While only 1 strain among 49 (2%) isolates from 
systemic S. aureus infection was expressing PVL 39. S. aureus expressing PVL is often 
related to primary skin infection, while the S. aureus non-expressing PVL is related to 
secondary infection after other dermal diseases such as bullous or pruritic diseases39. 
The skin lesion generated by PVL is dependent on PVL concentration. PVL concentration 
ranges from 0.27 mg/L to over 2 mg/L in pus of PVL-positive S. aureus skin abscess. When 
PVL concentration is superior 1 mg/L, large abscesses (diameter ≥5 cm) are observed38. 
Small PVL concentration (30 ng) induces dermal edema and erythema, high PVL 
concentration (300 ng) provokes widespread infiltrated erythema followed by skin necrosis 
after intradermal injection in rabbits39. In mice, skin does not react after intradermal 
injection PVL, even though the PVL doses reaches up to 3 μg39.  
1.4.1.2 PVL pathophysiology in pneumonia 
CA-MRSA carrying PVL could cause severe and fatal pneumonia within a short time. PVL-
positive S. aureus pneumonia is necrotizing pneumonia characterized by a bloody cough 
(haemoptysis) and a decrease of circulating leukocytes (leucopenia). Histopathological 
analysis shows extensive necrotic ulcerations and massive haemorrhagic necrosis in lung 
tissue40. This pneumonia is preceded by an influenza-like syndrome, then followed by high 
fever (above 39°C), tachycardia (>140 beats/min). The patients are healthy children or 
young adults.  
This severity is associated with PVL. Purified PVL is directly instilled into rabbit lung and 
causes severe inflammation and injury by recruitment and subsequent lysis of PMNs in 
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lung during several hours. Damaged PMNs could release cytotoxic granules and/or 
reactive oxygen metabolites and significantly increase the level of IL-8 and MCP-1 in lung. 
These cytokines amplify the recruitment of leukocytes and damage the integrity of 
alveolus41.  
1.4.1.3 PVL aggravates osteomyelitis 
S. aureus often induces infection in bone and joint. PVL aggravates osteomyelitis in both 
clinical and experimental observations. The osteomyelitis or arthritis caused by CA-MRSA 
carrying PVL have more severe damage and require longer antibiotic course and various 
surgical procedures. PVL-positive osteomyelitis or arthritis undergo rapid evolution toward 
multifocal osteomyelitis and/or multiple abscesses despite antibiotic treatment42. In 
experimental rabbit model, the bone is infected by PVL-positive CA-MRSA strain and its 
PVL-negative isogenic derivative. In presence of PVL, rabbit bone is deformed, muscle 
and joints are involved in infection, which is rarely found in PVL-negative strain 
osteomyelitis. The anti-PVL antibody significantly reduces the inflammation in 
osteomyelitis caused by PVL-positive S. aureus43.  
1.4.2 PVL effects 
1.4.2.1 PVL inducing calcium mobilization 
PVL induces an increase of intracellular calcium concentration in PMNs and neurons 
without membrane damages25, 44. This calcium mobilization is not associated with plasma 
membrane Ca2+ channels or pore formation, but with the sarcoendoplasmic reticulum 
calcium transport ATPase (SERCA)45,46.   
PVL induces an increase of intracellular calcium concentration after 100s, which increases 
linearly within 10 min. The extracellular calcium influences PVL effects in calcium 
mobilization. In presence of physiologic calcium concentration, PVL application incites an 
increase of the intracellular calcium concentration in PMNs. In absence of extracellular 
calcium, PVL forms pore on PMNs, while the intracellular calcium concentration is not 
affected47.   
PVL induces an increase of intracellular calcium concentration without pore-forming in 
primary cerebellar granular neurons and dorsal root sensory neurons. This calcium 
increase is accompanied by glutamate release from primary cerebellar granular neurons25.  
 
1.4.2.2 PVL inducing cell death 
PVL can induce necrosis or apoptosis of PMNs, which are dependent on the PVL 
concentration. At high concentration, PVL induces necrosis by osmotic lysis, which might 
be due to pore formation on cytoplasmic membrane. At low concentration, PVL induces 
apoptosis by Bax-independent signaling pathway48. PVL is also related to neutrophil cell 
death during neutrophil extracellular traps (NETosis). NETosis is a recently described 
process of neutrophils trapping and killing of S. aureus, which leads to lytic cell death. PVL 
has been found to be associated to this process49.  
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Cell apoptosis related to PVL is also demonstrated on keratinocytes: S. aureus strains are 
engulfed into endosomes by human epidermal keratinocytes (RHEK-1) within 1 h. PVL-
positive S. aureus could successfully disrupt endosomes and replicate intracellularly. After 
6 h, PVL induces significantly caspase-dependent keratinocyte apoptosis50. 
 
1.4.2.3 PVL inducing release of inflammatory factors 
PVL is reported to target human and rabbit monocytes, macrophages and PMNs, but not 
to lymphocytes, which implies that PVL disturbs directly the innate immune system. PVL 
can also induce reactions on cerebral and radical ganglion neurons25.  
PVL induces different cell reactions in different cell types. PVL incites PMNs to secret 
granule content in a dose-dependent way. PVL induces proinflammatory factors release 
such as histamine, leukotriene B4 and IL-8 from neutrophils51, 52. Histamine is a potent 
vasodilator. Leukotriene B4 and IL-8 are chemokines which attract leukocytes to 
inflammatory sites. Those factors promote and facilitate PMNs-tissue infiltration. PVL 
influences the production of radical superoxide in PMNs: at low concentration, PVL induces 
PMNs to produce moderate superoxide anion; at high concentration, PVL inhibits radical 
superoxide formation. The production of free radical superoxide molecules could damage 
the tissues, while their inhibition could help S. aureus to spread53.  
PVL activates monocytes and macrophages to produce NLRP3 inflammasome, a signaling 
complex, which incites the release of IL-1β and IL-1854. IL-1β and IL-18 can further induce 
lung epithelial cells to secret chemokines and recruit leukocytes in PVL-positive MRSA 
necrotizing pneumonia55.  
PVL could incite neurons, resulting in calcium mobilization and glutamate release.  
In total, PVL effects result in leukocyte recruitment and death, vasodilation, cells invasion 
and tissue necrosis. 
 
1.4.2.4 PVL retrograde transport 
After PVL binding to C5aR, the receptor is phosphorylated and PVL is internalized with the 
phosphorylated receptor45. Immunolabeling and confocal microscopic techniques were 
used to trace the PVL retrograde transport. It showed that PVL accumulated first in 
lysosomal compartments 10 min after PVL application and reached to Golgi network 3 h 
after PVL application. Cell apoptosis was observed 3 h and peaked 6 h after PVL 
application. PVL induced Ca2+ release from the ER within 10 min, unexpectedly not from 
lysosome, which indicated that PVL-induced calcium mobilization was not related to the 
pore formation. The initial process of interaction between PVL and C5aR seems to play 
great role in PVL-induced calcium mobilization and cytotoxicity, independently from pore 
formation56.  
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Figure 4: PVL retrograde transport 
Step 1. LukS-PV binds to C5aR; Step 2. Recruitment of LukF-PV; Step 3. Internalization 
of PVL with phosphorylated C5aR; Step 4. Transfer to lysosome (10 min-3 h); Step 5. 
Transfer to Golgi (after 3h); Apoptosis occurs at 3 h and peaks at 6 h after PVL application. 
1.4.3 PVL treatment  
Considering the severity of S. aureus infection caused by PVL, PVL should be targeted as 
a new treatment. Different antibiotic families have very different effects in PVL secretion. 
Oxacillin enhances PVL release, while clindamycin, linezolid, fusidic acid and rifampicin 
inhibit PVL expression. The other antibiotics do not have influence on PVL expression. It 
has been proposed to combine clindamycin, linezolid, fusidic acid and rifampicin with other 
antibiotics to treat possible PVL-carrying S. aureus infection43. Those antibiotics could 
inhibit the production of many staphylococcal exotoxins in vitro. Combination those 
inhibitory antibiotics with other antibiotics needs be further studied in clinical studies.  
Humanized heavy chain-only antibodies (HCAbs) against PVL two components (LukS and 
LukF) prevent PVL binding and pore formation. In a rabbit PVL-induced endophthalmitis in 
vivo model, HCAbs (anti-LukS-PV, anti-LukF-PV) prevent effectively ocular inflammation 
and show therapeutic potential57.  
Among a series of molecules tested to inhibit PVL, calixarenes show the property of 
inhibiting PVL. P-sulfonato-calix[n]arenes can abolish S protein binding to membrane. This 
inhibitory effect is also observed in a rabbit model of PVL-induced endophthalmitis58. All 
those PVL inhibitors are still in an experimental stage. 
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1.5 Retinal structure 
1.5.1 General structure 
1.5.1.1 The cell layers of retina  
The retina is innermost, light-sensitive nervous layer that lines the inner surface of the back 
of the eyeball, in which stimulation by light occurs, initiating the sensation of vision.             
The light penetrates retina and is absorbed by photoreceptors. The photoreceptors 
transform the light into electrical message, which is sent to all the succeeding neurons of 
retina, reaching to central system by the visual pathway (Figure 5). The retina contains 
several structural layers, from the most inner layer to the most outer layer are as follows: 
the inner limiting membrane (ILM), which is constituted by a membrane and endfeet of 
Müller cells. ILM is the interface between retina and vitreous and functions as demi-barrier, 
which prevents large molecules from penetrating into retina; the nerve fiber layer (NFL), 
which contains axons of ganglion cells which constitute optical nerve; the ganglion cell 
layer (GCL), which contains two kinds of cells, ganglion cells and displaced amacrine cells; 
the inner plexiform layer (IPL), which is neuropil containing the axons or synapses of 
nearby cells and some microglial cells; the inner nuclear layer (INL), which is constituted 
by cellular soma of bipolar, horizontal, amacrine and Müller cells; the outer plexiform 
layer (OPL), which is another neuropil containing process of bipolar cells and horizontal 
cells and synaptic pedicles of photoreceptors; the outer nuclear layer (ONL), which 
contains rod and cone photoreceptors; the outer limiting membrane (OLM), which is 
adherent junctions between Müller cells and photoreceptors; the pigment epithelium 
layer, which constitutes the outer ocular-blood barrier (Figure 6). 
1.5.1.2 The retinal vasculature 
The arterial intra-retinal branches supply three layers of capillary networks: the radial 
peripapillary capillaries, and the inner and the outer layers of capillaries (Figure 7). From 
NFL to OPL, the retinal structure is vascularized by retinal capillaries from central retinal 
artery. ONL is avascular and gets nutrients from the choriocapillaries which are supplied 
by choroidal arteria. The fovea is exceptional and avascular, in which cone photoreceptors 
are maximally concentrated and other retinal layers are absent.  
1.5.1.3 The blood-retina barriers 
The retina has two blood-retina barriers (BRB), the outer BRB, which is constituted by tight 
junctions among retinal pigment epithelium and inner BRB which is constituted by tight 
junctions among intra-retinal vessels. The molecules selectively pass through these BRBs, 
which is the principal mechanism to maintain retinal homeostasis and function. 
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Figure 5: The structure of eye 
(Gaurab Karki, 2018, Human Eye: Anatomy, parts and structure. 
http://www.onlinebiologynotes.com/human-eye-anatomy-parts-structure) 
 
 
 
 
Figure 6: The organization of retina  
(Helga Kolb, Webvision: Simple Anatomy of the Retina by Helga Kolb. 
https://webvision.med.utah.edu/book/part-i-foundations/simple-anatomy-of-the-retina/) 
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Figure 7: Simple illustration of ocular vasculature 
Left: choroid and retinal vessels consist ocular vasculature. Right: retinal vessels are 
consisted in three layers: radial peripapillary capillaries (superficial), and the inner and the 
outer layer of capillaries (intermediate and deep). The choroidal vessels are under RPE 
and supply blood to the outer portion of the retina. 
Abbreviation: GCL: ganglion cell layer; INL: inner nuclear layer; NFL: nerve fiber layer; 
ONL: outer nuclear layer; RPE: retinal pigment epithelium. (Image from Jing Chen 
Laboratory website). 
1.5.2 Müller cells 
1.5.2.1 Müller physiologic function 
Müller cell population is intense and well organized in retina, which provides architectural 
support to retinal neurons. Their cell bodies are situated in the inner nuclear layer. Their 
processes extend through the entire retinal thickness, their endfeet forming the inner 
limiting membrane and their outer processes supporting photoreceptors. They also form 
endfeet on retinal large retinal blood vessels. Anatomically, Müller cells are tightly related 
to all retinal cells and blood vessels59. 
Müller cells participate in many retinal physiologic functions. They regulate retinal blood 
vessels and maintain blood-retinal barrier. They provide metabolic and nutritional support 
to retinal neurons, maintain retinal physiologic homeostasis (water/ion and pH), uptake or 
recycle neuronal transmitters, provide scaffold for neuronal cells orientation during retinal 
development, release neuroactive or vasoactive substances59. Müller cells secrete 
neuronal trophic molecules such as nerve growth factor to support neuronal survival and 
neuritogenesis60. 
1.5.2.2 Müller gliosis 
In some species, Müller cells can regenerate retinal neurons after retinal damage. For 
example, zebrafish retinal Müller cells produce neural progenitor cells following neuronal 
damage and death61. While in mammalian, Müller cells undergo gliosis in response to 
retinal damages and infections, which is important for protecting and repairing neurons 
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from diverse harmful stimulus. The hallmark of retinal Müller cell gliosis is the shape 
change resulting from rapid upregulation of glial fibrillary acidic protein (GFAP) following 
acute retinal injury62. The time-dependent Müller cell gliosis is significantly associated with 
retinal functional impairment and alteration of retinal gene expression63. Human Müller 
cells may produce IL-6 mRNA and proteins after stimulation of IL-1β or LPS64. Müller gliosis 
modifies the expression of glutamine synthetase, reduces the K+-conductance on their 
membrane, releases neurotrophic factors and antioxidants. The Müller gliosis can also 
release detrimental factors such as nitric oxide and VEGF, leading to detrimental glial scar, 
which could disturb the retinal function59. The increase of intermediate filament expression 
in Müller gliosis is correlated with cell stiffness, which could impede the nerve 
regeneration65. In retinal detachments, Müller cell processes migrate abnormally to the 
outer part of retina and undergo mitosis and gliosis, resulting in subretinal glial scar66. 
1.5.2.3 The inflammatory reaction of Müller cell 
Müller cells express innate immune receptors and are capable to sense both pathogen- 
and host-derived ligands67. Müller cells express Toll-like receptors (TLRs) 1-10, the major 
family of pattern recognition receptors in innate immune response68. Müller cells express 
also intracellular NOD-like receptors (NLRs), which are correlated with TLRs and regulate 
inflammatory reaction69. After detecting these pathogens, Müller cells react intensely and 
release proinflammatory cytokines, chemokines and nitric oxide (NO). During S. aureus 
endophthalmitis, Müller cells are activated and secret proinflammatory cytokines (IL-6, 
TNF-α, and IL-1β), chemokines (IL-8), and antimicrobial peptide (IL-37)70. In endotoxin-
induced uveitis, Müller cells express NO and TNF-α71. Müller cell-derived VEGF is the key 
factor in inducing retinal vascular lesions, vascular leakage and retinal cytokines 
productions72.  
1.5.2.4 Müller cell gliosis results in retinal edema 
Müller cells express water transports coupled to potassium channels, which can be 
influenced during retinal inflammation. Kir4.1, the main potassium channel in retina, and 
Aquaporin 4 (AQP4), the predominant water channel colocalize on Müller cells. During 
uveitis, Kir4.1 and AQP4, 5 expressions are significantly decreased on cytoplasm 
membrane of Müller cells73. Aquaporin 11, expressed exclusively on Müller cells, 
decreases significantly during uveitis, which is related to Müller cell swelling and retinal 
edema74. When the homeostasis of ion and water influx is disturbed by inflammation, 
Müller cells undergo swelling and neurons suffer from the abnormal osmotic stress59.  
Müller gliosis is related to retinal swelling. In endotoxin (LPS)-induced ocular inflammation, 
Müller cells hypertrophy and increase the immunoactivity of GFAP. Electrophysiology 
shows the downregulation of inward K+ currents and depolarization of Müller cell 
membrane. The intracellular Müller cell edema can increase extracellular fluid 
accumulation75. In retinal inflammation, retinal Müller cells are activated and transformed 
into gliosis, accompanied by decrease of potassium and water channel protein expression, 
which results in Müller cell swelling and dysfunction of retinal fluid absorption, leading to 
retinal edema and degeneration74, 76.   
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1.5.3 Microglial cells 
In retina, microglial cells have two origins: blood-cell born cells and mesodermal cells. In 
rabbit retina, microglial cells are located in nerve layer and inner plexiform layer, with small 
cell bodies and long ramified processes panning the around areas.  
1.5.3.1 Microglial cell is sensitive to the changes of 
environment 
Microglial cells monitor their environments and can migrate to damaged areas and 
phagocytize apoptotic cells and debris. In murine newborn, some retinal ganglion cells 
undergo physiological apoptosis. Microglial cells migrate to ganglion cell layer and 
transform into amoeboid phagocytic microglia77. In pathological condition when retina is 
injured, microglial cells are activated and transform into active amoeboid form to participate 
in inflammation, removal of cellular debris and glial scar78.  
Microglial cells have potential to act as macrophages and dendritic cells during immune 
responses79. Retinal microglial cells express CD45, CD68 and some macrophage antigens, 
suggesting that they are potential macrophages in retina79. Retinal microglial cells share 
many characteristics with dendritic antigen presenting cells. They express constitutive 
MHC class II antigens, HLA-DR, CD45 and nucleotidase80. Microglial cells are very 
sensitive to the changes of environment. Time-lapse confocal imaging shows that 
microglial cell processes are in dynamic movement (extension and retraction) and can 
rapidly transform their morphology and migrate in response to retinal injury81. In vitrectomy, 
microglial cells undergo reversible morphologic transformation without Müller cells 
activation or obvious neuronal damages82. 
 
1.5.3.2 Retinal microglial cell activation 
Retinal microglial cell activation is a common hallmark of various retinal degenerative and 
inflammatory diseases and the early phenomenon in response to retinal injuries and 
inflammations83. Retinal microglial cells demonstrate a broad range of morphologic 
changes in different activated stages. Early activated changes include enlargement of the 
soma, retraction and shortening of processes, and increase of the expression of myeloid 
cell markers. Microglial cells are slightly activated but can easily resume to a resting state. 
At more activated state, microglial cells are transformed into amoeboid form, a round 
cellular soma without processes84, which can turn into post-activated state with a reduced 
number of processes or undergo apoptosis by overactivation (Figure 8)85. Activated 
microglial cells can express proinflammatory cytokines, chemokines, growth factors, 
neurotrophins, reactive oxygen and nitrogen species. In autoimmune uveoretinitis, 
microglia migrate to the photoreceptor cell layer where they generate TNF-α and 
peroxynitrite86. Hypoxia induces microglial cells to express inflammatory factors, TNF-α 
and IL-1β, which can further cause ganglion cell apoptosis87.  
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Figure 8: The activated states of microglial cell in response to various stimuli 
Resting microglial cell is ramified and can transform into different activated states. Some 
active microglial cells reduce their processes but resume easily to resting state (phenotype 
1). Some active microglial cells turn into amoeboid form (phenotype 2), which undergo 
death by overreaction (reactive phenotype 3) or migrate and return into post-activated state 
with a reduced number of processes (reactive phenotype 2.1 and 3.1). (F. RohanWalke et 
al, 2014). 
 
1.5.3.3 The regulation of microglial cell activation 
The activation and gene expression of microglial cells are influenced by two systems: 
receptors detecting pathogens and the balance between excitatory and inhibitory stimuli. 
The abnormal substances can be detected by an array of receptors expressed on 
microglial cells, such as Toll-like receptors (TLRs) detecting microbiological substances85. 
It is commonly admitted that microglial cells can monitor the overall neuronal condition by 
the balance between excitatory and inhibitory stimuli. The capacity of microglial cells to 
undergo inflammatory response is restrained by their microenvironment, especially those 
from neurons. It is widely proved that microglial cells are regulated by several ligand-
receptor systems, such as CD200-CD200R, CD22–CD45, CX3CL1-CX3CR1, and 
neurotransmitters-receptors, such as TGFβ- TGFβ receptor and dopamine-dopamine 
receptor.  
TGFβ predisposes retina to the IL-10 release88. CD200R is expressed on microglial cells. 
CD200, an inhibitory gland of CD200R, is wildly expressed on retinal cells and vascular 
endothelium. CD200 binds to CD200R on microglial cells, which incites inhibitory 
intracellular signaling cascade to block pro-inflammatory activation. When the balance of 
CD200:CD200R axis is disrupted, retinal microglial cells are activated89. CX3C chemokine 
receptor 1 (CX3CR1) can promote the dynamism of microglial cell process and cellular 
migration90. The chemokine [C-X3-C motif] ligand 1 (CX3CL1), a gland for CX3XCR1, is 
expressed on retinal neurons. The CX3CL1-CX3CR1 signaling regulates microglial 
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dynamism and maintains the microglial distribution in retina91. Retinal microglial 
morphology and dynamic behavior are also influenced by neurotransmitters such as 
glutamate and GABA release92, 93.  
 
1.5.3.4 Microglial cells interact with Müller cells 
Activated microglial cells interact with activated Müller cells through neurotrophic factors, 
cytokines and chemokines, which influence further the neuronal survival. In response to 
retinal damage, microglial cells are activated and release neurotrophic factors such as 
nerve growth factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor 
(GDNF). Those neurotrophic factors can modulate Müller cells to release GDNF and basic 
fibroblast growth factor. Those neurotrophic factors influence photoreceptor survival94. In 
co-culture of activated microglial cells, Müller cells increase the expression of GDNF and 
leukemia inhibitory factor, which protect photoreceptors from oxidative stress and 
proinflammatory factors. Activated microglial cells can activate Müller cells, the activated 
Müller cells can further activate microglial cells95. 
1.5.4 Amacrine cells 
Amacrine cells are interneurons, located at the second synaptic level of light pathways, 
which is consisted of the photoreceptor-bipolar-ganglion cell chain. Amacrine cells do not 
have true axons, only long processes. They play a role in modulating and interposing the 
signal transmitter96. Amacrine cells occupy more than 40% of the inner nuclear cells and 
are classified into more than 22 different morphological subtypes, only one type of 
amacrine cells makes up more than 5% of total amacrine cell population. The classification 
is based on cell shape, biochemistry and location in the inner plexiform layer. Amacrine 
cells from different classification connect with different bipolar cells and ganglion cells and 
contain different neurotransmitters97. Some amacrine cells are dopaminergic, some are 
glycinergic such as AII amacrine. "Starburst" amacrine cells use acetylcholine as excitatory 
neurotransmitter and GABA as inhibitory neurotransmitter98. Amacrine cells A2 contain 
substance P; some amacrine cells accumulate serotonin99 (Table 3).  
Neurobiotin injected to individual cell can diffuse across gap junctions to label neighboring 
neurons. This tracer coupling reveals the presence of gap junctions among coupled retinal 
neurons throughout the cellular network. In retina, except for starburst amacrine cells, 
amacrine cells are intensively coupled with other amacrine and ganglion cells. This 
coupling is directional: ganglion cells can pass neurobiotin to amacrine cells, but amacrine 
cells rarely can pass neurobiotin to ganglion cells100. AII amacrine cells are coupled with 
calbindin-positive bipolar cells101. 
1.5.5 Retinal ganglion cells 
In retina, photoreceptors transform light into visual information and pass it to interneurons 
in retina. Retinal ganglion cells collect all the information and send it to the brain by their 
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axons through optical nerve. Retinal ganglion cells are divided into around 20 types 
according to their morphology, synaptic connections and light responses. Three major 
ganglion cells types (midget, parasol and small bistratified cells) occupy approximately 70% 
of all ganglion cells. The other ganglion cells are heterogenous102. In mammal retina, 
ganglion cells fail to regenerate and undergo apoptosis, when their axons are injured or 
cut103.  
1.5.6 Retinal neurotransmitters 
Table 3. The distribution of neurotransmitters in retina 
Neurotransmitters Expressed on retinal cells Principal role 
Glutamate AII photoreceptors, bipolar and 
ganglion cells 
excitatory 
GABA amacrine cells which also 
contain other neurotransmitters 
and horizontal cells in center 
inhibitory 
Glycine small-field types of amacrine 
cells (such as AII amacrine) 
and some bipolar cells 
inhibitory 
Acetylcholine Starburst amacrine cells Excitatory, co-localize GABA 
Dopamine one or more types of amacrine 
cells 
Co-exists with other 
neurotransmitters, regulate gap 
junctions 
Serotonin A17 and A18 amacrine cells Co-exists with GABA 
Substance P Some amacrine cells and some 
ganglion cells 
SP amacrine cells co-localize 
GABA; SP ganglion cells 
colocalize glutamate 
CGRP Inner retina, ganglion cells -- 
Others Amacrine cells -- 
Abbreviations: GABA: gamma-aminobutyric acid; SP, substance P; CGRP, Calcitonin 
gene-related peptide. 
 
In retina, l-glutamate (excitatory), gamma-aminobutyric acid (GABA) and glycine (inhibitory) 
are the principal neurotransmitters in retinal synapses. Other neurotransmitters are 
acetylcholine, dopamine, serotonin and substance P. Glutamate immunoreactivity is in 
photoreceptor, bipolar and ganglion cells. GABA and glycine immunoreactivities are in 
amacrine and some bipolar, horizontal and ganglion cells104. Dopamine, acetylcholine and 
serotonin are in some amacrine cells. Glutamate is excitatory neurotransmitter. Glutamate 
release is largely mediated by calcium-dependent vesicular processes105. It is taken up by 
glutamate transporters expressed on Müller cells. Ganglion cells express glutamate 
receptors, the kainite/AMPA and NMDA. Müller cells increase ganglion cell survival through 
the increase of glutamate transporter expression106. GABA is the primary transmitter and 
substance P is the secondary transmitter in A22 amacrine cells. Substance P is also 
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expressed by some retinal ganglion cells. In rabbit, 25%-30% of retinal ganglion cells 
express substance P107. Calcitonin gene-related peptide (CGRP) immunoactivity is found 
in the whole retina, with more intense staining in some cells in INL and GCL108.  
1.5.7 The calcium channels on retinal cells 
Voltage-dependent calcium channels (VDCCs) are involved in transmitter release, 
hormone secretion, gene transcription, cell regulation and synaptic plasticity in excitable 
cells109. VDCCs are transmembrane proteins consisted by three subunits: transmembrane 
α1 subunits, extracellular α2δ subunits and intracellular β subunits. VDCCs could be 
divided into two major families according to reaction in response to the voltages changes: 
high voltage-activated (HVA) channels such as the L-, P/Q-, N- and R-type channels and 
low voltage-activated (LVA) channels such as the T-type calcium channels 110. Retinal 
ganglion cells express L-, N-. P/Q- and T- type VDCCs, as demonstrated by 
pharmacological blockades of these calcium channels111. 
There are also some non-VDCCs, which are activated by glandes or depletion of calcium 
store: the activation of receptor-operated calcium channels (ROCCs) depends on the 
activation of a range of receptors such as nicotinic acetylcholine receptors (nAChR). The 
store-operated calcium channels (SOCCs) are activated by depletion of the calcium store 
within the sarcoplasmic reticulum112, 113.   
The transient receptor potential channels (TRPs) are wildly expressed on cellular 
membrane and are divided into seven subfamilies: TRPC (canonical), TRPV (vanilloid), 
TRPM (melastatin), TRPP (polycystin), TRPML (mucolipin), TRPA (ankyrin) and TRPN. 
The TRPs are non-selective cation channels, except a few which are highly Ca2+ 
selective114. The TRPs can be activated by a variety of mechanisms, such as ligands, 
voltage changes, temperature and metabolic products. The activated TRPs cause 
depolarization and initiate immobilization of cations (such as Ca2+ and Mg2+), which is 
involved in many physiological and pathological processes115.   
Cytoplasmic calcium is mostly stored in endoplasmic reticulum (ER) and mitochondria. 
Calcium is released from ER by activation of inositol trisphosphate receptors (IP3R) and 
ryanodine receptors (RyR), which are mediated by other cytoplasmic membrane receptors, 
such as glutamate receptors113, 116. The calcium recharge in ER is mediated by the sarco-
/endoplasmic reticulum calcium ATPase (SERCA)117. Mitochondria take up calcium 
through the calcium uniporter and release calcium by sodium-calcium exchange, which is 
much slower in physiological conditions118. The release of cytoplasmic calcium to 
extracellular compartment is through the plasma membrane calcium ATPase (PMCA) and 
the sodium-calcium exchanger (NCX)119. The lysosome can release calcium after being 
activated by nicotinic acid adenine dinucleotide phosphate (NAADP). NAADP is formed by 
ADP-ribosyl cyclase CD38 after transmembrane receptors being activated by their 
glands120 (Figure 9).  
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Figure 9: The sources of neuronal calcium mobilization 
The extracellular calcium inflow after activating AMPA, NMDAR, VGCC and TRPC. The 
intracellular calcium is released from endoplasmic reticulum and mitochondrion after 
activating mGluR, RyR and IP3R. 
Abbreviations: AMPA, calcium-permeable α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; NMDAR, N-methyl-D-aspartate glutamate-type receptors; VGCC, 
voltage-gated calcium channels; nAChR, nicotinic acetylcholine receptors; TRPC, 
transient receptor potential type C channels; IP3R, inositol trisphosphate receptors; RyR, 
ryanodine receptors; mGluR, metabotropic glutamate receptors. PMCA, plasma 
membrane calcium ATPase; NCX, the sodium-calcium exchanger; SERCA, the sarco-
/endoplasmic reticulum calcium ATPase. (Grienberger, C et al, 2012) 
1.6 Endophthalmitis  
Bacterial endophthalmitis is an infection of internal part of eye, which is associated with 
bad visual outcomes121. It is diagnosed by clinical symptoms (pain, decrease of vision, 
hypopyon, opaque vitreous, retinal reaction), combined with biological analysis such as 
culture of samples from vitreous and aqueous humor122. But there is about 20% of clinical 
endophthalmitis which are negative in culture of samples obtained from aqueous humor 
and vitreous. This might be due to viral infection or technique limitation123. Thereby, the 
diagnosis of endophthalmitis is based on clinical symptoms and systemic risk factors 
together with multiple biological analyses122. The visual outcomes vary from recovery to 
loss of vision, depending on many factors such as the virulence of the pathogen and the 
delay of treatment124. 
Bacterial endophthalmitis often results in poor prognosis. Only 43%–53% of patients can 
achieve 20/40 or better visual acuity (VA), and about 20% have 20/100 or worse even after 
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appropriate treatment management125, 126. Enucleation or evisceration are still common 
options in severe cases of endophthalmitis127. Recently, treatments such as vitrectomy and 
intravitreal injections of antibiotics have been introduced. However, visual outcomes are 
not significantly improved126. 
1.6.1 The classification of endophthalmitis 
Endophthalmitis is divided into post-operative, post-traumatic and endogenous 
endophthalmitis according to the initial condition. The post-operative endophthalmitis 
occurs after ocular intervention surgery, post-traumatic endophthalmitis occurs after the 
bleach of eyeball in accident. Endogenous endophthalmitis is resulted from metastasis of 
pathogen from other organs through ocular barrier. Those three kinds of endophthalmitis 
present different pathogenic characteristics and different difficulties in treatment121.  
1.6.1.1 Post-operative endophthalmitis 
The rate of endophthalmitis after ocular surgical intervention is very low, between 0.05% 
to 0.37%, depending on the types of intraocular surgery121. But post-operative 
endophthalmitis remains great prudence for surgeons considering the great number of 
ocular surgery and bad visual outcomes. The factors contributing to bad outcomes include 
intracapsular cataract surgery, poor presenting visual acuity, presence of vitreous cells, 
inability to visualize the optic disc on indirect ophthalmoscopy, presence of vitreous 
membranes on ultrasonography, and a culture-positive vitreous biopsy128. One important 
factor is the virulence of the organism isolated from intraocular samples. Intraocular 
infections caused by virulent strains such as S. aureus, enterococci, Bacillus, or Gram-
negative strains are often difficult to treat and result in bad vision129.  
In post-operative endophthalmitis, the most common pathogens detected are Gram+ 
bacteria, occupying 94%. The Endophthalmitis Vitrectomy Study (EVS) reported that 84% 
of Gram+ endophthalmitis cases resulted in at least 20/100 VA and 50% of these cases 
resulted in at least 20/40 VA, while only 30% of endophthalmitis cases caused by virulent 
organism attained 20/100 VA129. 
Among these Gram+ bacteria, the coagulase-negative staphylococci (CoNS) is the most 
frequent, occupying 47 to 70% of all the cases. S. aureus is the second, occupying about 
10%130. Most endophthalmitis caused by CoNS result in good visual outcomes, but some 
present delayed-onset, chronic and often painless inflammation, even severe ocular 
damages such as retinal detachments131.   
1.6.1.2 Post-traumatic endophthalmitis 
The rate of endophthalmitis after penetrating ocular trauma ranges from 3.3% to 17%, 
which is about 100 times greater than that of post-operative endophtalmitis121. The setting 
place of accident influences greatly the incidence of endophthalmitis. In rural places, the 
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penetrated eyes have 30% incidence of endophthalmitis. While in urban place, the 
penetrated eyes have 11% possibility to develop endophthalmitis132. Also, the delayed 
removal of intraocular foreign body (IOFB) and the type of IOFB increase significantly the 
incidence of endophthalmitis after accident133. Other factors associated with poor visual 
outcomes include trauma by needle (hypodermic or sewing), poor presenting visual acuity, 
inability to visualize the optic disc on indirect ophthalmoscopy, presence of vitreous 
membranes on ultrasonography, breach of lens capsule, and delayed primary repair and 
culture-positive vitreous biopsy128, 134.   
S. aureus is the most common virulent organism isolated from post-traumatic 
endophthalmitis. The second frequent virulent bacterium is B. cereus, which is ten times 
more likely to be isolated from post-traumatic endophthalmitis than from post-operative 
endophthalmitis128. The CoNS, such as Corynebacterium, and Propionibacterium acnes, 
are considered as nonvirulent microorganisms, but they can also result in bad visual 
outcomes135.  
1.6.1.3 Endogenous endophthalmitis 
The endogenous endophthalmitis occurs when organisms migrate from other infectious 
organ via the bloodstream and enter the internal eye by overcoming the blood–ocular 
barrier136. The rate of endogenous endophthalmitis is low, 2-8% of total endophthalmitis. 
But they have very poor visual outcomes137. The patients have usually 
immunocompromised condition, and it is easy to misdiagnose and delay the treatment. 
Blood sample culture (74%-94%) is more often positive than interocular sample culture 
(56%)138. The causative bacteria to endogenous endophthalmitis include the Gram+ 
microorganisms (S. aureus, Bacillus spp, CoNS, group B streptococci, Streptococcus 
pneumoniae, and Listeria monocytogenes) and Gram- microorganisms (Escherichia coli, 
Neisseria meningitidis, Pseudomonas aeruginosa, and Klebsiella spp). The rates of 
causative organisms vary geographically. The opportunistic fungus Candida albicans 
represents particularly more than 50% of the cases of endogenous endophthalmitis in 
Europe139. Gram- organisms are reported as the most common causative organisms from 
East Asian hospitals, while Gram+ organisms are more common in North America138.  
1.6.2 Inflammatory changes in retina during 
endophthalmitis 
During endophthalmitis, retina undergoes rapidly inflammatory changes to react the 
invading pathogens, such as cytokines and chemokines release, neutrophils infiltration. 
Those inflammation could modify retinal architecture, resulting in function loss. 
1.6.2.1 Cytokines and chemokines release 
Cytokines, chemokines, and adhesion molecules are released in bacterial endophthalmitis. 
TNF-α, IL-1β, and CINC (rat homologue of IL-8) are detected in the vitreous within 6 h and 
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elevated significantly 24 h after intravitreal injection of S. aureus140. In experimental B. 
cereus endophthalmitis, the significant increase of TNF-α occurs at 4 to 6 h postinfection141. 
IL-1β, IL-6, and MIP-3α increase in the aqueous humor and vitreous humor from eyes with 
endophthalmitis142.  
1.6.2.2 Inflammatory cells infiltrate into retinal tissue 
Severe infection is often accompanied by infiltration of neutrophils. In B. cereus and S. 
aureus induced endophthalmitis, the recruitment and activation of neutrophils within the 
eye are noticed within several hours141, 143. Neutrophils infiltrate into the retina 24 h after 
PVL injection57. The neutrophils infiltration is essential for eliminating the invaded 
pathogens. The depletion of neutrophils delays the onset of severe ocular inflammation, 
but also prevents adequate clearance of bacteria143. But the generation of toxic reactive 
oxygen and other inflammatory mediators by neutrophils cause irreversible tissue damage 
in the eye and impair the visual functions144. 
1.6.2.3 Retinal architectural changes and function loss 
Retinal structural changes during endophthalmitis include photoreceptor layer folding, 
retinal detachment, and complete dissolution of retinal cell layers121, 130. Retinal Müller cells 
expand vertically the whole retina and play a role in maintaining the retinal integrity and 
participating in many physiological processes145. Müller cell dysfunction is tightly related to 
retinal structural alterations146, 147. The upregulation of GFAP is a hallmark of gliosis62. So, 
GFAP increase in Müller cells is considered as a signal of retinal architecture deformation. 
B. cereus (100 CFU) is intravitreally injected in mice and toxins are intraocularly produced 
and herein interact with Müller cell. The increase of GFAP immunostaining is detected as 
early as 4 h post-infection, which is paralleled with the decline of retinal function141.    
Blood-retina barrier (BRB) is constituted of inner and outer blood-retinal barriers. These 
barriers protect retina from toxic cells and molecules and maintain ocular physiology and 
function148, 149. The zonula occludens between endothelial cells in retinal vessels are 
impaired by ocular inflammation, resulting in damage of BRB150. The BRB permeability is 
hallmark of retinal structure integrity. Leakage from BRB appears early during 
endophthalmitis and restores after 1 month151. B. cereus infects retinal pigment epithelium 
(RPE) cell monolayer, leading to the decrease of the expression of occludin and zonula 
occludens-1, and cytotoxicity to RPE152. Retinal Müller cell processes connect closely to 
retinal vessels. Bacteria or bacterial toxins activate retinal Müller cells and cause high 
permeability of BRB 153.  
1.6.3 Treatment: vitrectomy and intravitreal antibiotic 
From 1995, the diagnosis and treatment have improved. For diagnosis, culture and PCR 
analysis are routinely used to analyze the samples form anterior chamber and vitreous. 
For management, the vitrectomy and intravitreal antibiotic increase, while subconjunctival 
and intravenous injection of antibiotic decrease154. Vitrectomy surgery debrides infecting 
organisms, the toxins and inflammatory cells from vitreous cavity, which is valuable in the 
treatment of endophthalmitis155. The rate of vitrectomy is about 45% in United States126.  
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The vitrectomy is an effective adjunct to anti-microbial therapy in suspected 
endophthalmitis cases following intraocular surgery. The immediate vitrectomy (within 6 h) 
is especially of significant benefit to patient who have only light perception129. The 
vitrectomy could somehow improve final ocular condition for patients with only light 
perception126. The vitrectomy could maintain ocular formation and structure and prevent 
the globe shrinkage and chronic inflammation154. Many reports agree that vitrectomy 
should be performed without delay in severe cases of endophthalmitis, especially those 
presenting IOFBs126, 156, 157.  
The intravitreal injection of antibiotic is an important treatment. The systemic antibiotic 
administration of vancomycin and aminoglycosides could partially penetrate blood-ocular 
fluid barrier due to the increase of BRB permeability caused by intraocular inflammation158. 
But the systemic antibiotic does not demonstrate additional benefits in combination with 
intravitreal antibiotic administration159. The intravitreal antibiotic should cover most possible 
and multidrug resistance strains160. The appropriate antibiotics include gentamicin with 
vancomycin or clindamycin, the fourth-generation fluoroquinolones such as gatifloxacin 
and moxifloxacin which penetrate BRB and have broad-spectrum of antibacterial activity160. 
Considering the possible toxicity of fluoroquinolones and aminoglycosides, the routine 
intravitreal administration consists of 1.0 mg of vancomycin and 2.0 mg of ceftazidime161, 
162.  
The vitrectomy and intravitreal antibiotic contribute to eliminate pathogens from ocular 
cavity to control the evolution of endophthalmitis. But retinal function is disturbed even at 
the very early stage of infection. Although great improvement in diagnosis and 
management is achieved, the visual outcomes are not always significantly improved.  
1.7 Animal model 
1.7.1 Intravitreal injection 
1.7.1.1 The employment of intravitreal injection 
Posteriors ocular diseases, such as age-related macular degeneration (AMD), diabetic 
retinopathy (DR), diabetic macular edema (DME), infection, occlusion of retinal vein, often 
cause severe visual acuity loss. The prognosis of posterior ocular diseases depends on 
the efficiency and safety of delivery drugs to posterior segment of eye. Delivery of drug to 
posterior segment of eye is always challenging, due to anatomical and physiological 
barriers of the eye. The methods include systemic administration of medicament, 
periocular and intravitreal injection, and local eyedrop.  
Systemic administration is a traditional way to treat severe intra-ocular disease. But many 
drugs cannot freely pass BRB. If drugs can pass through BRB because of specific structure 
of drugs or the pathogenic BRB break-down, it requires also a great bolus to achieve 
sufficient intraocular concentration and could cause systemic unwanted side-effects. Eye 
drop can infiltrate into ocular surface tissue such as cornea and conjunctiva. But it 
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penetrates slowly in intra-ocular space and cannot be used to treat posterior diseases. 
Periocular injection, including sub-conjunctive and posterior ocular injection, can improve 
the concentration and duration of drug in periocular tissue. But it cannot efficiently deliver 
drug to intraocular posterior segment.   
Intravitreal injection of medication has many advantages. It can immediately deliver 
medication to vitreous and retinal tissue and maintain the concentration of medication in 
vitreous for long time even when small quantity of medicament is injected. Since 1940s, 
intravitreal application of antibiotic was studied to treat endophthalmitis. Triamcinolone 
acetonide is the first widespread drug administrated by intravitreal injection. Since then, 
many novel medications, such as anti-vascular endothelial growth factor (VEGF), 
dexamethasone, fluoquinolone and ocriplasmin, have been developed to be administrated 
by intravitreal injection. Medications are intravitreally injected to treat different posterior 
ocular diseases: triamcinolone to treat macular edema; anti-VEGF agents to treat retinal 
neovascular disease; antibiotics, antivirals and antifungals to treat endophthalmitis. 
Intravitreal injection presents some disadvantages including elevation of intraocular 
pressure or glaucoma, endophthalmitis and retinal decollement. For intravitreal injection of 
corticosteroid, the most frequent complication is the elevated intraocular pressure and 
glaucoma. Intravitreal anti-VEGF and anti-microbials injections have relatively a low 
complication rate. The incidence of lens injury is 0.006% (2/32,318) and retinal detachment 
is 0.013% (5/35,942). The rate of suspected endophthalmitis is 0.018% after bevacizumab 
and 0.027% after ranibizumab injections. Sterile inflammation is observed after Avastin 
injections. Increased intraocular pression is observed after repeated injection of anti-
VEGF163. 
1.7.1.2 Intravitreal injection in experiment 
Intravitreal injection is also used in experiment. Adeno-associated viral (AAV) gene therapy 
has potential of treating retinal disorders such as retinitis pigmentosa and age-related 
macular degeneration. Intravitreal administration of gene vectors can provide safe and 
efficient gene delivery164. 
Intravitreal injection of bacteria, bacterial products and other medications is a common 
method to analyze their effects on retina. In this way, products can immediately be 
delivered to retina with little disturbance of physical ocular functions and anatomy.   
1.7.1.3 The mechanism of passage  
Diffusion in vitreous 
Vitreous gel is bloodless and contains more than 98-99% water. In addition to water, an 
extensive and delicate meshwork of collagen fibrils with glycosaminoglycan and 
hyaluronan is filled in vitreous. Owing to those solid components, vitreous humor is viscous 
and has a gelatinous consistency. The diffusion of drugs depends on microstructure and 
microrheology of vitreous. The pore size of meshwork and electrocharged characteristics 
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are two key factors to influence the diffusion in vitreous of intravitreal medication.  
The composition and microstructure of bovine vitreous are similar to those of human 
vitreous. The mesh pores of bovine vitreous are estimated as large as 2 micrometers. 
Recently, it was shown that the pore size is 550 ± 50 nm, with some pores as large as 1000 
nm. Large particles (> 500 nm) cannot easily pass through meshwork and diffuse slowly165. 
If particles exhibit adhesive interactions with meshwork, they diffuse slowly. In vitreous, 
glycosaminoglycans are negatively charged. Positive charged particles are trapped by 
negative meshwork and diffuse slowly. Negative charged particles are repelled by the same 
charge of meshwork. If anionic particles are in small size and at low concentration, they 
can fluently diffuse in vitreous. At high concentration, anionic particles cumulate and 
generate enough strong adhesive interactions to collapse collagen fibrils, resulting in 
immobilized particles in vitreous165.  
In conclusion, the size, surface charge and concentration influence the diffusion of 
intravitreal injection medications in vitreous165. The vitreous gel is not homogeneous and 
the diffusion of medication in vitreous could be heterogeneous. PVL is positive charged in 
physiological pH. 
Diffusion in retina 
After penetrating the vitreous gel, drugs reach to retina. The retina is semipermeable 
membrane. It is reported that molecule larger than 100 kDa could not easily pass the retinal 
layer to the subretinal space, due to barriers formed by inner limiting membrane (ILM), 
outer limiting membrane (OLM) and Müller cells. The inner and outer plexiform layers are 
also the sites of highest resistance to diffusion166. ILM is a basal membrane between the 
endfeet of Müller cells and vitreous. The pore size of human ILM is estimated to be 10 nm. 
ILM acts as a biological and electrostatic barrier with a net negative charge, preventing 
macromolecular drug to penetrate into the retina. ILM is a barrier to gene vector delivery 
to specific retinal cells. After digestion of ILM, the efficiency of delivering gene vector to 
retina is improved164. Müller cells could uptake the diffused molecules, which is mediated 
by receptors. OLM is formed by tight junctions between the apical processes of Müller cells 
and inner segments of the photoreceptors. Albumin and gamma-globulin cannot pass 
through an intact OLM. However, the limit of particle size to penetrate OLM is not quite 
clear167. 
In total, the maximum size of molecule capable of diffusing freely across retina is 76.5 +/- 
1.5 kDa (6.11 +/- 0.04 nm) in human, 86 +/- 30 kDa (6.38 +/- 0.88 nm) in rabbit166. The 
molecular mass of PVL is around 60 kDa.  
Drug clearance 
The intravitreal drugs could be cleared by metabolism in vitreous or elimination by blood 
circulation. Vitreous contains minor amounts of metabolic enzymes, the principal 
elimination is through blood circulation, then by metabolic clearance in liver and renal 
excretion to the urine167. 
Ocular clearance mechanisms limit the duration of drugs delivered by intravitreal injection. 
Pharmacokinetic of intravitreal drugs is dependent on their molecular characteristics and 
ocular factors such as ocular volume, vitreous liquefaction, lens status and prior vitrectomy.  
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1.7.2 Retinal explant culture 
1.7.2.1 The advantage of explant model  
The primary cells culture from dissociated retina is useful to elucidate the direct effect of 
one type of cells. But it is time-consuming, expensive and has limits in reproducing 
conditions in vivo for absence of intercellular interaction168. Retinal explant is an important 
alternative between dissociated primary cell culture and animal model in vivo. First, retinal 
explant maintains the neurons in situ and in contact with other cells and extracellular matrix 
au maximum. For this reason, explant culture provides more predictive results for 
experiments in vivo. Second, retinal explant provides an easily controlled environment. The 
medicament can be directly applied on the surface of explant in a more manageable and 
direct manner. The serum-free medium has accurate and defined ingredients, ensuring the 
reproducibility of experiments. Third, retinal explant undergoes rapid regression of the 
blood vasculature, resulting in lack of retinal and choroidal blood supply. It can eliminate 
the possible potential disturbance of myeloid cells in blood circulation and the effects of 
BRB break-down169. 
 
 
 
Figure 10: Simple illustration of explant system 
The fresh retinal explant is deposited on polycarbonate membrane of an insert. This insert 
is placed in a well of a plate. The well is filled with 2 ml culture medium, just in contact to 
the membrane.  
1.7.2.2 Introduction of this method 
The retina is dissected from fresh eye and placed immediately on semipermeable 
polycarbonate membrane inserted in a well containing culture medium. The photoreceptor 
layer is facing downward on membrane which is kept just in contact to culture medium. 
This culture system keeps retinal explant in fluid-air condition, which is essential for explant 
culture and allows adding supplement in culture medium and on the surface of retinal 
explant (Figure 10).  
This technique begun around 1976 with Xenopus laevis retina and adult golden fish retina 
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to study the effect of prior optic nerve crush170. In 1981, the mouse retina was used as 
retinal explant to study ganglion development after optic nerve cut171. Since then, 
organotypic retinal culture was wildly used in various researches mainly for retinal neurons. 
The animal species does not influence the explant culture and many species have 
successfully been used in retinal explant culture, such as fish, mice, rats, rabbits, chickens, 
monkeys, pigs, bovines, and postmortem humans169.  
1.7.2.3 Retinal explant morphology and genetic changes   
Retinal explant decreases their thickness but preserve their cell layers. For adult mouse 
retinal explant, the retinal thickness decreases by half even though the retinal layers are 
preserved 4 days after culture172. Human retina culture demonstrates progressive retinal 
degeneration with decrease of plexiform layer thickness, reduction in the number of 
nuclei173. The retinal explant lacks choroid and retinal blood supply. This decrease of retina 
thickness might be due to the degeneration of retinal vasculature.  
The mean RNA yield of retinal explant decreases. Mean RNA yield per microgram of adult 
mouse retina is decreased by almost 75% at 1-day culture172. RNA yield of pig colonic 
explant dropped from 505.0 ± 48.64 μg/mg to 227.6 ± 25.52 μg/mg at 6 h and 159.3 ± 
24.19 μg/mg at 12 h of incubation. After 3 h incubation, RNA integrity was also 
decreased174. This decrease might be due to the decrease of rhodopsin RNA expression 
and RNA instability because of the dramatic changes of condition after isolation. 
Retinal photoreceptors undergo apoptosis 4-day after culture, while ganglion cells undergo 
physically apoptosis in neonatal retinal explant in the first hours after culture175. In neonatal 
rat retinal explant, retinal ganglion cells underwent physiologically apoptosis 6 h and 
peaked at 48 h after culture. Photoreceptor underwent apoptosis 6-day after culture176. 
Another study showed that apoptosis of photoreceptor appeared and increased greatly 
after 4-day culture172. This apoptosis of photoreceptor results from ER stress and is related 
to damages of inner retina173, 177.   
The activation of Müller and microglia cells occurs in retinal explant. In rat retinal 
organotypic explant, microglial cells present features of activation: amoeboid form and 
retraction of processes. After 6 days culture, microglial cells regain their ramified 
morphology178. One day after culture, TNF-α, IL-6 and MCP-1 are detected in the culture 
supernatant, microglial cells undergo proliferation as revealed by Ki67, a cell proliferation-
associated marker179. In neonatal rabbit retinal explants, Müller cells upregulate GFAP and 
decrease glutamine synthetase180.   
Retinal explant is better to culture with serum free medium in addition of appropriate 
neurotrophic factors. Retinal explant in medium containing serum is more often associated 
with tissue degradation, cell death than in serum free medium181. Glial cell line-derived 
neurotrophic factor added into medium can improve preservation of photoreceptors and 
horizontal cells182.  
In conclusion, retinal explant undergoes some changes in the first few days culture. In 
different studies of retinal explant, the culture method might be very different, such as rat 
or rabbit, postnatal or embryo retina, in defined serum-free media or serum-containing 
medium. 
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1.7.2.4 The employment of retinal explant  
In the first two decades, retinal explant was used to study degeneration of retinal neurons 
induced by axotomy. In recent years, retinal explant culture enriches its functions by 
combining with other experimental technologies and is proved to be a good model to study 
pathogenic mechanism and possible treatment.  
1.) Organic retinal explant is wildly used to study retinal development, CNS regeneration 
and neurodegeneration from the beginning of this technique. Embryo retinal explant 
combining with gene transfer is used to study retinal cell differentiation and retinal 
developement183, 184. Adult retinal explant is also employed to study the neuronal survival 
and axon regeneration, the endothelial cells angiogenic responses169, 185, 186. Retinal 
explant is employed to search the retinal survival mechanisms and to test potential novel 
neuroprotective agents in the treatment of retinal vascular and neurodegenerative 
diseases.   
2). Combining retinal explant with cell labelling technologies, such as gene transfection cell 
labelling, calcium labelling and retrograde labelling, can facilitate the use of time-lapse 
imaging or screening system in research187. Animal is genetically transformed to have 
fluorescence-expressing retinal cells, such as Thy1-YFP mouse. Combining time-lapse 
imaging to fluorescent retinal explant can view ganglion cells dendritic arbors and evaluate 
the neuroprotective effects of neurotrophic agents over a course of several days188. The 
ganglion cells can also be labeled by retrograde injection of FluoroGold before eye isolation. 
This screening system provides fast, reproductive and sensitive method to detect 
neurotoxicity189.  
3). In a more controlled environment, retinal explant can be developed as pathology model 
to study retinal disease mechanisms and to test potential treatments with less animal 
suffering. The serum-free culture medium ensures metabolic quantitation and 
pharmacological interfering190. Culture in hypoxic conditions, retinal explant can establish 
retinal ischemic model to investigate hypoxic retinal neuropathies and possible 
treatment191.  
4). Retinal explant can help the developments of gene therapy and stem cell therapy to 
treat retinal diseases. The gene therapy is delivery of DNA to retina to cure hereditary 
retinal diseases. It needs vector tropism to target specific type of cell, which ensures the 
efficiency of gene transduction. It is currently performed by intravitreal injection of vector 
and genes in animal model. But the difference of receptors among species could influence 
the results in human. To better evaluate the transduction efficiency of vector, organic 
explant culture with human postmortem retina is a good model192, 193. Adding progenitor 
cells to retinal explant culture can imitate the intravitreal retinal stem cell therapy. 
Progenitor cells are added on the surface of retinal explant. They migrate and differentiate 
in retina, which can improve some function and reduce retinal cell loss181, 194. 
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1.8 Objectives 
Bacterial virulence is related to bad visual prognosis of bacterial endophthalmitis. PVL is a 
well characterized virulent toxin of S. aureus, which is related to severe infections. Instead 
of intravitreal injection of bacteria, we injected intravitreally PVL in rabbit eyes to analyze 
directly the effects of toxin on retina. We wanted to study early PVL effects on retina and 
know if PVL could induce inflammation in neural tissue after targeting neurons. Namely, 
we looked at identifying PVL retinal cell targets and analyzing the eventual inflammatory 
retinal response. Understanding PVL effects on retina could help to better understand the 
mechanisms of toxin leading to bad visual prognosis. This might provide some evidences 
for new therapeutic strategy to treat bacterial endophthalmitis.  
In the first article, we employed intravitreal injection of PVL in an in vivo rabbit model. 
Whereas, in the second article, we tried to figure out if it was possible to obtain similar 
results in an ex vivo model, using retinal explants. Indeed, we developed retinal explant, 
which seemed to be a less expensive and more manageable model to study the effects of 
PVL on retinal cells and the possible cellular relationship after infection.  
One of the main results, somehow surprising, was that PVL targeted retinal neurons, which 
seemed to induce glial cell activation and retinal inflammation. We were then interested in 
searching in the literature if neurogenic inflammation was already reported in retina and by 
which mechanism inflammation was enhanced. Even if neurogenic inflammation has not 
been studied in retinal infections, it has been described that bacterial toxins induce 
neurogenic inflammation during cerebellar and skin infections.  
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2. Materials and Methods 
2.1 PVL 
2.1.1 PVL purification 
PVL is composed by two components, LukS-PV and LukF-PV. Their genes are located in 
a bacteriophage. The genes of LukS-PV and LukF-PV, from S. aureus strain V8 (ATCC 
49775), were fused to Glutathion-S-Transferase (GST) in the plasmid pGEX6P-1. This 
fusion was carried by GST fusion protein SystemTM (Pharmacia), which allowed the 
overexpression, purification and detection of inserted protein in Escherichia coli BL21. The 
inserted plasmids were transferred to E. coli BL21. When E. coli BL21 containing 
recombined plasmid Pgex6p-1 was cultured to DO600nm 0.4-0.6, 0.2 mM IPTG was added 
to the overnight culture to induce the expression of inserted plasmids. The bacteria were 
then centrifuged and grinded by French Pressure Cell Press (SLM AMINO). The lysate 
was centrifuged, and the supernatant was collected. The concentration of supernatant 
protein was measured by quantifying GST. The combined protein was purified by affinity 
chromatography on Glutathion Sepharose 4BTM (Amersham-Bioscience). The elution 
containing GST activity was collected and treated by PreScission Protease® (GE 
Healthcare, Villacoublay, France) to cleave GST from the combined protein. The cleaved 
protein solution was passed cation-exchange fast-performance liquid chromatography to 
purify LukS-PV and LukF-PV, separately. The purity and identification of protein was 
assessed by SDS-polyacrylamide gel electrophoresis and radial gel immunoprecipitation 
before storage at −80 ◦C. This method can obtain 99% purity of LukS-PV and LukF-PV. 
2.1.2 Evaluation PVL effects by PMNs 
2.1.2.1 Purification of human PMNs 
PMNs were prepared from buffy coats of healthy donors of either sex, provided by the 
Etablissement Régional de Transfusion Sanguine de Strasbourg, France. The white-cell-
enriched blood was diluted by 0.9 % NaCl (1/3, v/v). 5 ml perfusion solution (Plasmion; 
Lab. Roger Bellon, Neuilly sur Seine, France) was added to 20 ml of blood cell dilution. 
Blood cells were left to sedimentate for 30 min, and then centrifuged. The sediment was 
washed in HEPES buffer (140 mM NaCl, 5 mM KCl, 10 mM glucose, 0.1 mM EGTA, 10 
mM HEPES, 3 mM Tris base, pH 7.3). Blood cells were collected and diluted to 40 ml by 
0.9% NaCl (1/3, v/v), and then was layered on 12 ml of J Prep (Techgen International, 
Voisins le Bretonneux, France). After 20 min centrifugation (800 × g), the pellet was 
suspended in 30 ml of 0.9% NaCl and added to 10 ml of 6% (w/v) dextran, which was left 
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to sedimentate for 30 min and was centrifuged for 10 min at 800 × g. The pellet was 
suspended in HEPES buffer and the contaminating erythrocytes were removed by 
hypotonic lysis (45 s). The dilution was centrifuged and washed in HEPES buffer. The final 
suspension was adjusted to 6 × 106 PMNs / ml.  
2.1.2.2 Evaluation of PVL effects by optic microscope  
PMNs concentration was adjusted to 1 × 106/ml. A series of PVL concentrations (0.25 mM, 
2.5 mM, 25 mM, 250 mM) were added to PMNs dilution in different tubes. At 5 min and 10 
min, 6.6 µL PMNs dilution was added to Glassitc Slide and viewed under optic microscope. 
Results: PMNs were lysis at 5 min treated by 2.5 mM PVL. PVL was in good quality. 
2.1.3 Evaluation of PVL effect in different culture media 
using cytometry 
Purpose: Different culture media contained different calcium and zinc concentrations, 
which could influence PVL effects in calcium mobilization. Some media did not provide 
their ingredients. The purpose was to ensure that culture medium did not cause bad 
influence on PVL effects during explant culture.  
It was proved that PVL could cause increase of cytoplasmic calcium concentration in PMNs 
during several minutes. The variation of calcium concentration in PMNs was recorded by 
measuring intensity of Fluro3 fluorescence with flow cytometry. In order to evaluate PVL 
effect in different culture medium, we measured the intensity of Fluo3 fluorescence of 
PMNs diluted in different culture medium and treated by 25 nM PVL suing cytometry.  
 
  
Flow cytometry 
Flow cytometry data were obtained using a FACSort cytometer (Becton Dickinson, Le Pont 
de Claix, France) equipped with a 15-mW argon laser tuned to 488 nm. PMNs were diluted 
to 1*106 / ml in different media (Table 4). PVL and Fluo3AM (2 mM, DMSO) were added 
into it. PMNs were classically distinguished by forward and side light scatter, and then their 
fluorescence was recorded during 10 min. Fluorescein and Fluo3 fluorescence intensities 
were recorded in the FL1 channel (emission wavelength, 530 nm). The FACSort cytometer 
was set in such a way that calibrated fluorescent microbeads (Immuno-Brite; Coulter 
Corporation, Hialeah, FL) displayed the same fluorescence intensity for each experiment. 
Thus, mean fluorescein fluorescence intensity was expressed in standardized 
fluorescence units. Variations of the intracellular Ca2+ levels were determined by measuring 
the intensity of Fluo3-AM fluorescence (Table 5). 
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Table 4. The components of tested tubes  
Numbers 1 2 3 4 5 6 7 8 
Culture 
Medium 
Neurob
asal A 
i-CO2 HBSS RPMI Neurob
asal A 
i-CO2 HBSS RPMI 
PVL 25nM 0 0 0 0 10 µL 10 µL 10 µL 10 µL 
Fluo-3AM 2mM 4 µL 4 µL 4 µL 4 µL 4 µL 4 µL 4 µL 4 µL 
Total 1 ml PMN 1 x 106/ml 
 
Table 5. Intensity of Fluo3 fluorescence measured by cytometry 
Numbers 0 min 2 min 4 min 6 min 8 min 10 min 
1 171.46 191.48 191.03 204.62 220.16 197.08 
2 127.67 132.81 124.41 127.42 133.33 135.54 
3 155.31 151.8 151.1 161.51 165.7 168.67 
4 114 123.1 117.26 125.83 124.6 125.83 
5 255.53 331.01 359.86 447.45 543.17 627.68 
6 132.66 136.1 136.17 169.87 214.26 262.44 
7 149.28 188.34 189.74 247.15 285.42 297.01 
8 115.12 114.62 122.41 147.7 210.64 309.1 
 
 
Conclusion: The four media (Neurobasal A, i-CO2, HBSS, RPMI) do not influence PVL 
effect in mobilizing calcium. 
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2.2 Animal and surgical procedure  
2.2.1 Ethics of the protocol 
The animal experiments were approved by the Ministère de l’Education nationale, de 
l’Enseignement Supérieur et de la Recherche, France (APAFiS no. 4986). The surgical 
procedure was performed in accordance with the guidelines in the laboratory of the 
Association for Research in Vision and Ophthalmology within the accredited A67-482-34 
and B67-482-34 animal facilities. 
For retinal explants, the rabbits were euthanized before the enuclearation of eyes. No 
special protocle was required. 
2.2.2 Anesthesia, PVL intravitreal injection and 
euthanasia 
Anesthesia 
Pigmented rabbits (Bleu de Champagne) were aged one year and weighted 3.5–4 kg. They 
were anesthetized by intramuscular injection of combined ketamine (20 mg/kg Virbac, 
Carros, France) and xylazine (3 mg/kg Bayer Healthcare, Puteaux, France). After 3-5 min, 
the rabbit began to lose conscience. The anesthetic state of rabbit was evaluated by 
touching the eyes: if there was no palpebral reflex, the anesthesia was fine. 
 
PVL intravitreal injection  
Two drops of oxybuprocaine chlorhydrate (Théa, Clermont-Ferrand, France) were added 
to conjunctiva as local anesthesia. PVL was diluted in phosphate-buffered saline (PBS) (3 
µg/50 µL) and intravitreally injected with a 30-Gauge needle. The inserted point was 4 mm 
behind the corneal limbus. 
In in vivo PVL-injection endophthalmitis model, there was three control eyes which was 
injected with 50-µL PBS using the same technique. After PVL injection, animals were 
sacrificed at pointed times (30 min, 1, 2, 4 and 8 h). There was three different eyes for each 
time point.  
 
Euthanasia 
After intramuscular anesthesia with combined ketamine-xylazine (as mentioned above), 
22-Gauge catheter was inserted in the marginal auricular vein and a lethal dosage of 2-mL 
Pentobarbital Dolethal® (Vetoquinol, Lure, France) was injected through this catheter. 
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2.2.3 Retinal explant preparation and organotypic 
culture 
Retinal explant requires a swift extraction of retina from intact eye and the retinal flat 
mounting on a hydrophilic membrane with minimum disturbance of the tissue. Briefly, 
pigmented rabbits were sacrificed, and eyes were enucleated as mentioned above. Eyes 
were immerged in cold i-CO2 medium and transported on ice to the laboratory.  
In aseptic condition, each eyeball was immersed in disinfection medium (Pursept A, xpress 
Germany) and washed with cold i-CO2 medium. Under a stereomicroscope equipped with 
an internal light source, the eye was held in place with a paire of blunt-ended forceps and 
18-gauge needle was inserted into the eye at the ora serrata to make a hole. A pair of fine 
spring scissor was inserted into the hole and made a circumferential incision around the 
limbus, dividing the ocular globe into anterior and posterior eyecups. The vitreous was 
removed, and the posterior eyecup was placed into another dish containing fresh i-CO2 
medium and was cut into 4 pieces 7×7 mm, avoiding the visible blood vessels and myeline. 
The peripherial sclera was held with fine forceps, choroid was teared away from the sclera 
and the optic nerve was cut with fine scissor. The neuroretina was detached gently from 
the pigment epithelium by tearing the choroid.  
The retina was transferred using a micropipette (3.5 ml), the tip of which as cut a few 
millimeters to widen the opening. Once the retina was within the transfer pipette, it can be 
oriented to vessel side facing up by drawing the medium up and down. The retina was 
dropped with photoreceptor layer facing up on membrane which was inserted into 
Transwell® culture dishes (Corning Inc., Corning, NY). After flat-mounting was complete, 
all the remaining dissection medium around the retina was aspirated away. During 
mounting the retina on membrane, retina should not be touched. Then, 2 ml culture 
medium, neurobasal-A (Gibco, Life technologies, Carlsbad, USA) supplemented with 
Penicillin-Streptomycin (100 U/mL) mixture, was added into culture well. The culture 
medium level was maintained in contact with the support membrane beneath the explant. 
The retinal explants were incubated at 37 °C with 5% CO2 in a humidified atmosphere.  
A series of PVL concentrations were prepared: 0.176, 0.352, 1.76 and 12.48 µM. Our 
previous study used PVL (3 ug/50 ml), equal to 1.76 µM. So, 1.76 µM PVL was used as 
the reference concentration. A 10-μL droplet of PVL diluted in culture medium was 
deposited on the surface of nerve fiber layer in each explant after retina flat-mounting. An 
equivalent volume of culture medium was deposited onto the surface of control explants. 
Retina explants were collected at different time points (30 min, 2, 4, 8 and 24 h), and fixed 
immediately with 4% paraformaldehyde or stored at -80 °C according to the design (Table 
8).  
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Table 6. The numbers of explants at different time points and with different PVL 
concentrations  
Time 
points 
control 0.176 µM 
PVL 
0.352 µM 
PVL 
1.76 µM PVL 12.48 µM 
PVL 
30 min 3 fixed 3 fixed 3 fixed 3 fixed 3 fixed 
2 h 3 fixed 3 fixed 3 fixed 3 fixed 3 fixed 
4 h 3 fixed; 4 frozen 3 fixed 3 fixed 3 fixed; 4 frozen 3 fixed 
8 h 3 fixed; 4 frozen 3 fixed 3 fixed 3 fixed; 4 frozen 3 fixed 
24 h 3 fixed; 4 frozen 3 fixed 3 fixed 3 fixed; 4 frozen 2 fixed 
 
2.3 Immunohistochemistry 
2.3.1 Preparation of paraformaldehyde 16% 
Added 16 g paraformaldehyde in powder in 100 ml PBS.  
Heated them to 60~70 °C with stirring until the powder was dissolved.   
Added 1-2 drops of NaOH (1 M) to clarify the dilution. 
Adjusted dilution PH to 6.9 with HCl. 
Filtered dilution through 0.45 μm membrane and stored it at -20 °C 
2.3.2 Tissue for immunohistochemistry 
The eyes were intravitreally injected with 100 µL of 4% (wt/vol) paraformaldehyde (Thermo 
Fisher Scientific, Rockford, IL, USA) immediately after rabbit sacrifice, and were then 
oriented and enucleated. The cornea, iris, and crystalline lens were immediately removed. 
The eye globe was fixed for 3 h in 4% paraformaldehyde. The dissected eyes were 
successively immersed in 10% (wt/vol) and 20% (wt/vol) sucrose and stored in 30% (wt/vol) 
sucrose overnight at 4 °C.  
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2.3.3 Vertical section 
For a better cryosection, the retina was separated from the pigmented epithelium. The 
temporal zone of 1–5 mm near the optic disc was isolated and then immersed in optimal 
cutting temperature compound (Sakura Finetek, Torrance, CA, USA). Vertical cryostat 8-
µm-thick sections were mounted on a Super FrostTM Plus microscope slides (Thermo 
Fisher Scientific, Rockford, IL, USA) and stored at −20 °C. 
2.3.4 Tissue for whole mount 
The fixed retina was identified and stored at −80 °C. 
2.3.5 Immunohistochemistry for retinal sections 
Immunohistochemistry was performed to analyze the retinal cells targeted by PVL. Retinal 
sections were permeabilized in 0.05% (v/v) TritonX-100 for 1 h and then were blocked with 
10% (v/v) donkey or goat serum (Sigma-Aldrich, St. Louis, MO, USA) for 1 h. Retinal 
sections were incubated with primary antibody or lectin (see Table 7 for details) at 4°C 
overnight in a humidity chamber. Retinal sections were then incubated for 1 h at room 
temperature with fluorescent secondary antibodies or TUNEL (except when lectin was 
used) (see Table 7 for details). The sections were counter-stained with Hoechst 33258 and 
mounted in 10% (v/v) Mowiol® solution (Polysciences, Eppelheim, Germany). Images of 
fluorescent sections were obtained using an epifluorescence Olympus BX60 microscope 
connected to a Hamamatsu C11440 digital camera. 
2.3.6 Immunohistochemistry for retinal whole mounts 
The retinal whole mounts were incubated in conical small wells and transferred with 3 ml 
pippet. Retinal whole mounts were permeabilized 0.2% (v/v) TritonX-100 for 30 min. The 
staining steps were the same as those of section immunoistochemistry. At last, the retinal 
whole mounts were mounted on slides and covered with thinner and smaller cover slides 
in 10% (v/v) Mowiol® solution.  
2.3.7 Cell counting   
Different microscope fields (266 µm × 266 µm) of vertical retinal immunofluorescent images 
were randomly captured by the camera. 
 
For PVL-endophtalmitis in vivo model  
The proportions of PVL-positive RGCs and DACs were measured in the RGC layer. PVL-
positive cells were double-labeled by PVL and cell-specific markers for RGCs and DACs. 
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The percentages of PVL-positive RGCs and DACs in each time point were established by 
mean mounts of 3 different eyes (five different study fields for each eye). TUNEL positive 
cell counts for each time point and control were established by mean number of TUNEL 
positive cells from 3 eyes (5 different study fields for each eye). 
 
For retinal explant ex vivo model 
PVL-positive retinal cells were evaluated by double immunohistochemistry: PVL-positive 
cells were double-labeled by PVL and retinal cell-specific markers. The percentages of 
PVL-positive RGCs at each time point (30 min, 2, 4, 8 and 24 h with 1.76 µM PVL) were 
established by mean mounts of 3 explants (each explant had five study fields randomly 
captured by camera). The mount of TUNEL positive cells in each time point and 
concentration was established by mean mounts per study field (3 explants, 5 study fields 
for each explant).  
2.3.8 Statistical analysis  
Statistical analysis was performed with GraphPad InStat version 3.10. Statistical 
significance was calculated with one-way ANOVA using the Tukey-Kramer multiple 
comparisons test and paired t-tests. Statistical significance was assumed at p < 0.05. 
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Table 7. List of specific markers used in this study 
 Primary antibodies or lectin  
Target Antiserum Source Concentration 
PVL Rabbit anti-LukS-PV polyclonal EA-7290, Strasbourg, France  2 µg/mL 
C5aR Rabbit anti-C5aR polyclonal Abcam, Cambridge, UK 2 µg/mL 
Ganglion cells Guinea pig anti-RBPMS polyclonal UCLA Neurobiology, Los Angeles, CA, 
USA 
2 µg/mL 
Starburst amacrine 
cells 
Goat anti-ChAT polyclonal Chemicon Merck-Millipore, Temecula, 
CA, USA 
20 µg/mL 
Müller cells Mouse anti-GFAP polyclonal Bio-Rad AbD Serotec, Oxfordshire, 
UK 
2 µg/mL 
Microglial cells FITC-tagged GSAI-B4 Sigma Aldrich, Saint Louis, MO, USA 2 µg/mL 
amacrine cells Rabbit anti-Pax 6 polyclonal Abcam  2 µg/mL 
AII Amacrine cells Mouse anti-calretinin monoclonal Santa Cruz Biotechnology, 
Heidelberg, Germany 
2 µg/mL 
Horizontal cells Mouse anti-calbindin monoclonal Santa Cruz Biotechnology 2 µg/mL 
Nitrotyrosine Mouse anti-nitrotyrosine monoclonal Santa Cruz Biotechnology, 
Heidelberg, Germany 
2 µg/mL 
C5L2 Rabbit anti-C5L2 polyclonal GeneTex, San Antonio, TX, USA 2 µg/mL 
β-actin Rabbit anti-β-actin polyclonal Santa Cruz Biotechnology, 
Heidelberg, Germany 
1:2000 
IL-6 Mouse anti-IL-6 monoclonal Abbexa Ltd, Cambridge, UK 1:2000 
IL-8 Mouse anti IL-8 monoclonal Abbexa Ltd, Cambridge, UK 1:2000 
IL-1β Rabbit anti-IL-1β polyclonal Abbexa Ltd, Cambridge, UK 1:2000 
TNF-α Mouse anti-TNFα monoclonal Abbexa Ltd, Cambridge, UK 1:2000 
Secondary antibodies 
Anti-rabbit Goat and donkey polyclonal Alexa 
555nm-conjugated 
Life Technologies, Carlsbad, CA, USA 2 µg/mL 
Anti-goat Donkey polyclonal Alexa 488-
conjugated 
Molecular Probes, Eugene, OR, USA 2 µg/mL 
Anti-mouse Donkey polyclonal Alexa 488-
conjugated 
Abcam 2 µg/mL 
Anti-guinea pig Goat polyclonal Alexa 488-conjugated Abcam 2 µg/mL 
TUNEL DNA strand breaks Roche Life Science, Indianapolis, IN, 
USA 
--- 
Nuclei Hoechst 33258 Molecular ProbesTM, Eugene, OR, 
USA 
0.1µg/mL 
Anti-rabbit Anti-Rabbit IgG (whole molecule)–
Peroxidase 
Sigma Aldrich 1:10000 
Anti-mouse Goat anti-mouse IgG-Peroxidase Santa Cruz Biotechnology 1:10000 
Abbreviations: RBPM, RNA-binding protein with multiple splicing; CHAT, choline acetyl transferase; GFAP, 
glial fibrillary acidic protein; GSAI, Griffonia simplicifolia agglutinin isolectin. TUNEL, terminal 
deoxynucleotidyl transferase dUTP nick-end labeling. 
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2.4. Western blotting  
2.4.1 Tissue preparation for western blot 
The eyes were enucleated without any injection. Briefly, the conjunctiva was open then the 
ocular muscles were cut. Finally, the optical nerf was cut and the eye was immersed into 
cold i-CO2 medium. Eighteen-Gauge needle was inserted at 4 mm behind the corneal 
limbus and then removed. A micro-scissor was inserted into this pore and cut 
circumferentially the ocular globe. The cornea, iris, crystalline lens and vitreous were 
removed. The retina was gently peeled and removed to a tube with transfer pipette. The 
retina in tube was immediately stored at -80 °C. Retinal dissection was undertaken in cold 
i-CO2 medium within 10 min.  
2.4.2 Extraction protein from retina for western blotting 
RIPA buffer: 1% (v/v) NP-40, 0.1% SDS, 1% (w/v) sodium deoxycholate, 50 mM sodium 
chloride, 25 mM Tris-HCl pH 8.0 
One half of whole frozen retinas were placed in microfuge tubes of Eppendorf tuves. The 
tissue was immersed with 500 µL RIPA buffer containing an inhibitor protease cocktail 
(Roche). The tissue was homogenized by passing through a 22-Gauge needle and then 
26-Gauge needle several times in RIPA buffer. The tubes were sonicated for 20 s and then 
agitated for 2 h at 4 °C.  
The tubes were centrifuged for 20 min at 12,000 rpm at 4 °C in a microcentrifuge. The 
tubes were gently removed from the centrifuge and placed on ice. The supernatant was 
aspirated and identified, and then was immediately stored at -80 °C. The pellets were 
discarded.  
2.4.3 Quantify protein using BCA kit  
Prepared bovine serum albumin (BSA) 2.5 mg/mL in H2O. 
Prepared a series of BSA concentrations (Table 8) 
 
Table 8. The preparation of a series of BSA concentrations 
Numbers 1 2 3 4 5 6 7 
[BSA] µg/mL 0 200 500 800 1200 1600 2000 
BSA 2.5mg/ml 
(µL) 
0 4 10 16 24 32 40 
H2O (µL) 50 46 40 34 26 18 10 
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The samples were diluted 1/10e, a volume of 50 µL. One control was prepared with the 
same buffer. 
The necessary volume of reagent 660-nm Protein Assay (660-nm Protein Assay Reagent, 
Pierce Biotechnology) was prepared: 0.5 g detergent (IDCR; 2263) + 10 ml Pierce 660. 
Mix well the reagent. 
Added 750 µL reagent to all the BSA dilutions (50 µL, Table 8), sample dilutions (50 µL), 
and controls (50 µL). Mixed well and waited for 5 min. 
Read all samples and control at 660 nm by spectrometry.  
Noted the figures and developed equator using the figures of the series of BSA 
concentrations.  
Calculated the concentration of samples with this equator.  
2.4.4 Migration  
The SDS-PAGE gels were from commercial laboratory (Bio-Rad Laboratories, Hercules, 
CA, USA). Considering the weight of target proteins (10-50 kDa) to be revealed, we chose 
4-15% Tris-HCl gel. The samples (30 µg) were diluted to 20 µL in loading buffer and water. 
The sample mixtures were heated at +95 °C for 5 min and loaded in each lane. The gels 
were submerged in migration buffer and electrophoresed for 30 min at 200 V.  
2.4.5 Transfer 
After migration, proteins were transferred to a nitrocellulose membrane by wet transfer. 
The gel and membrane were sandwiched between sponges and paper (2 spongs / 3 
papers / gel / membrane / 3 papers / 3 sponges) and all were clamped tightly together. 
When the membrane was deposited on the gel, it needed ensure that no air bubbles have 
formed and all the papers, sponges and menbrane were wet in transfer buffer. Then, the 
sandwich was submerged in transfer buffer to which an electrical field was applied. The 
negatively-changed proteins travelled towards to positively-charged electrode. But the 
membrane (0.2 µm pore) stopped and bound them. The transfer was carried on for 1.5 h 
at 40 V.  
2.4.6 Staining of the membrane 
To prevent non-specific background binding of primary and/or secondary antibodies to the 
membrane, the membrane was blocked in 5% (w/v) skimmed milk diluted in PBS at room 
temperature for 1 h.  
The primary antibodies (see Table 7) were diluted in phosphate-buffered saline with 0.05% 
Tween® (PBST) to suggested dilution (1:500-1: 2000). One membrane can be stripped 
into two or three parts according to the design. The stripped membranes were incubated 
into primary antibodies dilution overnight at 4 °C. The membranes were washed three 
times in PBST while agitating. The membranes were incubated in Peroxidase-conjugated 
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secondary antibodies dilution (see Table 7) for 1 h at room temperature with agitation, then 
were washed three times in PBST while agitating.  
The membranes were developed using ECL Western blotting detection reagent (Bio-Rad 
Laboratories, Hercules, CA, USA). The digital images were captured by a 
chemiluminescence camera (ChemiDoc™ XRS, Bio-Rad). The protein expressions were 
quantified by densitometry analysis of Western Blots bands using BIO-1D software.  
2.5 Real-time RT-qPCR 
In PVL-endophthalmitis in vivo model, we analyzed tested retinas (PVL 4 h and PVL 8 h, 3 
eyes for each group) and control retinas (PBS 4 h, 6 eyes) using RT-qPCR to see the 
elevation of cytokines, the sign of retinal inflammation. 
In retinal explant ex vivo model, we analyzed PVL-treated explants (4 and 8 h, 4 explants 
for each time point) and control explants (4 and 8 h, 4 explants for each time point). 
2.5.1 Tissue preparation for RT-qPCR 
This is the same preparation as for western blot. 
2.5.2 RNA extraction  
Retina stored in 1.5 ml Eppendorf tube was removed from -80 °C and 600 µL TRIzol 
(Sigma, Saint-Louis, USA) was immediately added into it. Retina was passed several times 
23-Gauge then 26-Gauge needle to be homogenized. The homogenized retina was 
incubated for 10 min at room temperature (RT). Sixty µL of chloroform was added into tube 
and mixed well. The mixture was incubated for 5 min at RT. Then the tube was centrifuged 
at 10,000 x g at 4 °C for 15 min. The supernatant was carefully aspirated and put into a 
new tube. Then, 400 µL isopropanol was added into it and mixed well. The mixture was 
incubated for 10 min at RT. The tube was centrifuged at 10,000 x g at 4 °C for 10 min and 
all the liquid was poured. The pellet was kept and washed with 75% EtOH. The tube was 
centrifuged 10,000 x g at 4 °C for 5 min. The liquid was poured, and the pellet was kept. 
Another wash was repeated with 75% EtOH. The pellet was dried for 5 min at 65 °C and 
dissolved the pellet in 50 µL of water at 55 °C for 15 min. 
2.5.3 RNA quantification and integrity 
The final RNA solutions were quantified with spectrophotometry (NanoDrop; Thermo 
Scientific, Waltham, USA). Spectrophotometer showed absorbance measurements at 230 
nm, 260 nm and 280 nm, and concentration of nucleotides. The ratio of absorbance at 260 
nm and 280 nm was used to assess the purity of DNA and RNA. The ratio ≥1.8 was 
generally accepted as “pure” for RNA using for RT-qPCR; the ratio< 1.8 was unacceptable 
for RT-qPCR: too many DNA was mixed with RNA and needed to be treated with DAN-free 
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kit DNase. The ratio 260 nm/230 nm was used as the indicator of nucleic acid purity. 
Expected the ratio 260 nm/230 nm was commonly in the range of 2.0-2.2. If the ratio was 
appreciably lower than the expected, it may indicate the presence of contaminants which 
absorbed at 230 nm, such as EDTA carbohydrates and phenol. The sample needed to be 
washed again with 75% EtOH. 
2.5.4 DNase treatment with DNA-free kit DNase 
RNA (10 µg), 10 x DNase buffer 5 µL, TURBO DNase (Ambion, Life technologies), sterile 
water brought the volume up to 50 µL total. The components were added in this order: 
water, RNA, buffer, DNase. Mixed gently and centrifuged briefly the mixture, which was 
then incubated at 37 °C for 30 min. Add 5 µL DNase inactivation reagent and mixed well. 
Incubated 2 min at RT and centrifuged at 10,000 x g for 1.5 min and transferred the RNA 
to a fresh tube. 
2.5.5 Primers design 
The primer design was undertaken using Primer 3 website software. The results showed 
several choices of primers. The most adaptable primers were chosen by the general primer 
design rules, such as primer length 18-24 bps, annealing temperature around 60 °C, avoid 
repeats of nucleotide sequence at 3’ end. The successful primer design was verified by 
evaluating the purity of PCR product, which showed one sharp pick at melting curve and 
one band at agarose gel. 
 
Table 9. The sequences of primers used in this thesis 
Nom left primers right primers 
VEGF cgagaccttggtggacatctt tgcattcacatttgttgtgct 
SP acagcgaccagatcaaggag cccattagtccaacaaaggaa 
CGRP ggcgtaaacaaagtgggaag tggatctcaacagcagtcatag 
iNOS ccaagccctcacctacttcc aactcctccagcacctcca 
Actin-β gcgggacatcaaggagaag aggaaggagggctggaaga 
IL-1 ttgtcagtcgttgtggctct ggatttctgttgtgcatcct 
IL-8 tggctgtggctctcttgg atttgggatggaaaggtgtg 
IL-6 tcaggccaagttcaggagtg atgaagtggatcgtggtcgt 
TNF-α cgtagtagcaaacccgcaag tgagtgaggagcacgtagga 
MCP-1 aacgcttctgtgcctgct ggacccacttctgcttgg 
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2.5.6 RT 
Total RNA was immediately reverse transcribed (RT) using Superscript First-Strand 
Synthesis for RT-qPCR (Invitrogen, Life technologies). Briefly, Diethyl decarbonate (DEPC) 
(Sigma) treated H2O was added to RT mixture (0.5 µL random hexamers (200 ng/ml), 500 
ng total RNA, 1 µL NTP) to achieve a 12 µL volume. The mixture was gently centrifuged 
and then incubated at +65 °C for 5 min and placed in glass for 2 min. 
Then 0.5 µL of 0.1 M DDT, 0.5 µL of transcriptase, 4 µL of First Strand buffer, 3 µL of DEPC 
treated H2O were added to the mixture. Then, the total mixture was gently centrifuged and 
put into ThermoCycler, which was programmed at +42 °C for 50 min and at +70 °C for 15 
min. The cDNA was diluted in 3 times with DEPC treated H2O.  
2.5.7 PCR to check cDNA 
To ensure the cDNA was well produced, PCR was employed to reproduce β-actin using 
this cDNA. The mixture contained 2 µL cDNA, 0.125 µL Taq DNA Polymerase, 2.5 µL 10 x 
standard buffer, 0.5µL dNTPs, 2 µL forward and reverse primers (100µm), DEPC treated 
H2O which brought to 25 µL total. ThermoCycler was programmed as initial denaturation 
step at +95 °C for 5 min, 40 cycles of amplification (denaturation at +95 °C for 25 s, 
annealing at +58 °C for 20 s, extension at + 68 °C for 25 s), final extension at +68 °C for 5 
min, hold at +4 °C. The PCR products was verified by agarose gel electrophoresis (see 
below).  
2.5.8 Real-time qPCR 
5 µL of diluted cDNA, 10 µL SYBR mix (LightCycler 480 SYBR Green I Master, Roche, 
Basel, Switzerland), 2 µL of forward and reverse primers (100 µm), and 3 µL DEPC treated 
H2O were mixed and put into 96 wells plate. The plate was placed into Real-Time PCR 
System (Light Cycler 480, Roche). The primers were designed to have Tm around 60°C. 
PCR was programmed as initial denaturation step at + 95 °C for 10 min, 45 cycles of 
amplification (denaturation at + 95 °C for 15 s, annealing at + 60 °C for 20 s, extension at 
+ 72 °C for 15 s), and melting curve analysis (+ 60 °C to + 95 °C increment at + 0.3 °C). 
Products of RTs without reverse transcriptase were used as controls to assure no 
significant DNA contamination 
2.5.9 Production specificity verification  
The specificity of PCR products was verified according to one melting curve peak and one 
band in agarose gel electrophoresis. 
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2.5.9.1 Melting curve analysis  
SYBR Green I is fluorescence which bind double-stranded DNA. Both heterozygous and 
homozygous single-base variants could contribute to the fluorescence. DNA melting curves 
were acquired by measuring the fluorescence of SYBR Green I during a linear temperature 
transition. Melting curves could distinguish well between specific PCR product and non-
specific PCR product such as "primer-dimers" that often had a considerably lower Tm.  
2.5.9.2 Analysis on non-denaturing agarose gel 
electrophoresis 
Prepare agarose was diluted in concentration of 2% and 0.5 µg/ml ethidium bromide: 60 
ml 0.5 X TBE +1.2 g agarose in powder + 3 µL 10 mg/ml ethidium bromide; 
Mix well and heat to boiling with microwave oven, then pour the hot mixture to tank with 
comb, which is a mould for gel. Cool the mixture to form gel.  
Take away the comb and pour down enough TBE buffer to immerge the gel.  
Load 20 µL RNA or DNA samples with loading buffer into each lane. Set running voltage 
up to 10 V/cm and run electrophoresis.  
View the gel under chemiluminescence and take image with camera.  
The good PCR product showed one clear band at the appropriate site corresponding to its 
length. The good RNA sample showed two clear bands (28s rRNA and 18s rRNA from up 
to down separately), the intensity of 28s rRNA was almost two times of that of 18s rRNA.  
2.5.10 Statistical analysis 
The β-actin was used as reference gene and target genes were normalized using this 
reference gene. The method ∆Ct was used to calculate relative quantification between 
control retina and tested retina. The fold changes were calculated using 2-∆∆Ct. The tests 
were achieved in triplicates. The significant changes of every target gene were statistically 
analyzed with ∆Ct paired t-tests using GraphPad InStat version 3.10. Statistical 
significance was assumed at p < 0.05. 
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3. Results 
3.1 Article 1: Panton–Valentine Leukocidin Colocalizes 
with Retinal Ganglion and Amacrine Cells and 
Activates Glial Reactions and Microglial Apoptosis 
Preface 
The virulence of infecting bacteria is an important factor to influence the visual prognosis 
of bacterial endophthalmitis. PVL, one virulent leukotoxins of S. aureus, can cause severe 
necrotic tissue infection. Intravitreal injection of bacteria or bacterial products is an 
experimental model employed for a longtime. It imitates the natural pathway of pathogens 
invading to the interior of eyes. As PVL recognizes only human and rabbit C5aR, not murine 
C5aR, so rabbit model is the only available animal model for PVL study. Previous studies 
revealed that intravitreal injection of PVL could cause severe endophthalmitis in rabbit, 
producing retinal inflammation, breakdown of the blood–retinal barrier and neutrophils 
infiltration. Exploring the initial retinal cell target and the features of early inflammation can 
help understand the mechanism of PVL infection to retina, the development of following 
fulminant inflammation. This could well explain the role of bacterial virulence in bad visual 
prognosis of bacterial endophthalmitis. The objectives of this part are to identify PVL cell 
target and analyze the early inflammatory changes in rabbit retina, using PVL intravitreal 
injection in vivo model. 
  
In this PVL-endophthalmitis in vivo model, we found that PVL was always fixed specifically 
in retinal ganglion cell layer from 30 min to 8 h after injection. Using double-
immunohistochemistry, we showed that PVL increasingly colocalized with retinal ganglion 
cells (RGCs) within 2 h, while PVL transiently colocalized with displaced amacrine cells 
(DACs) within 4 h. The C5aR immunoactivity colocalized with RGCs, not with other retinal 
cells. Müller and microglial cells were increasingly activated after PVL injection from 30 min 
to 8 h. IL-6 mRNA and protein expression in retina increased and some microglial cells 
underwent apoptosis 4 h and 8 h after PVL infection, which might be associated with 
abnormal nitrotyrosine production in the retina.  
 
In a previous study, PVL reacted on cerebellar neuronal cells. This study showed that PVL 
could colocalize rapidly with RGCs and transiently with DACs, following inflammatory 
reaction in retina. In retina, only RGCs colocalized with C5aR immunoactivity, the specific 
receptor of PVL. PVL probably incited RGCs reaction through C5aR and initiated retinal 
inflammation. This study also showed the early inflammatory changes in retina, which 
could modify retinal structure, and furtherly recruit leukocytes to retinal tissue, interrupt the 
visual function, resulting in major consequences to the visual outcomes. Other animal 
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models, such as retinal explant and in situ sophisticated approaches, are needed to 
confirm those results, which could bring more insights about the sequential activity of 
retinal cells, the relation between PVL binding on neuronal cell and glial cell activation. 
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Supplementary Figure S1. 
 
Supplementary Figure S1. PVL colocalized with RGCs and few DACs 8 h after PVL injection. PVL 
(red fluorescence A, C) colocalized with RGCs labeled with anti-RBPMS antibody (green fluorescence B, 
C) in the retinal vertical sections. DACs labeled with anti-CHAT antibody (green fluorescence E, F) did not 
colocalize with PVL (red fluorescence D, F). 
Abbreviated symbols: RGCs, retinal ganglion cells; DACs, displaced amacrine cells; CHAT, choline 
acetyl transferase; RBPM, RNA-binding protein with multiple splicing; GCL, ganglion cell layer; OPL, outer 
plexiform layer; INL, inner nuclear layer; ONL, outer nuclear layer. OS, photoreceptor outer segments. 
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Supplementary Figure S2. TUNEL test were negative in controls and retinas 30 mins, 1 h, 2 h after 
PVL injection. The TUNEL test did not show any specific positive fluorescence in retina control(A), in 
retina 30 mins after PVL injection (B), in retina 1 h after PVL injection (C) and in retina 2 h after PVL 
injection (D). 
 Abbreviated symbols: TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling; GCL, 
ganglion cell layer; OS, photoreceptor outer segments. 
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Supplementary Figure S3. RGCs and DACs did not colocalize with TUNEL-positive cells. The 
TUNEL-Positive cells (green fluorescence A, B, E, F) did not colocalize with anti-CHAT labeled DACs (red 
fluorescence C, E), nor with anti-RBPMS labeled RGCs (red fluorescence D, F). Hoechst stained nuclei 
(blue fluorescence E, F). 
Abbreviated symbols: RGCs, retinal ganglion cells; DACs, displaced amacrine cells; TUNEL, 
terminal deoxynucleotidyl transferase dUTP nick-end labeling; CHAT, choline acetyl transferase; RBPM, 
RNA-binding protein with multiple splicing; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner 
nuclear layer; ONL, outer nuclear layer. 
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Supplementary Figure S4. The full-length blots for IL-1β, IL-8 and TNF-α. The primary antibodies 
were rabbit anti human IL-1β, mouse anti rabbit IL-8 and mouse anti-rabbit TNF-α from left to right. The 
lanes were put the same quantity proteins (40 ug/ lane) extracted form retina control, PVL 4 h, PVL 8 h 
from left to right according to the results of BCA kit. The specific bands for IL-1β were around the 21kDa, 
those for IL-8 were around 12kDa and those for TNF-α were around 21kDa. We could see that thses three 
factors have no sepecific bands in lanes of all samples (control, PVL 4 h, PVL 8 h) using western blotting 
method. 
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Supplementary Figure S5. The full-length blots for nitrotyrosine and β-actin. The first anti 
nitrotyrosine was treated with more detergents than the second anti nitrotyrosine. In this gel, all the lanes 
were loaded with the same quantity of test proteins (pvl 4h) and the same quantity of control proteins 
(40ug/lane) calculated with BCA kits. The anti-nitrotyrosine antibody recognizes free/protein-bound 3-NT 
which has no relation with molecular weight. The different bands correspond to different nitrotyrosine 
bound proteins that have between 37 kDa and 75 kDa molecular weight. The specific β-actin bands were 
showed around 42 kDa. The bots for nitrotyrosine and β-actin were from the same samples.  
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Supplementary Figure S6. The full-length blots for IL-6. The primary antibody was mouse anti human 
IL-6. The lanes were put the same quantity proteins (40 ug/ lane) extracted form retinas (control, PVL 4 h, 
PVL 8 h from left to right) according to the results of BCA kit. The specific bands were around the 24kDa. 
We could see clear bands in lanes around 24kDa of PVL 4 h and PVL 8 h, weak band around 24kDa in 
lane of control. 
 
Supplementary Figure S7. The full-length blots for β-actin with IL-6 The primary antibody was rabbit 
anti human β-actin, the lanes were put the same quantity proteins (40 ug/ lane) extracted form retinas 
(control, PVL 4 h, PVL 8 h from left to right) according to the results of BCA kit. The specific bands were 
around the 42kDa.   
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3.2 Article 2: Panton–Valentine Leukocidin Induces 
Neuronal and Microglial Apoptosis together with Müller 
and Microglial Cell Activation in a Rabbit Retinal 
Explant Model 
Preface 
In the first part of this study, we employed the intravitreal injection method, injecting 
intravitreally PVL and analyzing retinal structure and PVL location at different time points. 
We have identified RGCs as PVL target in retina and showed early inflammatory changes 
of retina, including glial cell activation, microglial cell apoptosis, increase of IL-6 and 
nitrotyrosine production. Other animal model is needed to confirm these results. PVL 
colocalized with retinal neuronal cells. Did this colocalization really significate PVL 
targeting those retinal cells? After targeting those retinal cells, what cellular reaction and 
mechanism did PVL induce? Could the inhibitors of the mechanism block PVL toxicity to 
retina? Those questions are difficult to study using in vivo model. Developing cell- and 
tissue-based in vitro models are important for the following studies to understand the 
mechanism of PVL infecting retina and testing of potential therapeutics. 
 
Intravitreal injection was constraint to test more different time point and different 
concentration of PVL for the reason of limited number of rabbit usages. Testing PVL with 
high concentration and longer time points might bring some more evident results to have 
more concrete conclusion. The retinal explant lacks choroid and retinal blood supply, it can 
exclude the possible interferences from break-down of blood-ocular barrier and infiltrated 
myeloid cells. PVL could be directly applied on the retinal surface without diffusion in 
vitreous. Compared to the animal model in vivo, retinal explant provides a more applicable 
and more easily controlled environment, which might show direct PVL effects in retina. In 
this second part, the objectives were to furtherly analyze PVL effects by testing different 
PVL concentrations and different PVL-treated time points in rabbit retinal explants, an ex 
vivo model which was important for the following studies to know the molecular mechanism 
of PVL-endophthalmitis.  
 
In retinal explants, PVL fixation was more rapid and the spectrum of colocalized cells was 
larger than in vivo model. PVL colocalized rapidly with ganglion cells, and later with some 
horizontal cells. PVL-positive cells were also observed in INL, which were probably a 
subpopulation of amacrine cells. Microglial and Müller cells were activated, and apoptotic 
cells were found in PVL-treated retinal explants, in a concentration and time dependent 
way. When treated by PVL at high concentration, Müller cells were dissociated, and retinal 
explant structure was largely destroyed 24 h after PVL treatment. The majority of TUNEL 
positive cells were a subpopulation of amacrine cells in INL and some microglial cells.  
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In retinal explants, PVL is applied on the surface of retina in a more manageable and direct 
way. Retinal explant could be employed in the future studies to explore the mechanism of 
PVL reacting on retinal cells and the potential therapeutic strategies. 
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Abstract 
Purpose: Panton–Valentine leukocidin (PVL) is a virulent leukotoxin of Staphylococcus 
aureus. A retinal explant was used as an ex vivo endophthalmitis model to identify PVL-
targeted retinal cells and to analyze the early retinal inflammatory response following PVL 
treatment. 
Method: Rabbit retinal explants were treated with PVL at different concentrations. PVL 
location and Müller and microglial cell activation were examined using 
immunohistochemistry at different time points following PVL treatment. Inflammatory 
factors were analyzed using RT-qPCR at 4 and 8 h following PVL treatment. These results 
were compared with those of untreated control explants. 
Results: PVL co-localized rapidly with retinal ganglion cells and with horizontal cells. PVL 
induced Müller and microglial cell activation, which resulted in structure alteration in the 
retina. Some amacrine and microglial cells underwent apoptosis. All the results increased 
in a PVL concentration- and time-dependent manner. In PVL-treated explants, 
inflammatory factor expression was lower than that in control explants, and the RNA yield 
significantly decreased. 
Conclusion: PVL co-localized with neuronal cells and incited Müller and microglial cell 
activation. Glial activation was associated with neuronal and microglial apoptosis together 
with retinal structural damage. These results demonstrated that PVL is an aggravating 
factor of S. aureus endophthalmitis. Retinal explant is a feasible and reproducible ex vivo 
model, which can be employed to explore the molecular effects of PVL on the retinal tissue. 
 
Key words: Panton–Valentine Leukocidin; apoptosis; Müller cell activation; microglial cell 
activation; retinal explant 
 
Main Points: In an ex vivo model of retinal infection, Panton–Valentine leucocidin, a toxin 
of S. aureus, colocalized with retinal neurons, and induced glial and microglial activation, 
and amacrine and microglial cells apoptosis in a concentration- and time-dependent 
manner. 
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Introduction 
Bacterial endophthalmitis is an acute ocular infection and often results in poor visual 
outcomes 1. The severity of bacterial endophthalmitis is related to virulence factors from 
infectious strains 2. Staphylococcus aureus is a common bacterium found in the human 
body and is often a virulent strain found in endophthalmitis cases. Genomic studies of S. 
aureus have failed to demonstrate the relationship between bacteria and their virulence 3. 
Conversely, it has been shown that the toxins secreted by S. aureus are related to its 
virulence 4. Analyzing the effects of toxins on the retina could reveal the mechanism by 
which virulent factors aggravate bacterial endophthalmitis and provide a new target for 
therapeutic strategies. 
S. aureus strains can produce five leukotoxins: two gamma-hemolysins (HlgA/HlgB and 
HlgC/HlgB), Panton–Valentine leukocidin (PVL), LukED, and LukAB 5. Leukotoxin is 
composed of two distinct proteins: class S (31–32 kDa) and class F components (33–34 
kDa). The class S component binds membrane receptors, which allow secondary 
interaction of the F component. Unaccompanied class S or F protein do not produce any 
effect on targeted cells 6. The PVL gene is present in most community-associated 
methicillin-resistant S. aureus, which is known for its virulence7. Horizontal transfer of this 
gene has been observed, and the percentage of PVL-carrying strains has been 
continuously increasing 8. PVL-encoding S. aureus strains are associated with necrotic 
lesions 9, and in some rare cases, could cause septic shock after furuncles and severe 
pneumonia 10. We previously demonstrated that PVL can also cause severe ocular 
inflammation 11-13. 
PVL employs human and rabbit C5a complement receptors (C5aR) to bind target cells and 
exert cytotoxicity. PVL has a species-specific preference and does not recognize mice 
C5aR, as the latter exhibits different sequences of amino acids in its second extracellular 
loop 5. Therefore, we used PVL-induced endophthalmitis in a rabbit model to investigate 
the early retinal damage caused by PVL. In this study, PVL co-localized with retinal 
ganglion cells (RGCs) and caused glial cell activation, as well as some microglial apoptosis. 
Inflammation was also triggered following a PVL infection, as IL-6 and nitrotyrosine 
increased after intravitreal PVL injection 14. 
 
Primary neuron culture from the dissociated retina is time-consuming and expensive and 
has a limited reproducibility under in vivo conditions. Retinal explants are an alternative 
between dissociated primary cell culture and animal models. It maintains the neurons in 
situ and in contact with other cells and the extracellular matrix physiologically, provides an 
easily controlled environment, and lacks a retinal and choroidal blood supply. It can 
eliminate the possible potential disturbance of myeloid cells in the blood circulation and the 
effects of blood–ocular barrier breakdown 15. 
 
We used retinal explants to analyze PVL effects at different concentrations and time points 
to further confirm PVL toxicity for the retina. We found that retinal explants are an excellent 
model to examine PVL toxicity for the retina, as the majority of our in vivo findings were 
confirmed in the retinal explant model. Indeed, PVL co-localized rapidly with RGCs, later 
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with some horizontal cells, and possibly with a subpopulation of amacrine cells. PVL 
induced Müller and microglial cell activation, which resulted in retinal structural changes. 
Some amacrine and microglial cells underwent apoptosis. All of these results increased in 
a PVL concentration- and time-dependent manner. 
  
Materials and methods 
PVL purification 
PVL (LukS-PV/LukF-PV) was purified as described in a previous study 16 by affinity 
chromatography on glutathione-Sepharose 4B followed by cation-exchange fast-
performance liquid chromatography after removal of glutathione S-transferase tag with 
Precision Protease (GE Healthcare, Villacoublay, France). Preparation homogeneity was 
assessed by radial gel immunoprecipitation and SDS-polyacrylamide gel electrophoresis 
before storage at −80 ◦C. 
 
Retinal explant preparation and organotypic culture 
The animal experiments were approved by the Ministère de l’Education nationale, de 
l’Enseignement supérieur et de la Recherche, France. The surgical procedure was 
performed in accordance with the guidelines in the laboratory of the Association for 
Research in Vision and Ophthalmology, in adherence to the ARVO Animal Statement.  
 
Retinal explant requires swift extraction of the retina and retinal flat mounting on a 
hydrophilic membrane with minimum disturbance of the tissue. Briefly, pigmented rabbits 
(Bleu de Champagne) aged 6 months and weighing 2.5–3 kg were anesthetized by a 
lumbar intramuscular injection of ketamine, 20 mg/kg (Virbac, Carros, France) and xylazine, 
3 mg/kg (Bayer Healthcare, Puteaux, France), followed by a lethal intravenous injection of 
2-mL Pentobarbital Dolethal® (Vetoquinol, Lure, France) through a 22-Gauge catheter 
inserted in the marginal auricular vein. The eyes were immediately enucleated after 
euthanasia and immersed in ice-cold CO2-independent medium (Gibco, Life technologies, 
Carlsbad, USA). Eyes were transported to aseptic condition. Each eyeball was immersed 
in disinfection medium (Pursept A, xpress Germany) and washed with cold i-CO2 medium. 
Under a stereomicroscope, the eye globes were diessected and the posterior segment was 
cut into four 7×7 mm pieces avoiding to cut out visible blood vessels and myelinilised retinal 
parts. The choroid was teared away from the sclera and the optic nerve was cut with fine 
scissor. The neuroretina was gently detached from the pigment epithelium by tearing the 
choroid off.  
  
The retina was dropped with photoreceptor layer facing down on membrane which was 
inserted into Transwell® culture dishes (Corning Inc, Corning, NY). After the retinal flat-
mounting, 2 ml culture medium, neurobasal-A (Gibco, Life technologies, Carlsbad, USA) 
supplemented with 1% antibiotic–antimycotic mixture, was added into the culture well. The 
culture medium level was maintained in contact with the support membrane beneath the 
explant. The retinal explants were incubated at 37 °C with 5% CO2 in a humidified 
atmosphere.  
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PVL-treated explants and contrl explants 
A series of PVL concentrations (0.176, 0.352, 1.76 and 12.48 µM) were prepared and 
applied to 3 or 7 (for 1.76 µM PVL) different explants at each time point (30 min, 2, 4, 8 
and 24 h). Our previous study used PVL (3 µg/50 ml), equal to 1.76 µM. So PVL 1.76 µM 
was used as reference concentration. A 10-μL droplet of PVL diluted in culture medium 
was deposited on the surface of nerve fiber layer in each tested explant after retina flat-
mounting. An equivalent volume of culture medium was deposited onto the surface of 
control explants. Retina explants were collected and immediately fixed by 4% (wt/vol) 
paraformaldehyde. Four explants treated by 1.76 µM PVL were immediately frozen at -
80°C for RT-qPCR at each time point (4, 8 and 24 h).  
 
Tissue processing 
The explants were fixed for 1 h in 4% (wt/vol) paraformaldehyde and then embedded 
successively in 10% (wt/vol) and 20% (wt/vol) sucrose and stored in 30% (wt/vol) sucrose 
overnight at 4°C. The fixed retinal explants were divided and immersed in optimal cutting 
temperature compound (Sakura Finetek, Torrance, CA, USA) for cryosections, or stored in 
plastic tube (0.5ml) directly at -80 °C for retinal whole-mounts. Retinal cryosections of 8 
μm were cut and mounted on a Super FrostTM Plus microscope slides (Thermo Fisher 
Scientific, Rockford, IL, USA) and stored at -20 °C.  
 
Fluorescent immunostaining  
Retinal sections were permeabilized in 0.05% (v/v) TritonX-100 for 1 h and then were 
blocked with 10% (v/v) donkey serum (Sigma-Aldrich, St. Louis, MO, USA) for 1 h. Retinal 
sections were incubated with primary antibodies (Table 1) at 4°C overnight in a humidity 
chamber. Washing with PBS x 1 for 3 times, retinal sections were then incubated for 1 h at 
room temperature with fluorescent secondary antibodies (Table 1). Some sections were 
continually incubated in terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) mixed solution for another 1 h. Washing with PBS x 1 for 3 times, sections were 
counter-stained with Hoechst 33258 and mounted in 10% (v/v) Mowiol® solution 
(Polysciences, Eppelheim, Germany).  
 
Retina whole mounts were permeabilized 0.2% (v/v) TritonX-100 for 30 min. The retina 
whole mounts were incubated in conical small wells and transferred with 3 ml pipette. The 
staining steps were the same as those of immunoistochemistry section. At last, the retinal 
whole mounts were mounted on microscope slides and covered with thinner and smaller 
cover slides in 10% (v/v) Mowiol® solution. Images of fluorescent sections and whole 
mounts were obtained using an epifluorescence Olympus BX60 microscope connected to 
a Hamamatsu C11440 digital camera. 
 
Cell counting 
Different microscope fields (266 µm × 266 µm) of retinal immunofluorescent images were 
captured by the camera. PVL-positive retinal cells were evaluated by double 
immunohistochemistry: PVL-positive cells were double-labeled by PVL and retinal cell-
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specific markers. The percentages of PVL-positive RGCs at each time point (30 min, 2, 4, 
8 and 24 h with 1.76 µM PVL) were established by mean mounts of 3 explants (each 
explant has five study fields randomly captured by camera). For TUNEL positive cells count, 
five different microscope fields were analyzed for each explant, three different explants for 
each time point and PVL concentration. The mounts of TUNEL positive cells in each time 
points and concentration were established by mean mounts of all study fields.  
 
RNA extraction  
TRIzol reagent (Sigma, Saint-Louis, USA) was added into tubes contained frozen retina. 
The retinas were passed through 23-Gauge needle then 26-Gauge needle several times 
to be homogenized. Total RNA was isolated using TRIzol reagent according to the 
manufacturer’s instructions. The total RNA concentration was quantified with 
spectrophotometry (NanoDrop; Thermo Scientific, Waltham, USA). The RNA yield of each 
explant was calculated as a total weight of extracted RNA versus explant weight. RNA yield 
of control explants and 1.76 µM PVL-treated explants were quadruple at each time point.  
 
Real-time RT-qPCR 
10 µg RNA aliquots were treated with DNA-free kit DNase treatment (Ambion, Life 
technologies) at 37 °C for 30 min according to manufacturer’s instructions. 5 µL of RNA 
solution after DNase treatment was immediately reverse transcribed (RT) using 
Superscript First-Strand Synthesis for RT-PCR (Invitrogen, Life technologies). Diethyl 
decarbonate (DEPC) (Sigma) treated H2O was added to RT mixture (0.5 µL random 
hexamers (200 ng/ml), 5 µL total RNA, 1 µL NTP) to achieve a 12 µL volume, then 
incubated at +65 °C for 5 min and placed in glass for 2 min. Then, 0.5 µL of 0.1 M DDT, 
0.5 µL of transcriptase, 4 µL of First Strand buffer, 3 µL of sterile H2O were added to the 
mixture. Then, the total mixture was put into a ThermoCycler programmed at +42 °C for 50 
min and at + 70 °C for 15 min. The cDNA was diluted 3 times with DEPC treated H2O. 
Then, 5 µL of diluted cDNA, 10 µL SYBR Green mix (LightCycler 480 SYBR Green I Master, 
Roche, Basel, Switzerland), 2 µL of forward and reverse primers (100 µm), and 3µL H2O 
were mixed and put into 96 wells plate. The plate was placed into Real-Time PCR System 
(Light Cycler 480, Roche). PCR was programmed as initial denaturation step at +95 °C for 
10 min, 45 cycles of amplification (denaturation at + 95 °C for 15 s, annealing at +60 °C for 
20 s, extension at + 72 °C for 15 s), and melting curve analysis (+60 °C to +95 °C increment 
at +0.3 °C). The specificity of PCR products was verified according to one melting curve 
peak and one band in agarose gel electrophoresis. Products of RTs without reverse 
transcriptase were used as controls to ascertain no significant DNA contamination.  
 
The primers were designed to have Tm around 60°C by using Primer3 software. The 
sequences of primers: β-actin forward primer 5’-gcgggacatcaaggagaag-3’, afterward 
primer 5’-aggaaggagggctggaaga-3’; IL-6 forward primer 5’-tcaggccaagttcaggagtg-3’, 
afterward primer 5’-atgaagtggatcgtggtcgt-3’; IL-8 forward primer 5’-tggctgtggctctcttgg-3’, 
afterward primer 5’-atttgggatggaaaggtgtg-3’; TNF-α forward primer 5’-
cgtagtagcaaacccgcaag-3’, afterward primer 5’-tgagtgaggagcacgtagga-3’; VEGF forward 
primer 5’-cgagaccttggtggacatctt-3’, afterward primer 5’-tgcattcacatttgttgtgct-3’; iNOS 
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forward primer 5’-ccaagccctcacctacttcc-3’, afterward primer 5’-aactcctccagcacctcca-3’. 
The β-actin was used as reference gene and target gens were normalized using this 
reference gene. The method ∆Ct was used to calculate relative quantification between 
control explants and PVL-treated explants. The fold changes were calculated using 2-∆∆Ct. 
The tests were triplicate. The significant changes of every target gene were statistically 
analyzed using ∆Ct paired t-tests.  
 
Statistical analysis  
Statistical analysis was performed with GraphPad InStat version 3.10. Statistical 
significance was calculated paired t-tests, unpaired t-tests or ANOVA test. Statistical 
significance was assumed at p < 0.05. 
 
Results 
PVL co-localized with RGCs and horizontal cells 
An anti-LukS-PV antibody (Table 1) was used to identify the PVL fixation after being 
deposited on the retinal explant. PVL co-localized with RGCs labeled with an anti-RBPMS 
antibody in the retinal section (Figure 1 A–C). In the retina, RGCs co-localized with C5aR 
immunoactivity (Figure 1 D–F). PVL co-localized with some horizontal cells labeled with an 
anti-calbindin antibody at 8 and 24 h after PVL treatment (Figure 1 G–L). The mean (± 
SEM) percentage of PVL-positive RGCs were 33.7% ± 5.5%, 44.3% ± 4.7%, 47.0% ± 6.2%, 
42.0% ± 4.0%, and 45% ± 3.1% for 30 min, 2, 4, 8, and 24 h after PVL treatment, 
respectively (Figure 2 A–P). The rate of PVL-positive RGCs did not significantly change 
between 30 min and 24 h after culture (p > 0.05, Figure 2 P). 
 
PVL immunoreactivity was also observed in some cells in the inner part of the inner nuclear 
layer (INL; Figures 1 A–C and 2 A–I). However, we could not identify the cell type. The 
immunolabeling showed that they were not cholinergic amacrine cells labeled with the anti-
ChAT antibody, AII amacrine cells labeled with an anti-calretinin antibody, or calbindin-
positive bipolar cells (Supplementary Figure S1). Using a polyclonal anti-Pax6 antibody, 
other subpopulations of amacrine cells corresponded to the PVL-positive cells in the INL 
(Supplementary Figure S1 J, K). Unfortunately, we could not find a commercially available 
anti-Pax6 antibody that recognized rabbit Pax6 and was developed from a species other 
than rabbit. Consequently, we could not perform double immunolabeling for anti-Pax6 or 
anti-PVL antibodies (developed from rabbit). 
 
Müller and microglial cells were dramatically activated early by PVL in a 
concentration- and time-dependent manner. 
Müller cells extended their processes through the whole retina to provide architectural 
support to retinal neurons. The hallmark of retinal Müller cell activation is a shape change 
resulting from rapid upregulation of glial fibrillary acidic protein (GFAP) following acute 
retinal injury 17. In control explants, Müller cells were regularly arranged on the inner side 
of the retina from 2 to 24 h after culture (Figure 3 A–D). Müller cells showed an abnormal 
extension in the outer nuclear layer in 1.76 µM PVL-treated explants, which increased from 
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2 to 24 h after PVL treatment (Figure 3 E–H) and from low (0.176 µM) to high (12.48 µM) 
PVL concentrations (Figure 4 A–H). Dissociation of Müller cell organization was observed 
24 h after culture in retinal explants treated with 1.76 µM PVL (Figure 3 H and Figure 4 G). 
At 24 h, a complete destruction of Müller cells was noted in the retinal explants treated with 
12.48 µM PVL (Figure 4 H and Supplementary Figure S2). The retinal architecture was 
damaged when treated with 12.48 µM PVL at 8 and 24 h (Supplementary Figure S2). This 
retinal disfigurement may be related to Müller cell dysfunction. 
 
Microglial cells could demonstrate a broad range of morphological changes at different 
activated stages, including an enlargement of the soma, retraction and shortening of 
processes, and transformation into an amoeboid form, a round cell soma without 
processes 18. In control explants, microglial cells began to retract their processes 8 h after 
culture, enlarged their soma and retracted their processes 24 h after culture (Figure 5 G, 
H). While in PVL-treated explants, microglial cells were transformed into the amoeboid 
form, losing all of their processes 2 h after PVL treatment (Figure 5 E, F, I, J). Microglial 
cells were sensitive to PVL treatment and were dramatically activated 2 h after culture from 
0.176 to 12.48 µM PVL (Figure 4 I–L). 
 
A subpopulation of amacrine cells underwent apoptosis in PVL-treated explants 
In control explants (n = 3 for each time point with five study fields for each explant), TUNEL-
positive cells were found 24 h after culture, and the mean number was 0.81 per study field 
(Figure 6 A–C and Table 2). In PVL-treated explants (n = 3 for each time point and PVL 
concentration with five study fields for each explant), several TUNEL-positive cells were 
found 4 h after treatment with 1.76 and 12.48 µM PVL. The mean numbers of TUNEL-
positive cells were 2.25 and 2.00 per study field, respectively (Figure 6 D, G and Table 2). 
TUNEL-positive cells significantly increased, and the mean numbers were 2.00 and 5.00 
per study field 8 and 24 h after 1.76 µM PVL treatment, respectively, and the mean numbers 
were 6.00 and 11.67 per study field 8 and 24 h after 12.48 µM PVL treatment, respectively 
(Figure 6 E, F, H, I and Table 2). In 12.48 µM PVL-treated explants, more TUNEL-positive 
cells were found than in 1.76 µM PVL-treated explants (**** p < 0.0001, Figure 6 J). 
 
In PVL-treated explants, the TUNEL cells were mostly situated in the inner part of the INL 
and several positive cells were in the ganglion cell layer. In control explants, a few TUNEL-
positive cells could be found in the whole retina 24 h after culture. In total, PVL-treated 
explants exhibited significantly more TUNEL-positive cells than control explants (****p < 
0.0001, Figure 6 K). 
 
Double immunohistochemistry with TUNEL and specific antibodies of retinal cell types 
demonstrated that some microglial cells (labeled with FITC-tagged GSAI-B4) were TUNEL-
positive in the whole retinal mount (Figure 7 A–C, a–c), TUNEL-positive cells also co-
localized with amacrine cells (labeled with an anti-Pax6 antibody) in the INL (Figure 7 D–
G, d–f). To further distinguish which subpopulation of amacrine cells were apoptotic, two 
specific antibodies were used and showed that starburst amacrine (labeled with an anti-
ChAT antibody) and AII amacrine (labeled with an anti-calretinin antibody) did not co-
90 
 
localize with TUNEL-positive cells (Supplementary Figure S3). TUNEL-positive cells did 
not co-localize with RGCs nor with calbindin-positive bipolar or horizontal cells 
(Supplementary Figure S3). 
 
Although RNA yield decreased in all explants, inflammatory factor expression was 
lower in PVL-treated explants than in controls. 
The total RNA was extracted from retinal explants by using a TRIzol reagent and quantified 
with spectrophotometry. The RNA yield was expressed by RNA production per microgram. 
Twenty-four hours after culture, the mean RNA yield significantly decreased by 81.2% (*p 
< 0.05) in control explants, the mean RNA yield was significantly reduced by 97.2% (***p 
< 0.001) in PVL-treated explants, and the mean RNA yield in PVL-treated explants 
decreased significantly more than in control explants (*p < 0.05) (Figure 8 A). 
 
RT-qPCR was used to analyze inflammatory factor expression in explants 4 and 8 h after 
culture. At these time points, control explants expressed more inflammatory factor mRNA 
than PVL-treated explants (Figure 8 B, C). Four hours after culture, control explants had 
increased the IL-6 and IL-8 mRNA expression (IL-6: 12.42 ± 6.40-fold change, IL-8: 19.13 
± 11.43-fold change). Conversely, IL-6 and IL-8 mRNA expression did not increase in PVL-
treated explants (Figure 8 B). 
 
Eight hours after culture, control explants had significantly increased IL-6 and IL-8 mRNA 
expression (IL-6: 7.63 ± 2.25-fold change, IL-8: 19.66 ± 1.0-fold change), together with 
PVL-treated explants (IL-6: 3.70 ± 0.98-fold change, IL-8: 6.36 ± 1.16-fold change). PVL-
treated explants expressed lower inflammatory factors (IL-6 and IL-8) than control explants 
(*p < 0.05, Figure 8 C). For control explants, IL-6 and IL-8 mRNA expression did not 
significantly change from 4 to 8 h after culture. Although IL-6 and IL-8 mRNA expression 
increased in PVL-treated explants, TNF-α expression significantly decreased (0.15 ± 0.02-
fold change). This was not the case for control explants. 
  
Discussion  
In retinal explants, PVL co-localized rapidly with RGCs, then with horizontal cells, and 
possibly with a subpopulation of amacrine cells in the INL. PVL incited Müller and microglial 
cell activation together with amacrine and microglial cell apoptosis in a PVL concentration- 
and time-dependent manner. 
 
We recently showed that PVL increasingly co-localized with RGCs from 30 min to 2 h after 
PVL infection and transiently with displaced amacrine cells in an in vivo rabbit model 14. In 
the present ex vivo study, PVL also rapidly co-localized with RGCs and later with horizontal 
cells. It is also possible that PVL targeted a subpopulation of amacrine cells: Some cells in 
the INL were PVL-positive and had the form and location of amacrine cells (Supplementary 
Figure S1 J, K). However, we could not precisely demonstrate this fact as antibodies for 
double immunolabeling were not commercially available for rabbit. Nevertheless, those 
cells were not bipolar, horizontal, starburst, or AII amacrine cells. They seemed to 
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correspond to amacrine cells labeled with an anti-Pax 6 antibody. Interestingly, the 
amacrine cells underwent apoptosis a few hours after PVL treatment. The differences in 
cell targeting between in vivo and ex vivo retinas might be because of different mechanisms 
of PVL diffusion in the retina. The retina is a semipermeable membrane. Even if the inner 
limiting membrane of the retina is considered a significant barrier for molecular diffusion, 
the inner and outer plexiform layers are likely the sites of highest resistance to molecular 
diffusion 19. During intravitreal injection, PVL diffuses into the retina but might be 
constrained in the ganglion cell layer by the diffusion resistance of the inner plexiform layer. 
In retinal explants, PVL diffused more profoundly in the retina and reached the INL (i.e., 
horizontal cells). The retinal explant lacks a blood supply and the retinal vasculature rapidly 
shrinks. This might modify the retinal homeostasis and decrease the capacity of diffusion 
resistance from the inner plexiform layer. Consequently, PVL could diffuse more efficiently 
through the retina. 
 
PVL caused apoptosis of a subpopulation of amacrine cells in PVL-treated explants. PVL 
could incite intracellular calcium increase and glutamate release from neuronal cells 20. 
The amacrine cells express ionotropic glutamate receptors. Excessive activation of 
ionotropic glutamate receptors could lead to amacrine cell death 21. The PVL-positive cells 
were RGCs and some neuronal cells in the INL, which might release excessive glutamate 
and incite apoptosis in amacrine cells. 
 
We showed that Müller cells were activated in a and PVL concentration- and time- 
dependent manner. The Müller cell reaction was also associated with some retinal 
structural damage. Significant destruction of the retinal structure occurred 8 h after PVL 
treatment and might be due to retinal edema. Müller cells are the primary cells responsible 
for K+ and fluid influx regulation in the retina 22. In retinal inflammation, Müller cells are 
activated and transformed into gliosis, which results in a significant decrease in potassium 
and water channel protein expression 23. Müller cells swell and the retinal fluid absorption 
function decreases, leading to retinal edema and degeneration 24. 
 
Microglial cell activation is a typical early phenomenon in response to retinal injuries and 
inflammation before retinal cell death 25. Activated microglial cells demonstrate various 
phenotypes with a different degree of stimuli and could undergo apoptosis by 
overactivation 26. In control explants, microglial cells were slightly activated at 8 and 24 h 
after culture. Microglial cells were significantly activated 2 h after PVL treatment, some of 
them were apoptotic, which might be because of the overaction incited by PVL. The 
activation and gene expression of microglial cells are influenced by the balance of 
excitatory and inhibitory stimuli from the microenvironment around the microglial cells, 
especially neurons which might incite a microglial inflammatory response 27-29.  
The mechanism of cell reaction incited by PVL is not well known. LukS-PV binds C5aR, 
which provokes calcium mobilization in neutrophils and neuronal cells (Jover et al., 2013). 
LukS-PV alone does not incite cell reaction. It needs the presence of LukF-PV for PVL 
cytotoxicity6, 20. Recently, it was identified that CD45 is one receptor for LukF-PV 30. In 
retina, it is clear that ganglion cells express C5aR and that some microglial cells express 
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CD45 31. However, we do not know if LukF-PV and CD45 have role in the 
activation/cytotoxicity of microglial cells.  
 
Our study shows that the inflammatory factor expression increased and microglial cells are 
slightly activated in control explants. Another study has shown the same inflammatory state 
of retinal explants. In rat retinal explants, microglial cells show features of activation. Some 
microglial cells became amoeboid and others retracted their processes. TNF-a, IL-6, and 
MCP-1 were detected in the culture supernatant using an ELISA test 1 day after culture 32. 
In PVL-treated explants, the increase of IL-6 and IL-8 expression was lower than in control 
explants and the TNF-α expression decreased, whereas Müller and microglial cells were 
dramatically activated earlier than expected. This discrepancy between morphological 
results and inflammatory factor expression is difficult to explain. Our previous results using 
an in vivo model demonstrated that PVL injection incited both morphological changes and 
inflammatory factor release. On the one hand, in PVL-treated explants, it is possible that 
Müller and microglial cells were too disturbed (Figure 4) to express inflammatory factors. 
On the other hand, in retinal explants, inflammatory factor release from cells other than 
Müller and microglial cells (neutrophils, macrophages, and mast cells) that infiltrate the 
retina from the blood circulation is not possible. However, in contrast to the in vivo model, 
there is no blood supply in retinal explants, which explains the discrepancy between the in 
vivo and ex vivo results. 
 
Our results showed that the RNA yield decreased more in the PVL-treated explants (by 
97.2%) than in the control explants (by 81.2%) 1 day after culture. One study showed that 
the RNA yield of nontreated retinal explants decreased by 75% 1 day after culture 33, which 
is in accordance with our results. The decreased RNA yield might be mainly because of a 
decrease in RNA expression and the instability of mRNA during dramatic changes of retinal 
homeostasis conditions 33, 34. These results demonstrate that PVL deteriorates the capacity 
of the retina to produce proteins. This effect might explain the decrease in inflammatory 
factor release in the PVL-treated explants. 
 
Conclusion 
Developing cell- and tissue-based in vitro models is essential to understand the 
mechanism of PVL infecting the retina and to perform tests for potential therapeutics. In 
this study using a retinal explant ex vivo model, we confirmed previous results from an in 
vivo model. PVL co-localized with retinal neurons and incited retinal inflammation, probably 
via Müller and microglial cell activation. In retinal explants, there was substantial evidence 
that PVL led to glial activation and later destruction; however, inflammatory markers usually 
associated with glial activation were not markedly increased. It is likely that glial destruction 
following PVL infection has limited the possibility of glial cells to secrete inflammatory 
factors. The lack of blood supply due to the retinal explants condition might also have 
played a role in the weak inflammatory response. Nevertheless, retinal explants are a 
useful and more manageable model to study PVL effects on the retina. PVL, or other 
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bacterial toxins, could aggravate bacterial endophthalmitis through neuronal and glial 
interaction. 
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Table 1. List of specific markers used in the current study 
 Primary antibodies or lectin  
Target Antiserum Source Concentration 
PVL Rabbit anti-LukS-PV polyclonal EA-7290, Strasbourg, France  2 µg/mL 
C5aR Rabbit anti-C5aR polyclonal Abcam, Cambridge, UK 2 µg/mL 
Ganglion cells Guinea pig anti-RBPMS polyclonal UCLA Neurobiology, Los Angeles, CA, 
USA 
2 µg/mL 
Starburst amacrine 
cells 
Goat anti-ChAT polyclonal Chemicon Merck-Millipore, Temecula, 
CA, USA 
20 µg/mL 
Müller cells Mouse anti-GFAP polyclonal Bio-Rad AbD Serotec, Oxfordshire, 
UK 
2 µg/mL 
Microglial cells FITC-tagged GSAI-B4 Sigma Aldrich, Saint Louis, MO, USA 2 µg/mL 
amacrine cells Rabbit anti-Pax 6 polyclonal Abcam  2 µg/mL 
AII Amacrine cells Mouse anti-calretinin monoclonal Santa Cruz Biotechnology, 
Heidelberg, Germany 
2 µg/mL 
Horizontal cells Mouse anti-calbindin monoclonal Santa Cruz Biotechnology 2 µg/mL 
Secondary antibodies 
Anti-rabbit Goat and donkey polyclonal Alexa 
555nm-conjugated 
Life Technologies, Carlsbad, CA, USA 2 µg/mL 
Anti-goat Donkey polyclonal Alexa 488-
conjugated 
Molecular Probes, Eugene, OR, USA 2 µg/mL 
Anti-mouse Donkey polyclonal Alexa 488-
conjugated 
Abcam 2 µg/mL 
Anti-guinea pig Goat polyclonal Alexa 488-conjugated Abcam 2 µg/mL 
TUNEL DNA strand breaks Roche Life Science, Indianapolis, IN, 
USA 
--- 
Nuclei Hoechst 33258 Molecular ProbesTM, Eugene, OR, 
USA 
0.1µg/mL 
Abbreviations: RBPM, RNA-binding protein with multiple splicing; CHAT, choline acetyl transferase; GFAP, 
glial fibrillary acidic protein; FITC, Fluorescein isothiocyanate; GSAI, Griffonia simplicifolia agglutinin 
isolectin. TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling. 
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Table 2. The mean number of apoptotic cells per study field 
PVL concentration 4 h  8 h  24 h  
0 (control) 0 0 0.81 
0.176 μM 0 0.22 2.50 
0.352 μM 0 1.36 3.67 
1.76 μM 2.25 2.00 5.00 
12.48 μM 2.00 6.00 11.67 
The table shows the mean number of apoptotic cells per study field of different explants 4, 
8 and 24 h after treatment of different PVL concentrations. The mean number of apoptotic 
cells was calculated from 3 different explants and 5 study fields of each explant (****p 
<0.0001). 
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Figure 1: Panton–Valentine leukocidin (PVL) co-localized with retinal ganglion cells 
(RGCs) and then with horizontal cells. RGCs co-localized with C5aR immunoactivity. 
PVL (red fluorescence) co-localized with RGCs labeled with an anti-RBPMS antibody 
(green fluorescence) (A–C), and C5aR immunoactivity co-localized with RGCs (D–F) in 
the retinal explants 2 h after PVL treatment. PVL also co-localized with some horizontal 
cells labeled with an anti-calbindin antibody (green fluorescence) in the outer limit of the 
INL 8 (G–I) and 24 h (J–L) after PVL treatment. 
Abbreviations: PVL, Panton–Valentine leukocidin; RGCs, retinal ganglion cells; RBPMS, 
RNA-binding protein with multiple splicing; C5aR, C5a receptor; GCL, ganglion cell layer; 
INL, inner nuclear layer; ONL, outer nuclear layer. 
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Figure 2: The rate of PVL-positive RGCs did not change from 30 min to 24 h. PVL 
(red fluorescence) co-localized with RGCs labeled with an anti-RBPMS antibody (green 
fluorescence) in the vertical retinal sections. The rate of PVL-positive RGCs was 33.7% ± 
5.5%, 44.3% ± 4.7%, 47.0% ± 6.2%, 42.0% ± 4.0%, and 45% ± 3.1% for 30 min (A–C, P), 
2 (D–F, P), 4 (G–I, P), 8 (J–L, P), and 24 h (M–O, P) after PVL treatment, respectively. No 
significant difference was observed for the rate of PVL-positive RGCs from 30 min to 24 h. 
The PVL immunoreactivity was also observed in some cells in the inner part of the INL 
before 4 h after PVL treatment (A–I). 
Abbreviations: PVL, Panton–Valentine leukocidin; RGCs, retinal ganglion cells; RBPMS, 
RNA-binding protein with multiple splicing; GCL, ganglion cell layer; INL, inner nuclear 
layer; ONL, outer nuclear layer, ns, no significant. 
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Figure 3: Müller cells were activated in PVL-treated explants. In control explants (A–
D), Müller cell processes labeled with an anti-GFAP antibody were regularly arranged in 
the inner part of the retina. In PVL-treated explants, Müller cells labeled with an anti-GFAP 
antibody showed an abnormal extension in the outer nuclear layer (ONL), which increased 
from 2 to 24 h after PVL treatment (arrow, E–H). At 24 h, the anti-GFAP labeling was visible 
in the whole retina, from the inner to the outer part, demonstrating the abnormal glial 
reactivity (H). 
 
Abbreviations: PVL, Panton–Valentine leukocidin; GFAP, glial fibrillary acidic protein; ONL, 
outer nuclear layer; INL, inner nuclear layer. 
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Figure 4: In PVL-treated explants, Müller and microglial cells were activated in a 
concentration- and time-dependent manner. A–H represent vertical retinal sections. I–
L represent whole retinal mounts. Müller cells labeled with anti-GFAP showed an abnormal 
extension in the ONL 8 h after PVL treatment, which increased from 0.176 to 1.76 µM PVL 
(arrow, A–C). Müller cells showed a dissociated arrangement when treated with 12.48 µM 
PVL (arrow, D). Müller cells showed an abnormal extension in the ONL 24 h after treatment 
with 0.176 and 0.352 µM PVL (arrow, E, F). Müller cells appeared damaged, and the retinal 
structure was dissociated when treated with 1.76 (arrow, G) and 12.48 µM (arrow, H) PVL. 
Two hours after culture, microglial cells labeled with FITC-tagged GSAI-B4 began to lose 
their processes with 0.176 µM PVL (arrow, I), their processes were dissolved with 0.352 
µM PVL (arrow, J), their processes disappeared with 1.76 (arrow, K), and their soma 
became smaller when treated with 12.48 µM PVL (arrow, L). 
 
Abbreviations: PVL, Panton–Valentine leukocidin; GFAP, glial fibrillary acidic protein; ONL, 
outer nuclear layer; INL, inner nuclear layer. 
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Figure 5: Microglial cells were activated 2 h after PVL treatment. A–J represents 
images of the whole retinal mount. Microglial cells were labeled with FITC-tagged GSAI-
B4. In control explants, microglial cells were normal before 4 h (A–C) and began to retract 
their processes 8 h after culture (arrow, G). At 24 h, mild enlargement of the soma and a 
retraction of processes of microglial cells were observed in control explants (H). In contrast, 
microglial cells were normal at 30 min (D) in PVL-treated explants (1.76 µM) but were 
drastically transformed into amoeboid forms and lost all their processes from 2 to 24 h after 
PVL treatment (arrow, E, F, I, J). 
 
Abbreviations: PVL, Panton–Valentine leukocidin; FITC, Fluorescein isothiocyanate; 
GSAI-B4, Griffonia Simplicifolia I Isolectin B4. 
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Figure 6: In PVL-treated explants, TUNEL-positive cells were found and increased in 
a concentration- and time-dependent manner. In control explants, no TUNEL-positive 
cells were detected 4 (A) or 8 h (B) after culture. However, a few TUNEL-positive cells were 
detected 24 h after culture (arrow, C). In PVL-treated explants (1.76 and 12.48 µM), 
TUNEL-positive cells were found and greatly increased from 4 to 24 h after treatment 
(arrow, D–I). The number of TUNEL-positive cells significantly increased between 1.76 (E, 
F) and 12.48 µM (H, I) PVL (J, ****p < 0.0001) and between PVL-treated explants to control 
explants (K, ****p < 0.0001). In 12.48 µM PVL-treated explants, the retinal structure was 
damaged 8 (H) and 24 h (I) after treatment. Retinal cell layers labeled with Hoechst dye 
were not distinguishable. 
 
Abbreviations: PVL, Panton–Valentine leukocidin; TUNEL, terminal deoxynucleotidyl 
transferase dUTP nick end labeling; GCL, ganglion cell layer; ONL, outer nuclear layer; 
INL, inner nuclear layer. 
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Figure 7: TUNEL-positive cells co-localized with microglial and amacrine cells in the 
INL. One microglial cell (labeled with FITC-tagged GSAI-B4) co-localized with TUNEL-
positive cell in the whole retinal mount (A–C, enlarged images a–c). The majority of 
TUNEL-positive cells were localized in the INL and co-localized with amacrine cells 
(labeled with an anti-Pax 6 antibody) in vertical retinal sections (D–G, enlarged images d–
f). 
 
Abbreviations: PVL, Panton–Valentine leukocidin; TUNEL, terminal deoxynucleotidyl 
transferase dUTP nick end labeling; GCL, ganglion cell layer; ONL, outer nuclear layer; 
INL, inner nuclear layer. 
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Figure 8: Although RNA yield decreased in all explants, the inflammatory factor 
expression was lower in PVL-treated explants than in controls. In control explants, the 
mean RNA yield per microgram was 613.0 ± 89.9 ng/ml at 4 h, 552.3 ± 143.9 ng/ml at 8 h, 
and 115.3 ± 17.4 ng/ml at 24 h. The mean RNA yield per microgram was reduced by 81.2% 
(*p < 0.05) 24 h after culture. In the PVL-treated group, the mean RNA yields per microgram 
were 701.0 ± 58.3 ng/ml at 4 h, 497.3 ± 81.7 ng/ml at 8 h, and 19.6 ± 2.4 ng/ml at 24 h. 
The mean RNA yield per microgram was significantly reduced by 97.2% (***p < 0.001) after 
24 h treatment. There was a significant difference in RNA yield between control explants 
and PVL-tested explants 24 h after culture (A, *p < 0.05). Control explants had significantly 
increased IL-6 and IL-8 mRNA expression 4 h after culture, whereas PVL-tested explants 
did not show significantly increased inflammatory factor mRNA. Control explants 
expressed more inflammatory factor mRNA than PVL-treated explants 4 h after culture: IL-
6, 12.42 ± 6.40 vs. 0.64 ± 0.05 (B, *p < 0.05); IL-8, 19.13 ± 11.43 vs. 0.51 ± 0.22 (B, *p < 
0.05); and TNF-α, 6.00 ± 2.50 vs. 0.28 ± 0.09 (B, *p < 0.05). At 8 h after culture, control 
and PVL-tested explants had significantly increased IL-6 and IL-8 mRNA expressions, 
whereas PVL-tested explants had a significantly decreased TNF-α mRNA expression. 
Control explants expressed more inflammatory factors mRNA than PVL-treated explants 
after culture: IL-6, 7.63 ± 2.25 vs. 3.70 ± 0.98 (C, *p < 0.05); IL-8, 19.66 ± 1.05 vs. 6.36 ± 
1.16 (C, *p < 0.05); TNF-α, 0.89 ± 0.04 vs. 0.15 ± 0.02 (C, *p < 0.05). The control explants 
did not significantly change the mRNA expression of IL-6, IL-8, or TNF-α from 4 to 8 h after 
culture. 
 
Abbreviations: PVL, Panton–Valentine leucocidin. 
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Supplementary Figure S1.  
 
Supplementary Figure S1: PVL did not colocalize with cholinergic amacrine cells, 
nor AII amacrine cells; nor calbindin-positive bipolar cells, nor horizontal cells 
before 4 h after PVL treatment. PVL (red fluorescence) did not colocalize with cholinergic 
amacrine cells labeled with an anti-ChAT antibody, nor AII amacrine cells labeled with an 
anti-Calretinin antibody. PVL did not colocalize with calbindin-positive bipolar cells, nor 
horizontal cells before 4 h after PVL treatment. It seemed that amacrine cells labeled by 
anti-Pax6 antibody (K) correspond to the PVL-positive cells in INL (J). 
 
Abbreviations: PVL, Panton–Valentine leukocidin; ChAT, Anti-Choline Acetyltransferase; 
GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. 
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Supplementary Figure S2.  
 
Supplementary Figure S2: Müller cells were activated and retinal structure was 
destroyed in PVL-treated explants. Müller cells labeled with an anti-GFAP antibody 
showed abnormal extension in ONL, and nuclei labeled with Hoechst began to show 
disordered organization 8 h after PVL treatment (1.76 μM PVL) (A, B). At 24 h, Müller cell 
processes were visible in the whole retina, nuclei could not show normal retinal structure 
in 1.76 μM PVL-treated explants (C, D). The Müller cells and nuclei were dissolved, retinal 
structure was destroyed 24 h after PVL treatment (12.48 μM PVL) (E, F).   
 
Abbreviations: PVL, Panton-Valentine leukocidin; GFAP, glial fibrillary acidic protein; ONL, 
outer nuclear layer. 
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Supplementary Figure S3. 
 
Supplementary Figure S3: TUNEL positive cells did not colocalized with RGCs, nor 
cholinergic amacrine cells, nor AII amacrine cells, nor calretinin-positive cells 
(bipolar and horizontal cells) in PVL-treated explants. The TUNEL positive cells did not 
colocalized with RGCs labeled with an anti-RBPMS antibody (A-C), nor with cholinergic 
amacrine cells labeled with an anti-ChAT antibody (D-F), nor with AII amacrine cells 
labeled with an anti-calretinin antibody (G-I), nor with calbindin-positive bipolar or 
horizontal cells labeled with an anti-calbindin antibody (J-L). 
 
Abbreviation: PVL, Panton-Valentine leukocidin; TUNEL, terminal deoxynucleotidyl 
transferase dUTP nick end labeling; RGCs, retinal ganglion cells; RBPMS, RNA-binding 
protein with multiple splicing; ChAT, Anti-Choline Acetyltransferase; GCL, ganglion cell 
layer; ONL, outer nuclear layer.  
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3.3 Article 3: Bacterial toxins aggravate bacterial 
endophthalmitis by interacting directly with neurons 
Preface 
Our studies showed that PVL colocalized with retinal neurons and induced early retinal 
inflammation, including glial cell activation and inflammatory factors production. Other 
previous study showed that PVL could incite intracellular calcium mobilization in primary 
neuronal cells, which was associated with glutamate release from these neuronal cells 
without any membrane damages. The mechanism by which PVL initiates retinal 
inflammation by firstly targeting retinal neurons is unknown. By looking for the mechanism 
by with bacterial toxins incited inflammation in other neuronal system, the retinal molecular 
basis and the clinical symptoms of bacterial retinal inflammation in literature, we tried to 
find the most possible mechanism by which PVL initiating retinal inflammation by firstly 
targeting neuronal cells in bacterial endophthalmitis. 
This review firstly supported the virulent role of bacterial toxins in aggravating bacterial 
endophthalmitis, and then examined how toxins induce inflammation in other neural 
systems. Bacterial components can directly act on neurons to produce neurogenic 
inflammation or stimulate neural circuits, both of which can modulate the innate immune 
response. This complex process is known as neuron-mediated inflammation. The retina 
has the molecular basis for innate immune response and neurogenic inflammation. It also 
discussed that the neuroretinitis, an infectious symptom induced by many kinds of bacterial 
and viral pathogens, is a disease probably resulting from retinal neuron-mediated 
inflammation by pathogens interacting directly on neuronal cells.   
We hypothesize that bacterial toxins are able to trigger neurogenic inflammation in the very 
early phase of endophthalmitis. Neurogenic inflammation may then evolve, interact, and/or 
modulate the innate immune response to bacterial infection. When the retinal structure is 
modified by inflammation, irreversible damage to the retinal tissue occurs, leading to a 
decrease of visual functions. Further studies are required to confirm this neuron-mediated 
inflammation induced by toxins initially targeting neuronal cells during bacterial 
endophthalmitis and, if confirmed, whether toxins could represent a new therapeutic target. 
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Abstract 
Bacterial endophthalmitis threatens the vision. The severity of bacterial endophthalmitis is related 
to the bacterial virulence. Bacterial toxins are evident virulence factors of bacteria. This study 
reviewed the proves in the literature that bacterial toxins might interact directly with neurons and 
induce neuron-mediated inflammation in retina. 
In the neural system, there are two types of inflammation that may be involved when bacterial toxins 
interact with neuronal cells: one type is related to innate immune recognition system through 
pathogen-associated molecular patterns and pattern recognition receptors (PRRs), whereas the other 
is related to neurogenic response, principally mediated by substance P (SP), calcitonin gene-related 
peptide (CGRP) and probably glutamate, which are released from neuron terminals following 
induction by noxious stimuli. In neural system, bacterial components can act directly on neurons to 
produce neurogenic inflammation or stimulate neural circuits, both of which can modulate the 
subsequent innate immune response. This complex process is called neuron-mediated inflammation. 
Retina presents biologic potential to undergo neuron-mediated inflammation: the retina expresses 
PRRs, SP, and CGRP, and has the molecular basis for innate immune response and neurogenic 
inflammation. The steroid is controversial for bacterial endophthalmitis and useless for toxin 
inducing endophthalmitis. We hypothesized that bacterial toxins can trigger neuron-mediated 
inflammation in the very early phase of endophthalmitis. This may interact, and/or modulate the 
innate immune response to bacterial infection, and finally aggravate retinal lesions. Further studies 
are required to confirm the exact role of toxins during bacterial endophthalmitis. 
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Introduction 
Bacterial endophthalmitis is an acute ocular inflammation that occurs because of postoperative, 
posttraumatic, or, in rare cases, endogenous bacterial infection. The bacterial infection causes the 
breakdown of the blood–ocular fluid barriers and infiltration of polymorphonuclear leucocytes into 
the retina, choroid, and other ocular tissues, resulting in enhanced release of complement and 
proinflammatory cytokines and modification of the retinal structure1. Bacterial endophthalmitis is 
often associated with a poor prognosis. Only 43%–53% of patients achieve 20/40 or better visual 
acuity (VA), and about 20% have 20/100 or worse even after appropriate therapeutic management2-
3. Enucleation or evisceration are still common options in severe cases of endophthalmitis4. Recently, 
treatments such as vitrectomy and intravitreal injections of antibiotics have been introduced; 
however, visual outcome was not significantly improved3.  
The visual outcomes vary from visual recovery to loss of eye depending on many factors such as 
the types of infectious bacteria and the delay of treatment5. It is well demonstrated that virulent 
bacteria often cause severe endophthalmitis. Endophthalmitis caused by coagulase-negative 
staphylococci (CNS) result usually in good visual outcomes, causing generally less damage to retina 
than Staphylococcus aureus, Enterococci, Bacillus, and Gram-negative bacteria6. However, some 
endophthalmitis caused by CNS present delayed-onset, chronic and often painless inflammation, 
even severe ocular damages such as late retinal detachments7. Other factors than bacterial strains 
may explain the various severity of bacterial endophthalmitis. 
S. aureus produces a large variety of toxins8. CNS serve as gene reservoirs for promoting S. aureus 
colonization and virulence, possibly via toxin gene transfer among the strains9. The toxin expression 
in Staphylococci is related to bacterial virulence8, 10, while the other virulence genes expressions, 
such as adhesin genes, fail to determine disease pathogenesis of Staphylococci strains11-12. Bacterial 
toxins might be the key factors which aggravate endophthalmitis, leading to a poor prognosis.   
This review examined the virulent role of bacterial toxins in endophthalmitis. We reviewed briefly 
the innate immune response to infections, and neurogenic inflammation initiated by bacterial toxins 
in the central neural system. The retina has the potential to undergo innate immune response and 
neurogenic inflammation. The steroid is useless for toxin inducing endophthalmitis. Therefore, it is 
likely that bacterial toxins initiate rapidly neurogenic inflammation by interacting directly on 
neuronal cells then trigger innate immune response, which may lead to retinal damage and 
aggravation of bacterial endophthalmitis.   
1. Bacterial toxins are related to severe bacterial endophthalmitis   
CNS occupy 38%–80% of bacterial endophthalmitis cases, among which Staphylococcus 
epidermidis represents 30%–82%13-16. Approximately 9% of S. epidermidis endophthalmitis have 
poor visual outcomes17. S. epidermidis is a common colonizer at the ocular surface. One explanation 
for the pathogeny of S. epidermidis in endophthalmitis is due to its multidrug resistance and 
formation of biofilm18. However, it remains controversial whether antibiotic resistance and biofilm 
formation could differ between infectious and noninfectious strains. It is also unclear whether these 
two factors play a key role in poor visual outcomes in endophthalmitis14, 19-20. There are a variety of 
genotypic and phenotypic differences in S. epidermidis strains from endophthalmitis cases and 
healthy ocular surfaces, and the infectious and healthy strains shared only a few genetic 
characteristics18, 21-22.  
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S. epidermidis may contain virulence factors, such as proteases, esterases, phenol-soluble modulins, 
and enterotoxin C, which are related to the severity of its infection9-10, 23. Enterotoxin C, a toxin of 
S. aureus, is found in some S. epidermidis strains (9%) that are related to severe clinical syndromes10. 
The expression of toxins in severe endophthalmitis caused by S. epidermidis remains to be 
elucidated.  
 
Whereas, the role of toxins in S. epidermidis infections is not well studied, the aggravating effect of 
toxins in S. aureus infection is well demonstrated. S. aureus accounts for 7.2% of bacterial 
endophthalmitis cases with positive culture and is associated with a poor visual prognosis: 50% of 
patients achieve a VA of 20/100 or less2. The pathogenesis of S. aureus depends on the production 
of a myriad of virulent factors, among which toxins are frequently expressed. Toxin production can 
differentiate virulent from nonvirulent strains24. S. aureus secretes a variety of pore-forming toxins, 
such as α-toxin and bicomponent leukotoxins, proteolytic toxins, and superantigens8. Among these, 
leukotoxins, particularly Panton–Valentine leukocidin (PVL), can cause severe ocular 
inflammation25-27. In a PVL-induced endophthalmitis rabbit model, PVL is colocalized with retinal 
ganglion cells, which express PVL-specific receptor, C5aR, resulting in glial cell activation, 
apoptosis of microglial cells, and IL-6 release 4 h after intravitreal PVL injection28. The breakdown 
of hemo–retinal barrier leads to inflammation and PMNs infiltration in retina 24 h after PVL 
intravitreal injection. These results demonstrate that PVL toxin can alter retinal tissue per se. 
Moreover, antibodies against PVL can attenuate PVL-induced endophthalmitis26.  
Treatments for endophthalmitis include intravitreal antibiotic injection and vitrectomy to eliminate 
the pathogen from the eye1. However, irreversible structural damages to retina could occur during 
the first several hours29. The toxin-induced retinal inflammation might explain the early 
modifications to retina in endophthalmitis, which may help to identify a new treatment strategy or 
prophylaxis to block retinal modifications and improve visual outcomes. 
2. The innate immune response to infections 
Microorganism infection is detected by innate pattern recognition receptors (PRRs), which include 
transmembrane proteins such as Toll-like receptors (TLRs) and C-type lectin receptors (CLRs), 
cytoplasmic proteins such as retinoic acid-inducible gene (RIG-I)-like receptors (RLRs), and 
nucleotide oligomerization domain (NOD)-like receptors (NLRs). PRRs in different zones have 
different functions: transmembrane PRRs are responsible for detecting extracellular pathogen-
associated molecular patterns (PAMPs), PRRs in the cytoplasm are usually specific for hydrophobic 
lipids and proteins, whereas PRRs in endosomes detect nucleic acids, especially viral genomes.30  
PRRs recognize PAMPs, which are conserved microbial structures or damage-associated molecular 
patterns released from host cells after injury. PAMPs include the classic molecular patterns such as 
lipopolysaccharide (LPS) and nucleic acids. Indeed, many microorganisms are sensed by PRRs 
detecting their genomes or nucleic acids, especially for viral detection30. PRRs trigger intracellular 
signaling, generally myeloid differentiation primary response gene 88 (MyD88)/nuclear factor-κB 
(NF-κB), or Toll/interleukin-1 receptor (TIR)-domain-containing adapter-inducing interferon-β 
(TRIF)-dependent signaling, and mitogen-activated protein kinase (MAPK)-p38/Jun signaling 
pathways, leading to transcriptional expression of inflammatory factors such as proinflammatory 
cytokines, interferons (IFNs), chemokines, antimicrobial proteins31. 
TLRs recognize bacterial components and induce NF-κB and IFN signaling to produce 
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proinflammatory cytokines 
TLRs are the most prevalent and studied PRRs. TLRs share a common extracellular leucine-rich 
repeat and a cytoplasmic TIR domain32. TLRs 1, 2, 4, 5, and 6 are located on the plasma membrane, 
whereas TLRs 3, 7, 8, and 9 are endosomal receptors. TLRs are responsible for detecting 
extracellular and endosomal PAMPs. Activated by PAMPs, TLRs elicit MyD88-dependent NF-κB 
or TRIF-dependent IFN signaling to produce cytokines or chemokines and IFNs32 (Figure 1). 
RLRs recognize intracellular viral RNA and induce NF-κB and IFN signaling 
RLRs recognize 5′-triphosphorylated, uncapped ssRNA, which is a common feature in many viral 
genomes. However, it is unable to recognize the capped 5′-triphosphorylated ssRNA from the host 
cell. RIRs include three RNA helicases: retinoic acid-inducible gene I (RIG-I), melanoma 
differentiation-associated gene 5 (MDA-5), and laboratory of genetics and physiology-2 (LGP-2)30. 
LGP-2 is considered a regulator. After recognizing viral RNA, RIG-I or MDA-5 are activated then 
interact with adaptor proteins such as mitochondrial antiviral signaling protein (MAVS). MAVS 
activates the IκB kinase-related kinase and then triggers the TRIF-dependent IFN signaling pathway 
and the NF-κB signaling pathway31 (Figure 1).  
NLRs recognize intracellular bacterial components and induce NF-κB and MAPK signaling 
NLRs are intracellular receptors comprising NOD1 and NOD2, which induce transcriptional 
upregulation of proinflammatory cytokine genes through the NF-κB and MAPK signaling pathways. 
NOD1 recognizes the structures of bacterial peptidoglycans; NOD2 recognizes ɣ-D-glutamyl-meso-
diaminopimelic acid and muramyl dipeptide. More often, NOD1 and NOD2 crosstalk with other 
PRRs and regulate the innate immune response33 (Figure 1).  
CLRs recognize microbiological carbohydrates and induce NF-κB and nuclear factor of 
activated T-cells (NFAT) signaling 
CLRs are transmembrane receptors that detect carbohydrates on microorganisms such as viruses, 
bacteria, and especially fungi. They activate MAPK, NFAT, and NF-κ B pathways to produce 
proinflammatory cytokines31 (Figure 1).  
 
The expression of PPRs on different cell types and subcellular structures is related to different 
immune responses34. TLR9 ligands, such as dsDNA, are retained in the endosomal vesicles of 
plasmacytoid dendritic cells (pDCs), while they are rapidly transferred to lysosomal vesicles in 
conventional dendritic cells. The ability to retain TLR9 ligands in endosomes makes pDCs have a 
more robust IFN production than conventional dendritic cells35. High level of TLRs 2, 4 expressions 
is observed on macrophages, which produce mainly cytokines. Whereas TLRs7, 9 are mainly 
expressed on pDCs, which are responsible to produce cytokines and type I IFNs (IFN-α and IFN-
β)32. 
3. Neurogenic inflammation  
Neurogenic inflammation occurs after the activation of peripheral sensory neuron terminals by 
various physical or molecular stimuli, characterized by releasing substance P (SP) and calcitonin 
gene-related peptide (CGRP) or other biological substances (e.g., glutamate), which interact with 
neural, immune, and endothelial cells36. SP and CGRP are released from small-diameter sensory 
neurons, which is ultimately dependent on intracellular Ca2+ mobilization37. The receptors of CGRP 
and SP are expressed on endothelial and myeloid cells, and in the peripheral and central nervous 
systems38. CGRP and SP are potent vasodilators that act synergistically. SP acts on postcapillary 
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venules39, and CGRP acts on arterioles to produce plasma extravasation and vascular permeability38. 
CGRP is a 37-amino-acid peptide37. Many receptors and ion channels can be activated to release 
CGRP from sensory nerves in response to various factors or conditions such as bradykinin (BK), 
low pH, capsaicin, nicotine, ouabain, and ischemia40. CGRP binds to CGRP1 receptor and incites 
production of cAMP in endothelial cells41, resulting in arteriolar vasodilation and increase of blood 
flow to inflamed tissues42. CGRP has diverse immunomodulatory actions when it targets myeloid 
cells, such as potential anti-inflammatory effect43. CGRP colocalizes often with SP in C-fiber nerves 
in dorsal ganglion neurons and skin. CGRP can be cleaved by protease released from infiltrated 
mast cells, which is induced by SP44 (Figure 2).   
SP is an 11-amino-acid polypeptide. SP and its receptors are expressed in the peripheral and central 
nervous system as well as the immune system45. During neurogenic inflammation, SP induces 
cyclooxygenase-2 (Cox-2) expression and stimulates adhesion and infiltration of neutrophils to vein 
endothelial cells46-47, resulting in vein gap formation and plasma extravasation. After binding to its 
receptors, SP stimulates the NF-κB signaling pathway, which produces IL-8 in human astrocytoma 
cells48 and modulates maturation and responsiveness of immune cells49. CGRP and SP release into 
tissue may cause edema and neutrophil infiltration. Antagonists of the CGRP1 receptor (CGRP8–37) 
and SP receptors (RP67580) attenuate this edema50. SP binds to neurokinin1 (NK1) receptor on the 
cytoplasmic membrane and is internalized with the NK1 receptor and transported to endosomes. 
This internalization reduces the number of NK1 receptors on the cell surface, and SP is 
intracellularly degraded. This desensitization of SP is effective in limiting SP action39. SP can also 
be degraded by extracellular enzymes. The extracellular proteolysis of SP limits the concentration 
and effect of SP51 (Figure 2). 
Glutamate is a possible direct factor of neurogenic inflammation. Glutamate is a classical excitatory 
neurotransmitter and can be toxic when released in excess. Glutamate binds the N-methyl-D-
aspartate receptor (NMDAR) and induces calcium influx, triggering calcium-dependent proteins 
and signaling cascades that could promote neural death or survival. This dual effect is due to distinct 
NMDAR subpopulations, which are mediated by the concentration of glutamate. Some NMDARs 
bind to death signaling proteins, which could be activated by high concentration of glutamate to 
produce noxious substance such as the nitric oxide52.  
During neurogenic inflammation, the direct factors (SP, CGRP, and possible glutamate), exert the 
principal effects, namely, vasoactive action and immunomodulation36. Other neuropeptides, such as 
BK and neurotrophic factors, act as transmitters to enhance the release and the action of direct 
neurogenic factors. They initiate the transduction cascades and increase the influx of calcium and 
protein phosphorylation, resulting in neural hypersensitivity and release of direct neurogenic factors 
53-54.  
Peripheral neurons, especially nociceptor neurons, could detect numerous noxious stimuli 
(serotonin, endothelin, histamine, BK, ATP, TNF-α, and interleukin) through various receptors (G 
protein–coupled receptors (GPCR), receptor tyrosine kinases, and TNFR family) or ion (Na+, K+, 
and Ca2+) channels36. The cAMP and PKC signaling pathways are the main cellular mechanisms 
that regulate neuronal inflammatory reactions. The MAPK pathway can also participate in 
regulating neuronal inflammation36. Cytokines, prostaglandins, nitric oxide, opioids, and adrenergic 
substances are produced by primary afferent nociceptors after being triggered by neuropeptides55 
(Figures 2 and 3).  
4. The interaction between the innate immune response and 
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neurogenic inflammation 
The innate immune response and neurogenic inflammation interact tightly. Immune cells and 
neurons share many pathogen recognition receptors, such as transient receptor potential ion 
channels56 and TLRs 3, 4, 7, and 957-58. The neurotransmitters released from neurons not only 
activate vasculature but also initiate immune cells59. Neuropeptides can activate immune cells to 
secrete cytokines and chemokines. For example, SP stimulates mast cells to release TNF-α60. 
Anatomically, CGRP is closely associated with Langerhans cells; CGRP could inhibit the antigen 
presentation of Langerhans cells61. CGRP influences immune responses through mediating Th1 and 
Th2 cells, and upregulates IL-4 production from T cells62. Cytokines play an important role in 
communication between neurons and innate immune cells. IL-1β induces Cox-2 and prostanoid 
release in neurons63. The disturbance of neuron–immune mediation could cause autoimmune and 
allergic diseases58.  
5. Pathogen components can directly interact with neurons 
Nociceptor neurons possess some PPRs as immune cells, and also present other stimulus receptor-
related detection systems such as GPCRs and ligand-gated ions channels64-65, through which 
bacterial pathogens can bind to neuronal cells and incite neuronal depolarization, leading to rapid 
calcium mobilization and CGRP release66. 
Bacterial formyl peptides and α-hemolysin, substances of S. aureus, bind to their receptors, formyl 
peptide receptors and a disintegrin and metalloprotease 10, respectively, leading to calcium 
mobilization and depolarization of isolated nociceptors. Neuropeptides (CGRP, galanin, and 
somatostatin) are released from purified nociceptors following heat-killed S. aureus stimulation67. 
Neuropeptides induce the vasodilation and capillary permeability in neurogenic inflammation. They 
can modulate directly innate immune response. CGRP decreases TNF-α production from 
macrophages and suppresses the lymphadenopathy during S. aureus infection. This immune 
modulation of neuropeptides occurs later than the acute vascular action of neuropeptides67. T2R38, 
a test receptor expressed in bitter sensory neurons, can be directly stimulated by Pseudomonas 
aeruginosa and undergo calcium-dependent nitric oxide production, contributing to antimicrobial 
effects68. Leukotoxins secreted by S. aureus, HlgC/HlgB and PVL, activate calcium mobilization 
and glutamate release from primary sensory neurons and cerebellar granular neurons69. In PVL-
injection endophthalmitis, PVL colocalizes with retinal ganglion cells which express PVL-specific 
receptor, C5aR, resulting in glial cell activation and increase of IL-6 expression28 (Table 1).  
The neural circuits could maintain immune system homeostasis during bacterial infection through 
modulating the system of acetylcholine-α7 nicotinic acetylcholine receptor (α7 nAChR). The 
sensory neurons detect injury or infection and send information to central neurons. The central 
neurons produce and send neural circuits through the vagus nerve to the spleen or other immune 
organs in which acetylcholine-producing T cells are incited to release acetylcholine70,27. 
Acetylcholine binds to α7 nAChR on immune cells and triggers anti-inflammatory pathway and 
regulation of cytokine release from innate immune cells (Figure 3)71. In nematodes, neural circuits 
regulate the innate immune system to maintain homeostasis and promote the survival after being 
infected by pathogens72. The neural circuits and neuropeptides can also modulate the immune 
reactions of lymph nodes73,74,67(Figure 3). 
Bacteria or their components can directly activate peripheral sensory neurons and induce neuron-
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mediated inflammation. Indeed, in the first phase of neural inflammation, bacteria trigger neural 
circuits and/or neurogenic inflammation, resulting in vasodilation and vascular permeability; then, 
during the second phase, immune cells infiltrate and produce cytokines to eliminate the pathogens. 
On one hand, the neurotransmitters promote the infiltration of immune cells. On the other hand, 
they modulate the amplitude of innate immune response in the second phase (Figure 3).  
6. Bacterial toxin might aggravate endophthalmitis by neuron-
mediated inflammation  
The retina expresses neuropeptides and PPRs 
The retina expresses neuropeptides and their receptors, the molecular bases for neurogenic 
inflammation. Neuropeptides (CGRP, neuropeptide Y, vasoactive intestinal peptide, and SP) are 
present in the adventitia and perivascular space within the optical nerve in monkey and rat, where 
the CGRP and SP immunoreactivities are fully colocalized75. SP immunoreactivity is evidently 
expressed in displaced amacrine and ganglion cells in rabbit and rat retina76-78. CGRP and its 
receptors immunoreactivities are detected on the nerve fiber layer, ganglion cell layer, and inner 
nuclear cell layer79.  
Retinal ganglion cells and amacrine cells are the main cells that express SP, CGRP, and other 
neuropeptides. Their nerve processes are localized in the inner plexiform layer, where the retinal 
vasculature is dense78. This anatomical colocalization of vessels and neuropeptides may contribute 
to regulation of the retinal circulation75. 
The retina also expresses PRRs. Müller cells express TLRs 1–10 and NLRs, which recognize 
pathogens. TLRs agonists or pathogens (S. aureus, P. aeruginosa, and Candida albicans) activate 
Müller cells to produce proinflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-8) and nitric oxide80. 
Mouse cone photoreceptor lines express functional TLRs 1–9 and respond to pathogen stimuli. 
Primary photoreceptor is identified to express TLR481-82. Microglial cells express TLRs 2–4 that 
play an important role in recognizing pathogens and neural inflammatory reaction83.  
The steroid is controversial for bacterial endophthalmitis and useless for toxin inducing 
endophthalmitis 
The efficient treatment for bacterial endophthalmitis is consisted by anti-infection and anti-
inflammation. However, the usage of steroid as anti-inflammation in bacterial endophthalmitis is 
controversial84. The bacterial endophthalmitis treated by steroid adjunct to antibiotic has good 
outcomes than those treated by antibiotic alone, but it is uncertain the effects of steroid on the 
resolution of endophthalmitis and harms to eye85. The major concern to use steroid is that steroid 
could suppress the immune response to eliminate bacteria, resulting in aggravating the infection84, 
86. 
The effects of steroid on bacterial endophthalmitis is dependent on the early timing of administration, 
varying according to the virulence of bacteria84. Some studies showed that early (less than 24 h) 
intravitreal injection of antibiotic concomitant steroid results in good outcomes, even for the virulent 
bacterial strains, such as S. aureus, B. cereus87-89. The intravitreal injection of steroid concomitant 
with antibiotic before 5 h incidence of infection is efficient to control experimentally induced 
Pseudomonas endophthalmitis. While the same treatment is given after 10 h incidence of infection, 
the retina is destroyed even though the infection is controlled90. When the intravitreal 
dexamethasone with antibiotic is administrated 24 h after intravitreal injection of S. epidermidis, 
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the treatment could decrease the intraocular inflammation91-92. When dexamethasone with antibiotic 
is given at 48 h after intravitreal injection of S. epidermidis, the treatment does not reduce the 
intraocular inflammation even though the infection is controlled91.  
Steroid is not useful for endophthalmitis caused by toxin expressing stains84. The antibiotic and 
steroid administrated 1 day after the infection do not improve endophthalmitis caused by 
enterococcus faecalis toxin expressing strains, while the endophthalmitis caused by E. faecalis non-
toxin expression strains responded well to those treatment86. In B. cereus exotoxins inducing 
endophthalmitis, the concomitant injections of dexamethasone with antibiotic could not attenuate 
the retinal necrosis and inflammation93. Steroid bind to its receptor, which could suppress multiple 
inflammatory transductions, such as MAPK, NF-κB and activator protein-194. Bacterial toxin 
induces retinal inflammation as early as 4 h28, 93, probably by the mechanism of neuron mediated-
inflammation, which is dependent on the rapid calcium mobilization and might not be influenced 
by steroid anti-inflammatory effects. 
The retina expresses TLRs, SP, and CGRP proteins in the optical nerve and inner layers of the retina. 
We deduce that bacterial toxins could rapidly interact with neurons through their specific receptor(s) 
to release neurotransmitters, resulting in vascular excavation and breakdown of the blood–retinal 
barrier during the early stages of bacterial endophthalmitis. Retinal inflammation is amplified by 
innate immune cell infiltration and the retinal glial cell activation. Irreversible retinal damage result 
in poor visual prognosis, despite efficient antibiotic treatment.  
Conclusions 
Bacterial pathogens may interact directly with neurons to produce neuropeptides, neural circuits and 
innate immune response. Neuropeptides and neural circuits modulate the following innate immune 
response. The retina expresses a variety of receptors and neuropeptides, presenting the possibility 
for neuron-mediated inflammation. We deduce that bacterial toxins induce neurogenic inflammation 
and subsequently innate immune response during bacterial endophthalmitis. To improve the 
prognosis of bacterial endophthalmitis, the bacteria must be eliminated and, additionally, the 
bacterial toxins must also be blocked to cause the early inflammatory processes.  
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Table 1. Bacterial pathogens directly act on neurons to cause effects 
Pathogen 
molecules 
Receptors  neurons effects 
LPS TLR4/ 
CD14 
primary dorsal root 
ganglia neurons 
Intracellular Ca2+ increase, 
CGRP release 
Formyl peptides FPRs isolated nociceptors Ca2+ influx and 
depolarization of neurons,   
α-haemolysin ADAM10 isolated nociceptors Ca2+ influx and 
depolarization of neurons, 
Heat-killed S. 
aureus 
 purified nociceptors Neuropeptides (CGRP, 
galanin, somastatin) were 
highly expressed 
P. aeruginosa T2R38 bitter sensory 
neurons 
Calcium-dependent NO 
production 
PVL, HlgC/HlgB  primary sensory 
nerves from dorsal 
root ganglia, 
Ca2+ mobilization, glutamate 
release 
PVL C5aR retinal ganglion cells Retinal glial cells activation, 
IL-6 expression increase, 
NO production increase, 
retinal microglial apoptosis 
Abbreviation: LPS, Lipopolysaccharides; TLR4, toll-like receptor 4; CD14, cluster of 
differentiation 14; FPRs, formyl peptide receptors; ADAM10, a disintegrin and 
metalloprotease 10; T2R38, taste 2 receptor member 38; NO, nitric oxide; PVL, Panton–
Valentine leukocidin; C5aR, C5a receptor. 
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Figure 1: The innate immune system response to infection. The transmembrane 
PRRs, CLRs and TLR-1, 2, 4 and 5 detect extracellular PAMPs. The endosomal PRRs 
detect intracellular penetrating PAMPs. After PAMPs interacting PRRs, the transduction 
pathways are activated, including NF-κB, IFNs, NFAT and MAPK, which could modulate 
genes transcription and produce inflammatory cytokines, chemokines and IFNs. 
 
Abbreviations: PAMPs, pathogen-associated molecular patterns; PRRs, pattern 
recognition receptors(PRRs); TLRs, Toll-like receptors (TLRs); CLRs, C-type lectin 
receptors (CLRs); RLRs, cytoplasmic proteins RIG-I-like receptors (RLRs); NLRs, 
nucleotide oligomerization domain(NOD)-like receptors(NLRs). NF-κB, nuclear factor 
kappa-B kinase; IFNs, type I interferons; NFAT, nuclear factor of activated T-cells; MAPK, 
mitogen-activated protein kinase.  
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Figure 2: The inflammatory signaling pathways in neurons. The noxious stimuli act 
through various receptors or ions channels on neurons. 1)The neural transmembrane 
receptors (CPGR, RTKs, TNFR family) detect noxious stimulus and substances. The 
cAMP, PKC and MAPK signaling pathways incite intracellular calcium mobilization and 
alter genes transcriptions to produce endogenous mediators. 2) Other stimulus and 
substances react directly on neural ions channels, which initiate calcium influx and incite 
intracellular calcium mobilization. Calcium binding proteins can alter genes transcriptions. 
3) Lysosome, endoplasmic reticulum and mitochondria play also great role in mobilizing 
intracellular calcium. 4) The increase of intracellular calcium could lead to SP and CGRP 
release from neuronal vesicles. 
 
Abbreviations: R, receptors; RTKs, receptor tyrosine kinases; TNFR, tumor necrosis 
factor receptors; cAMP, cyclic adenosine monophosphate; PKC, protein kinase C; MAPK, 
mitogen-activated protein kinase; C, channels; L, lysosome; M, mitochondria; ER, 
endoplasmic eeticulum; V, vesicle; N, nuclear; SP, substance P; CPGR, G-protein-
coupled receptors.  
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Figure 3: The neural circuits and neuropeptides modulate innate immune response. 
After detecting infections or injury, the sensory neurons release neuropeptides and send 
information to central neurons. The central neurons produce neural circuits sending to 
spleen or other immune organs through vague nerve. The neural circuits incite 
acetylcholine-producing memory T cells to produce choline, which binds to α 7 nAChR 
expressed on immune cells and lymphoid nodes to modulate innate immune response. 
The released neuropeptides, such as SP and CGRP, could cause two phases of neural 
inflammation: the first phase (Ⅰ), SP and CGRP act on arteriole and venules to cause 
plasma extravasation and permeability; the second phase (Ⅱ), they act on immune cells 
and lymphoid nodes to modulate the innate immune response. 
 
Abbreviations: α 7 nAChR, α 7 nicotinic acetylcholine receptors. SP, substance P; CGRP, 
calcitonin gene-related peptide. 
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4.  Discussion  
In this study, we showed that PVL alone without S. aureus could induce severe retinal 
inflammation, due to PVL active effects towards neuronal cells and glial cells. One 
phenomena demonstrated in vitro on PMNs is that PVL binds to C5aR before being 
internalized into cytoplasm56. In retina, we did not demonstrate whether or not PVL bound 
to C5aR on retinal ganglion cells. Because C5aR was present on retinal ganglion cells, we 
hypothesized that PVL bound to the receptors and was internalized into neuronal cells. It 
could also diffuse across gap junctions to neighboring neurons. It is interesting to note that 
PVL also colocalized with amacrine cells and horizontal cells which do not express C5aR. 
Further study should try to figure out whether PVL was really internalized into neuronal 
cells, and if yes, by which mechanism. Is C5aR involved in this process? Does another 
receptor play a role in the process especially on amacrine and horizontal cells? Those 
points are crucial to understand and better characterize the infection process.  
This characterization of the role of C5aR is a complex task. Indeed, PVL and its S 
component recognize only human and rabbit C5aR, and not the murine C5aR. This 
preference of animal species makes the research on PVL effects more complicated. First, 
the research on rabbit is more limited than mouse or rat. There are much less commercial 
antibodies available for rabbit species, which limits our researches. Second, there is no 
transgenic rabbit, especially it is impossible to get C5aR knock-out rabbit. Third, it is better 
to test PVL cellular reaction on isolated retinal neuronal cells or retinal neuronal cell lines. 
However, there is no reliable cell line for rabbit or human retinal neurons. Retina is small 
and contains many kinds of neurons and glial cells. The possible technique to isolate one 
type of retinal neurons is immunopanning, which requires enough rabbit retina and special 
antibodies which recognize the rabbit cells. It needs time to establish this technique to 
isolate retinal neuronal cells.  
  
In this study, we obtained some controversial results concerning the neuronal apoptosis 
and cytokine production between the in vivo model and the ex vivo model.  
In the in vivo model, PVL induced apoptosis of some microglial cells, no neuronal apoptosis 
was observed. But in the ex vivo model, there was some amacrine cells which underwent 
apoptosis 8 h after PVL treatment. As we already discussed that this difference might be 
due to different diffusion of PVL in retina between two models, we could extend the time to 
24 h after intravitreal PVL injection and see if some amacrine cells underwent apoptosis. 
In general, the glial cell activation is associated with neuronal cell death during infection 
process. It is somehow astonishing that PVL induced in vivo glial cell activation and no 
neuronal cell apoptosis, even if in ex vivo model amacrine cell apoptosis was observed. In 
both models, no ganglion cells underwent apoptosis, whereas it seemed to be the most 
PVL-targeted cell type.  
More conflicting results were observed concerning cytokines production. PVL induced IL-
6 increase in in vivo model, whereas IL-6 expression decreased in PVL-treated explants 
compared to controls. Beyond the differences between the two models and the possible 
reasons why apoptosis and cytokines production were different, those conflicting results 
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raise questions about the reliability of retinal explant model. We believe that retinal explant 
can be used to study PVL effects and eventual treatments by evaluating glial cell activation 
and amacrine cell apoptosis. Concerning cytokine and inflammation pathways, it should 
be interesting to look for other cytokines and/or neurotransmitters than IL-6. The results in 
ex vivo model may indicate that IL-6 is not main factor to trigger glial cell reaction. As 
reported in our review, bacterial toxins could induce neurogenic inflammation. Recently, it 
has been shown that HlgAB directly induced calcium influx through transient receptor 
potential ion channels in dorsal root ganglion neurons195. It is highly possible that PVL 
initiate neurogenic inflammation after binding to retinal neuronal cells. The principal 
neurotransmitters for neurogenic inflammation are CGRP, SP and glutamate. We tried to 
reveal the change of CGRP immunoactivity on retinal tissue in ex vivo model. Unfortunately, 
we did not find specific CGRP immunoreactivity in rabbit retinal tissue. This might be due 
to unspecific antibody which recognizes human CGRP. Indeed, no commercial antibody 
for rabbit CGRP was available. Another explanation is that PVL-positive neuronal cells 
released other neurotransmitters, such as glutamate or SP, to induce neurogenic 
inflammation. Larger spectrum of neurotransmitters could be researched, such as SP, 
CGRP and glutamate in in vivo or ex vivo models. 
 
Perspectives of research 
 
Murine model for testing PVL effects on retina 
Human C5aR knock-in mouse was used to tested PVL effects. The neutrophils of this C5aR 
humanized mouse showed a reduced sensitivity to PVL. The humanized mouse is only 
partly humanized, the proteins in the subsequent signaling pathway could influence the 
effects. Recently, it was found that CD45 was the receptor of F component of PVL and 
influenced the sensitivity of neutrophils of C5aR humanized mouse to PVL31. Maybe, we 
could test PVL effect on retina using human C5aR and CD45 knock-in mouse in future 
studies.  
 
Neurotransmitters and retinal explant 
We hypothesize that amacrine cell apoptosis might be due to excessive glutamate release 
induced by PVL. We could previously treat retinal explant with inhibitors of glutamate 
receptors for a short time and evaluate amacrine cell apoptosis induced by PVL. If the 
apoptosis induced by PVL decreased significantly in retinal explants treated by inhibitors 
of glutamate receptors compared to non-treated retinal explants, it could prove that 
amacrine cell apoptosis is due to excessive glutamate release. 
 
Research for other receptors for PVL 
We could add antibodies against S or F components of PVL in PVL solution and to see if 
those antibodies could effectively block PVL effects on retinal explants by evaluating the 
glial cell activation and amacrine cell apoptosis. We hypothesize that there might be 
another mechanism, possible another receptor except for C5aR, for PVL targeting 
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neuronal cells in retina. We could test this hypothesis by adding antagonism of C5aR to 
retinal explant and evaluate PVL effects on retina. 
 
Calcium imaging 
The calcium mobilization is the mechanism to release neurotransmitters and initiate 
neurogenic inflammation. Ganglion cells are in the surface of retinal explant, which is easy 
to be visualized for calcium imaging. To further confirm calcium mobilization after PVL 
infection, Fura-2 and PVL could be applied on the surface of retinal explants and 
intracellular calcium mobilization could be visualized through Fura-2 fluorescence with 
microscope equipped with filter (340 nm/380 nm) and camera. This calcium imaging could 
prove that PVL interacting with retinal ganglion cells through calcium mobilization.  
The antagonisms of neurotransmitters and calcium channels could be added to retinal 
explants and evaluate the changes of PVL effects on retina. This could further explore the 
molecular mechanism of PVL effects on neuronal cells.  
 
Clinical study 
PVL positive S. aureus strain is rare in France, but much more frequent in developing 
countries. The prevalence of PVL positive S. aureus was 12.5% of all the S. aureus isolates 
from hospitalized patients in east China196, 35.6% among the hospital isolates in Nepal197, 
57% of S. aureus infections isolates in western and central Africa198, 73.91% of all S. 
aureus isolates from pediatric patients in Colombia199. A clinical study showed that the 
prevalence of PVL positive S. aureus was 10% among the S. aureus isolates from 
endophthalmitis in United Sates200. We could furtherly evaluate the impact of PVL on 
endophthalmitis by clinical study in the developing countries in which the prevalence of 
PVL positive S. aureus is much higher. The endophthalmitis caused by S. aureus will be 
included. We collect S. aureus strains and analyze the prevalence of PVL positive S. 
aureus in endophthalmitis. We will compare the symptoms and prognostic of PVL positive 
S. aureus endophthalmitis with those of PVL negative S. aureus endophthalmitis. We could 
also analyze IL-6 level in the aqueous humor or vitreous from patients of those S. aureus 
endophthalmitis. Moreover, some antibiotics inhibit PVL release, such as clindamycin, 
linezolid, fusidic acid and rifampicin. We could do clinical study to test the combination of 
those inhibitory antibiotics in antibiotic treatment to see if there will be difference in 
prognosis of S. aureus infection.  
  
 
133 
 
5. Conclusion 
PVL is a virulent leukotoxin of S. aureus, associated with CA-MRSA infections. It presents 
active effects towards leukocytes and neuronal cells. We explored PVL effects on retina, a 
neuronal tissue, and tried to find the processes of bacterial toxins aggravating bacterial 
endophthalmitis.  
We employed two different rabbit models to study the PVL effects on retina: intravitreal 
injection of PVL in vivo animal model and retina explant ex vivo model. We showed that 
RGCs were the major cell targets of PVL through the presence of C5aR. PVL induced early 
retinal inflammation such as Müller and microglial cell activation and some microglial cell 
apoptosis. Those two models showed some different results: In in vivo animal model, PVL 
transiently colocalized with displaced amacrine cells, nitrotyrosine and IL-6 expression 
increased in retina. In ex vivo explant, PVL colocalized later with some horizontal cells and 
also possibly with a subpopulation of amacrine cells. Some amacrine cells in INL 
underwent apoptosis after PVL treatment. Those results clearly demonstrated that PVL 
alone without S. aureus bacteria could induce great inflammation in retina after targeting 
neurons.  
The two models we developed, in vivo and ex vivo, help to understand the aggravating role 
of PVL in retinal staphylococcal infection. They also allow to further explore the biologic 
mechanisms leading to PVL effects on retinal neurons and to test potential new therapeutic 
strategies.  
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8. Résume de la thèse en français 
Title   
Rôle de la leucocidine de Panton-Valentine dans l’infection oculaire staphylococcique : 
Etude des cibles cellulaires et des conséquences inflammatoires tissulaires rétiniennes sur 
des modèles d’endophtalmie in vivo et ex vivo chez le lapin 
Introduction 
S. aureus est une bactérie Gram positif, la prévalence du portage permanent est d’environ 
25%, tandis que la colonisation transitoire est d’au moins 60%. C’est une des espèces les 
plus couramment isolée en milieu hospitalier, la deuxième bactérie responsable 
d’infections nosocomiales. Il colonise dans les zones humides, telles que les narines, les 
aisselles. S. aureus cause beaucoup de maladies, de l’infections dermiques a l’infections 
viscérales et certains syndromes potentiellement mortels. S. aureus a une morbidité et une 
mortalité importantes dans le monde entier, en raison de ses facteurs de virulence et ses 
multiples résistances aux antibiotiques. 
S. aureus résistant à la méthicilline, ou encore appelle SARM, a été découvert en 1961. 
Ce dernier produit une nouvelle protéine résistante aux antibiotiques β-lactamines. Cette 
protéine est codée par le gène staphylococcal mec (SCCmec), qui existe en 9 types 
différents selon leurs tailles, les plus grands codent aussi des résistances a d’autres 
antibiotiques. Au début, les souches de SARM étaient confinées aux hôpitaux. Depuis 
les années 1990s, les infections à SARM ont progressé dans la population générale 
endors de toutes hospitalisation. Elles sont appelées CA-SARM ou bien SARM 
communitaire.  Les SARM communitaire sont différents des SARM hospitalier par leurs 
caractéristiques génotypiques, épidémiologiques et cliniques. Les SARM hospitalier 
porte SCCmec de type I, II ou III et sont résistants à de nombreuses classes 
d'antibiotiques. SARM communitaire qui portent de petits gènes SCCmec de type IV ou V 
sont sensibles aux antibiotiques non β-lactamines. Le SARM hospitalier sont rarement 
porteurs du gène de la PVL, tandis que de 60 à 100% des souches de SARM 
communitaire portent le gène de la PVL.  
Les facteurs de virulence de S. aureus comprennent les exoenzymes, les facteurs 
d’adhésion et les toxines. Les exoenzymes contrôlent la colonisation et la dissémination. 
Le facteur d’adhésion aide S. aureus à adhérer aux cellules, et à la matrice 
extracellulaire. Les toxines ont une fonction plus offensive en s’attaquant directement au 
système immunitaire et aux cellules de l’hôte. Le but est de bloquer la réponse 
adaptative. 
Les leucocidines ciblent les leucocytes. Cinq leucocidines à deux composés sont été 
identifiés chez des S. aureus d’origine humaine. Les gènes de HlgA/B, HlgC/B, LukA/B 
sont dans le génome “core” du chromosome et ils sont exprimés chez 99% des souches. 
Le gène de LukE/D se trouve dans un îlot de pathogénicité, exprimés par 50 à 75% des S. 
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aureus. Le gène de la PVL se trouve dans 3 bactériophages. Il est exprimé chez 2 à 10% 
de tous les isolats cliniques de S. aureus en Europe, et chez 10 à 60% dans les pays en 
développement en Afrique ou en Asie. Les composés se fixent par l’intermédiaire de 
récepteurs, différents selon les toxines et parfois différents en fonction des cibles 
cellulaires (spécificité / espèces animales). 
Les leucocidines sont composés de 2 protéines : une protéine de classe S et une protéine 
de classe F. Ces deux protéines doivent agir ensemble pour produire un effet sur les 
cellules ciblées. Le composé de classe S se fixe en premier à la membrane de la cellule 
ciblée, permettant la fixation du composé de classe F. Il y a ensuite, sois une 
oligomérisation puis formation du pore octamérique, sois une internalisation. La structure 
monomérique de la PVL a été résolue. La structure oligomérique du pore créé par la PVL 
a été décrite du pore de l’α-hémolysine. 
LukS-PV se fixe sur les récepteurs C5a. Récemment, CD45 a été identifié comme le 
récepteur de LukF-PV. Dans le processus de l’internalisation de la PVL, LukS-PV se lie au 
C5aR, permettant l'interaction secondaire du composé LukF-PV. Ils sont internalisés dans 
les cellules avec le C5aR phosphorylé. La PVL s’accumule d’abord dans les 
compartiments lysosomaux et atteint le réseau de Golgi en 3 heures.  
La PVL a une préférence pour les monocytes, les macrophages et les PMNs chez 
l’humains et le lapin, mais pas chez les rongeurs. La PVL peut également induire des 
réactions sur les neurones cérébraux et radicaux. La PVL peut entraîner une nécrose des 
tissus au cours de l'infection telles que les furoncles, la pneumonie nécrosante aiguë et 
l'ostéomyélite. La PVL induit une augmentation du calcium intracellulaire sans dommage 
pour la membrane. 
L’augmentation du calcium intracellulaire commence à 100 s avec une augmentation 
linéaire pendant 10 min. Cette mobilisation du calcium provient du réticulum 
endoplasmique, et non des réserves calciques du lysosome. L'influx de calcium est un 
processus distinct de la formation du pore. Mais le processus initial d'interaction entre la 
PVL et le récepteur joue un grand rôle dans la mobilisation du calcium. 
La PVL induit différentes réactions dans différents types de cellules. Pour les PMNs, la 
PVL provoque l’apoptose ou une nécrose, une sécrétion d'IL-8, de leucotriène-B4, 
d’histamine, des enzymes granulaires et des radicaux oxygénés. La PVL active les 
monocytes et les macrophages pour produire l'inflammasome NLRP3 qui provoque la 
libération d'IL-1β et d'IL-18. Pour les neurones, la PVL entraîne la mobilisation du calcium 
et la libération de glutamate. Au total, la PVL entraîne le recrutement et la lyse des 
leucocytes, favorise la vasodilatation, l'invasion des cellules, et la nécrose des tissus. 
La rétine est le tissu neuronal la plus interne du globe oculaire. Elle transforme la lumière 
en message électrique et envoie cet influx nerveux au système nerveux central pour former 
une image. Histologiquement, la rétine est constituée de 10 couches. Elle est constituée 
des cellules neuronales comme les cellules ganglionnaires, l'amacrine, les cellules 
bipolaires et les photorécepteurs, et des cellules gliales comme les cellules de Müller, les 
cellules microgliales et les astrocytes. Les cellules de Müller prolongent la rétine. Les 
cellules microgliales sont dans la partie interne de la rétine. Les cellules ganglionnaires 
sont dans la couche superficielle du côté interne de la rétine, dont les axons constituent le 
nerf optique. Du coté interne, la rétine est vascularisée par l’artère de la rétine, qui est 
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divise en trois couches des vaisseaux. A l’extérieur, les nutriments sont apportés par 
l’artère choroïde. 
L'endophtalmie bactérienne est une infection bactérienne à l'intérieur de l'œil. Les 
symptômes sont la baisse de l’acuité visuelle, la douleur et la rougeur oculaire, l’hypopion. 
L'endophtalmie est divisée en endophtalmie postopératoire, post-traumatique et endogène 
selon l'état initial. Les réactions inflammatoires de la rétine comprennent : la libération de 
cytokines, l’infiltration des neutrophiles, la perte architecturale et fonctionnelle de la rétine 
Le pronostic endophtalmie est variable. Des endophtalmies ont de mauvais pronostic, 
même après une prise en charge appropriée, telle qu'une vitrectomie et une antibiothérapie 
intravitréenne. Environ 20% des patients ont une acuité visuelle de 20/100 ou moins, 
même l’énucléation. De nombreux facteurs contribuent au mauvais pronostic, tels que le 
retard de la mise en place du traitement et le type de bactérie infectieuse. L’endophtalmie 
causées par des souches virulentes telles que S. aureus, sont souvent difficiles à traiter et 
entraînent une baisse de l’acuité visuelle. 
Objectif 
La virulence de la bactérie isolée est un facteur important pour le pronostic d’endophtalmie. 
S. aureus est la bactérie virulente la plus fréquente dans l’endophtalmie, la PVL est une 
toxine qui s’attaque aux cellules de l’hôte. Nous voulons analyser le rôle de la PVL dans 
l'endophtalmie et rechercher si la PVL pourrait affecter la rétine par des cibles neuronales. 
À la place de la bactérie, nous avons injecté la LPV dans le vitré du lapin. Donc, nous 
avons cherché les cellules rétiniennes ciblées par la LPV et analysé la réponse rétinienne 
inflammatoire éventuelle. Et puis, nous avons employé l’explant rétinien et essayé de 
développer un modèle ex vivo, qui sera utilisable dans le futur.  
 
Résultats 
Article 1 
Nous avons fait l’injection intravitréenne de la LPV, les lapins ont été sacrifiés à 30 min, 1, 
2, 4 et 8 h. Nous trouvons la LPV localisée sur la couche de cellules ganglionnaires. Cette 
couche est constituée de deux types de cellules, les cellules ganglionnaires et les cellules 
amacrines déplacées. Nous avons fait deux double-marquages (anti-PVL et anti-RBPMS 
marquant les cellules ganglionnaires, anti-PVL et anti-CHAT marquant les cellules 
amacrines déplacées). Ces images montrent que la LPV est co-localisée avec les cellules 
ganglionnaires et les cellules amacrines déplacées, avec des tendances différentes. Le 
taux de cellules ganglionnaires positifs à la PVL a augmenté, passant de 47% à 30 min à 
98% à 2 h. Alors que le taux des cellules amacrines déplacées positifs pour la PVL a 
diminué, passant de 68% à 30 min à 5% à 4 h. Ces taux étaient stables de 4 à 8 h. Nous 
avons identifié l'expression de C5aR et C5L2 dans la rétine. Nous avons trouvé une 
immunofluorescence spécifique de C5aR dans la couche de cellule ganglionnaire. Nous 
avons fait deux double-marquages (anti-C5aR et anti-RBPMS, anti-C5aR et anti-CHAT). Il 
montre que C5aR est colocalisé avec les cellules ganglionnaires, mais pas avec les 
cellules amacrines déplacée. Alors qu’il n’a aucune immunofluorescence spécifique de 
C5L2 dans la rétine. 
Les cellules ganglionnaires sont colocalisées avec C5aR. La LPV est bien colocalisée avec 
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les cellules ganglionnaires. Nous pouvons en déduire que la PVL est liée au C5aR sur les 
cellules ganglionnaires. Les cellules amacrine déplacées n'exprimaient pas le C5aR, mais 
ils étaient colocalisés de manière transitoire avec la PVL. Nous pensons qu’il y a un autre 
mécanisme par lequel la PVL se fixe sur les cellules amacrine déplacées, probablement 
un autre récepteur. 
 
L’activation de la cellule de Müller est caractérisée par l’augmentation de la protéine acide 
fibrillaire gliale (GFAP). Les cellules de Müller sont marquées par l’anticorps anti-GFAP. 
Dès 30 min après l'injection de la PVL, les cellules de Müller expriment anormalement la 
GFAP dans la partie externe de la rétine. Contrairement au témoin, cette anomalie 
s’accentue de 30 min à 4 h.  
Quant aux cellules microgliales, à 2 h, leurs corps sont élargis et leurs dendrites sont 
atrophiés, c’est un état d'activation précoce. Après 4 h, leurs dendrites ont disparu. 
 
L'apoptose a été observée dans la rétine 4 h après l'injection de la PVL et augmente à 8 
h. Pour identifier le type cellulaire en apoptose, nous avons fait trois double-marquages 
(TUNEL et anti-RBPMS, TUNEL et anti-CHAT, TUNEL et GSAI-B4, une lectine marquant 
cellules microgliales). Les images montrent que la cellule en apoptose est une cellule 
microgliale. L’apoptose microgliale pourrait être due à l’activation excessive par la PVL. 
Alors qu’il n’y pas de double marquage pour les cellules ganglionnaires et les cellules 
amacrine déplacées.  
Les cellules gliales sont activées, qui est en général lié à l’apoptose neuronal dans la rétine. 
Cependant, dans cette étude, nous n'avons pu détecter aucun dommage neuronal au 
moins 8 heures après l'injection de la LPV. 
 
Nous avons également montré l'augmentation de l'immunofluorescence de la nitrotyrosine 
dans la rétine traitée par la PVL par rapport aux témoins. La nitrotyrosine est un métabolite 
d'oxygène nitrique. Concernant les facteurs inflammatoires, la RT-qPCR a montré que seul 
IL-6 a significativement augmenté. Le Western blot a également montré l'augmentation de 
la nitrotyrosine et de l'IL-6. L’augmentation de la nitrotyrosine reflète un processus 
inflammatoire avec une production de l'oxyde nitrique. L’expression accrue de l’IL-6 
pourrait être due l’activation gliales et jouer un rôle important dans l’inflammation de la 
rétine. 
 
Article 2 
Un des facteurs qui limite les recherches de la PVL sur la rétine provient du fait que la 
PVL ne reconnaisse que des récepteurs d’humain et du lapin. En termes d’éthique 
animal, l’usage de lapin est très limité pour l’expérimentation. L’explant ne dispose pas 
d’apport sanguin, dépourvu des leucocytes. On peut analyser directement les effets de la 
PVL sur les neurones rétiniennes. Dans le deuxième article, nous avons essayé de 
chercher s’il était possible d’obtenir des résultats similaires dans l’explant rétinien, un 
modèle ex vivo, en utilisant moins des lapins. La rétine est disséquée de l'œil et placée 
immédiatement sur une membrane semi-perméable insérée dans un puits. La membrane 
est maintenue juste en contact avec le milieu de culture. Ce système de culture maintient 
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l'explant rétinien en condition d'air liquide, optimale pour préserver la vitalité des 
explants. 
 
La PVL est localisée dans la couche de cellule ganglionnaire et la couche nucléaire interne. 
On a fait cinq double-marquages, anti-PVL et anti-RBPMS, anti-PVL et anti-CHAT, anti-
PVL et anti-Calbindin qui marque les cellules AII amacrine, anti-PVL et anti-Calretinin qui 
marque certaine cellules bipolaires et horizontale, anti-C5aR et anti-RBPMS. La LPV co-
localise avec des cellules ganglionnaires. Les cellules ganglionnaires co-localisent avec 
C5aR (en rouge). Les autre trois double-marquages (anti-PVL et anti-CHAT, anti-PVL et 
anti-Calbindin, anti-PVL et anti-Calretinin) sont négatifs avant 4 h. Nous n'avons donc pas 
réussi à identifier le type de ces cellules positives à la PVL dans la couche nucléaire interne. 
À 8 et 24 h après le traitement à la LPV, la LPV est co-localisé avec certaines cellules 
horizontales. Le pourcentage moyen des cellules ganglionnaires positives à la PVL était 
de 34% à 30 min et de 45% à 24 h. Le taux n'a pas changé significativement entre 30 min 
et 24 h.  
 
Dans les explants témoins, les cellules de Müller ont un aspect normal entre 2 et 24 h. 
Alors que, dans des explants traités à la PVL (1,76 µM), les cellules de Müller présentent 
une extension anormale dans la couche nucléaire externe, qui augmentent de 2 à 24 h. 
Quand les explants sont traités par la PVL à grande concentration, les cellules de Müller 
sont dissociées, les noyaux nucléaires sont désorganisés, l’architecture rétinienne était 
endommagée. Cette défiguration de la rétine peut être liée à un dysfonctionnement des 
cellules de Müller. 
Dans les explants témoins, les cellules microgliales ont rétracté leurs dendrites après 24 
h de la culture. Alors que dans les explants traités par la LPV, les cellules microgliales ont 
été transformées en forme amiboïde, perdant tous leurs dendrites à 2 h. Dans des explants 
traités par la PLV de différentes concentrations à 8 h et 24 h, les cellules de Müller 
présentent une augmentation de GFAP dans la couche nucléaire externe jusqu’à leur 
dissociation avec l’augmentation de la concentration de la PVL. À 2 h, les cellules 
microgliales perdent plus leurs dendrites, et le nombre des cellules microgliales diminue, 
les noyaux nucléaires sont plus petits avec l’augmentation de la concentration de la PVL. 
On peut voir que l’activation des cellules de Müller et microgliales augmentent avec la 
concentration de LPV. 
  
Dans les explants témoins, quelques apoptoses ont été trouvées seulement 24 h après la 
culture. Dans les explants traités par la PVL, plusieurs apoptoses ont été trouvées des 4 
h, et le nombre des cellules en apoptoses augmente à 8 et 24 h. Nous avons effectué les 
comptages des cellules en apoptose par champ d’étude. Le nombre des cellules en 
apoptose augment avec la concentration de la PVL et le temps du traitement. Au total, les 
explants traités à la LPV présentent beaucoup plus de cellules en apoptose que les 
explants témoins. 
Pour identifier quelles cellules sont en apoptose, nous avons fait des double-marquages 
entre TUNEL et des marquages spécifiques des types de cellules rétiniennes (TUNEL et 
anti-RBPMS, TUNEL et anti-CHAT, TUNEL et anti-calbindin, TUNEL et anti-Calretinin, 
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TUNEL et GSAI-B4). Ces images montrent que certaines cellules microgliales et cellules 
amacrines sont en apoptose. L’apoptose des cellules amacrines pourrait être dues à la 
libération excessive de glutamate provoquée par la PLV. Mais, les cellules 
ganglionnaires ne sont pas montrées apoptotiques. Ces trois sub-populations des 
cellules amacrines ne sont pas les cellules amacrines en apoptose.  
 
On utilise RT-qPCR pour analyser l’expression des facteurs inflammatoires. Quatre heures 
après la culture, les explants témoins ont augmenté l'expression de l'IL-6 et de l'IL-8. 
Inversement, l'expression d'IL-6 et d'IL-8 n'a pas augmenté chez les explants traités à la 
PVL. Après 8 h de la culture, les explants traités à la LPV ont augmenté l'expression d'IL-
6 et d'IL-8. Cependant, les taux de l’expression d’IL-6 et d’IL-8 restent en dessous des 
témoins. Il semble qu’IL-6 et IL-8 ne sont pas les facteurs responsables pour l’activation 
des cellules gliales, mais ils sont produits par les cellules gliales activées. Dans les 
explants traites à la LPV, les cellules de Müller et microgliales sont trop perturbées pour 
exprimer des facteurs inflammatoires. Le facteur causatif pour l’activation des cellules 
gliales reste à identifier.  
 
Article 3  
La PVL ciblait les neurones rétiniens et induit l'activation des cellules gliales et 
l'inflammation rétinienne. Par quel mécanisme ? Nous avons recherche dans la littérature 
et nous pensons que c’est probablement l’inflammation neurogène. 
L'inflammation neurogène survient après l'activation des terminaisons neuronales, qui 
libèrent des neurotransmetteurs, entraînant une extravasation plasmatique et une 
perméabilité vasculaire. Les principaux neurotransmetteurs sont le peptide lié au gène de 
la calcitonine (CGRP), la substance P et le glutamate, dont leur libération dépende en 
définitive de la mobilisation du calcium intracellulaire. Dans les littératures, les facteurs de 
virulence bactériens peuvent activer directement les neurones et provoquer la mobilisation 
du calcium intracellulaire et des effets inflammatoires. Nous en déduisons que la PVL 
interagit rapidement avec les neurones pour libérer des neurotransmetteurs, entraînant 
une extravasation vasculaire et une rupture de la barrière hémato-rétinienne. 
L'inflammation rétinienne est amplifiée par l'infiltration cellulaire immunitaire et l'activation 
des cellules gliales rétiniennes.  
Discussion 
Dans les deux modèles, les cellules ganglionnaires exprimant C5aR sont les cellules 
principales ciblées par la PVL. Des cellules amacrines sont aussi colocalisées avec la PVL. 
Mais ils montrent une affinité faible avec la PVL. Il y a peut-être un autre récepteur pour 
que la PVL se lie sur les cellules amacrines. 
Les différences de cibles cellulaires entre les rétines in vivo et ex vivo pourraient être dues 
à des mécanismes différents liés à la diffusion de la LPV dans la rétine. L’explant rétinien 
ne dispose pas d’un apport sanguin et le système vasculaire rétinien se contracte 
rapidement. La LPV pourrait diffuser plus efficacement à travers la rétine et atteindre les 
cellules horizontales. 
Dans les deux modèles, aucune cellule ganglionnaire n'est entrée en apoptose, alors 
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qu'elle semblait être le type de cellule privilégiée par la LPV. Ces résultats sont 
correspondants à la précèdent étude, dans laquelle la PVL provoque la mobilisation du 
calcium intracellulaire et la libération du glutamate chez neurones cérébraux et radicaux, 
sans provoquant la mort des neurones.  
La LPV induit une augmentation de l'IL-6 dans un modèle in vivo, tandis que l'expression 
de l'IL-6 dans les explants traités à la LPV est plus faible que chez les témoins dans notre 
modèle d’explant rétinien. Dans les explants rétiniens témoins, l’expression d’IL-6 and d’IL-
8 a augmenté à 4 et 8 h, mais les cellules gliales n’étaient pas activées avant 8 h. 
Etonnamment, sur les explants traite à la PVL, malgré une augmentation moindre de 
l’expression d’IL-6, les cellules gliales étaient actives des 2 h. IL-6 n’apparait donc pas 
comme le facteur responsable pour l’activation des cellules gliales. Le facteur causal pour 
l’activation des cellules gliales reste à identifier.  
Nous pensons que l’explant rétinien peut être utilisé pour étudier les effets de la PVL et les 
traitements éventuels en évaluant l’activation des cellules gliales et l’apoptose des cellules 
amacrines. En ce qui concerne les cytokines et les voies d'inflammation, il devrait être 
intéressant de rechercher d'autres facteurs inflammatoires comme les neurotransmetteurs 
dans l’explant rétinien ou dans le modèle in vivo.  
Perspectives 
L’explant est reproductible et facile à manipuler. Il permet de réduire le nombre de lapin 
utilise. Il pourrait servir aux recherches futures pour explorer le mécanisme moléculaire de 
la PVL sur les cellules neuronales.   
Les cellules ganglionnaires se trouvent à la surface de l'explant rétinien, ce qui facilite leur 
visualisation pour l'imagerie du calcium. Cette imagerie du calcium pourrait prouver que la 
LPV interagit avec les cellules ganglionnaires et provoque la mobilisation du calcium. Les 
antagonistes des neurotransmetteurs et des canaux calciques pourraient être ajoutés aux 
explants rétiniens, pour essayer de modifier les effets de la LPV sur la rétine et valider 
l’inflammation neurogène dans la PVL intoxication rétiniennes. Les inhibiteurs des 
récepteurs du glutamate pourraient valider l'hypothèse selon laquelle l'apoptose des 
cellules amacrines serait due à une libération excessive de glutamate. Le blocage de C5aR 
pourrait mettre en évidence d'autres récepteurs pour la LPV. 
S. aureus positive à la LPV est rare en France, 2-5%, mais beaucoup plus fréquente dans 
les pays en développement. Nous pourrions évaluer l'impact de la LPV sur l'endophtalmie 
par une étude clinique dans les pays en développement. On peut analyser la prévalence 
de S. aureus positive à la PVL, leur symptôme clinique et leur pronostic, ainsi que 
l'expression d'IL-6 dans l'humeur aqueuse. 
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